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ABSTRACT 
Solute carrier transporters belonging to the major facilitator family of 
membrane transporter are increasingly being recognized as a possible 
mechanism to explain inter-individual variation in drug efficacy and response. 
Genetic factors are estimated to be responsible for approximately 15-30% of 
inter-individual variation in drug disposition and response. The aims of this 
study were to determine the minor allele frequencies of 78 previously 
identified single nucleotide polymorphisms in the pharmacogenetically 
relevant SLC22A1-3 and SLC47A1 genes in the indigenous African population 
of South Africa. Secondly, to determine whether allele and genotype 
frequencies for these SNP were different from that reported for other African, 
Caucasian, and Asian populations. Thirdly, to infer haplotypes from the genetic 
information which can potentially be used in future to design and interpret 
results of pharmacogenetics association studies involving these genes and their 
substrate drugs. Finally, to determine whether the Xhosa population harbour 
novel SNPs in the SLC22A2 gene, that encodes the kidney-specific hOCT2. 
SNaPshot™ multiplex single base minisequencing systems were developed 
and optimized for each of SLC22A1, SLC22A2, SLC22A3, and SLC47A1 
covering the previously identified 78 SNPs. These systems were then used to 
genotype the alleles of 148 healthy Xhosa subjects residing in Cape Town, 
South Africa. In addition, the proximal promoter region and all 11 exons and 
flanking regions of the SLC22A2 gene of 96 of the participants were screened 
for novel SNPs by direct sequencing. The Xhosa subjects investigated lacked 
heterozygosity and were monomorphic for 91% of the SNPs screened. None of 
the SLC22A3 and SLC47A1 SNPs investigated was observed in this study. 
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Sequencing of the SLC22A2 gene revealed 28 SNPs, including seven novel 
polymorphic sites, in the 96 Xhosa subjects that were screened. The minor 
allele frequencies of the seven previously identified variant SNPs observed in 
this study were different compared to that observed for American and 
European Caucasian, and Asian populations. Moreover, the allele frequencies 
for these SNPs differed amongst African populations themselves. Eight and 
seven haplotypes were inferred for SLC22A1 and SLC22A2, respectively, for 
the Xhosa population from the information gathered with SNaPshot™ 
genotyping. This study highlights the fact that African populations do not have 
the same allele frequencies for SNPs in pharmacogenetically relevant genes. 
Furthermore, the Xhosa and other African populations do not share all reduced-
function variants of the SLC22A1-3 and SLC47A1 genes with Caucasian and 
Asian populations. Moreover, this study has demonstrated that the Xhosa 
population harbours novel and rare genetic polymorphisms in the key 
pharmacogene SLC22A2. This study lays the foundation for the design and 
interpretation of future pharmacogenetic association studies between the 
variant alleles of the SLC22A1-3 and SLC47A1 genes in the Xhosa population 
and drug disposition and efficacy. 
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CHAPTER 1 
1. LITERATURE REVIEW 
1.1. Introduction 
Inter-individual differences in the clinical efficacy and the toxicity of medication are 
common amongst patients (Kalow, 2006, Shastry, 2005). These inter-individual 
differences in drug response could be due to age, sex, body weight, nutrition, organ 
function, infections, co-medication, environmental factors, and genetic variation 
(Sadee and Dai, 2005, Shastry, 2005). In general, genetic factors are estimated to 
account for 15-20% of inter-individual variations in drug disposition and responses 
(Choi and Song, 2008). 
Adverse drug reactions (ADRs) are side effects experienced during drug therapy 
within the approved dosage and labelling recommendations for the specific drug 
(Daly, 2012). Severe ADRs are a significant clinical problem which may result in 
disabilities or permanent damage, congenital abnormalities or birth defects, 
hospitalizations, life-threatening events, and death (Daly, 2013). ADRs are amongst 
the leading causes of hospitalizations in the developed world, and the incidence of 
severe ADRs has been estimated at 6.2-6.7% in hospitalized patients (Bachtiar and 
Lee, 2013). However, in developing countries like South Africa ADRs are estimated 
to occur in 14% of hospitalized patients (Mehta et al., 2008, Warnich et al., 2011).  
Moreover, the incidence of fatal ADRs is estimated at between 0.15-0.3% in 
developed countries and may be five to ten times higher in developing countries 
(Bachtiar and Lee, 2013, Mehta et al., 2008). The economic impact of ADR-related 
hospitalizations has been estimated at $ 136 billion in the USA alone (Becquemont, 
2009, Bond and Raehl, 2006). 
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CHAPTER 1 
It has long been recognized that genetic variations in drug metabolizing enzymes 
underlie the inter-individual differences in drug response. However, polymorphisms 
in solute carrier transporters (SLCs) are increasingly being recognized as a factor 
accounting for inter-individual variation in drug response and being involved in the 
toxicity of drug treatment or predisposition to ADRs. These polymorphisms are 
attracting interest because SLCs are widely distributed in the epithelial membrane of 
the liver, kidney, and intestine and play an important role in the gastrointestinal 
absorption, biliary and renal uptake and excretion, and distribution to target sites of 
their substrate drugs. 
Approximately 40% of therapeutic drugs are organic cations or weak bases at 
physiological pH and are substrates of organic cation transporters (OCTs) and 
multidrug and toxin extrusion (MATEs) transporters (Neuhoff et al., 2003). The 
transport of OCs is mediated by OCTs in an electrogenic, and independently of 
sodium-gradient, and by MATEs through an oppositely directed proton gradient 
(Koepsell et al., 2007, Otsuka et al., 2005). Examples of clinically important drugs 
transported by OCTs and MATEs include the antidiabetic drugs metformin and 
phenformin, the antineoplastic drugs cisplatin and oxaliplatin, the anti-HIV drugs 
lamivudine and zalcitabine, and the histamine receptor antagonist cimetidine 
(Barendt and Wright, 2002, Busch et al., 1998, Ciarimboli et al., 2005b, Dresser et 
al., 2002, Kimura et al., 2005b, Jung et al., 2008). 
Previous studies have shown that human OCTs and MATEs are highly polymorphic 
in ethnically diverse populations (Sakata et al., 2004, Shu et al., 2003, Kang et al., 
2007). A number of these variants have been associated with reduced effect of 
therapeutic drugs, example the anti-diabetic metformin and the anti-neoplastic 
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imatinib. However, these aforementioned reduced-function genetic variants were 
however primarily found in studies with European participants and have not been 
consistently replicated for other ethnic groups (Chen et al., 2010b, Leabman et al., 
2003). 
Although Africa and South Africa harbour a significant proportion of genomic 
diversity and have a significant disease burden, the impact of this genomic diversity 
on the inter-individual differences in drug response is however understudied 
(Coovadia et al., 2009, Hardy et al., 2008, Tishkoff et al., 2009). Furthermore, 
pharmcogenomic and pharmacogenetic research in Africa is in its infancy and has 
primarily focused on drug-metabolizing enzymes (Hardy et al., 2008, Warnich et al., 
2011). Thus, this review summarizes our current understanding about the structure, 
distribution, substrate specificity, physiological roles of OCTs and MATEs and to 
discuss the importance of these transporters in the pharmacokinetics and 
pharmacodynamics of clinically important cationic drugs. 
1.2. Human genetic variation and its contribution to complex traits 
Human genetic variants are typically referred to as either common or rare, to denote 
the frequency of the minor allele in the human population. These variants are 
classified as single nucleotide polymorphsisms (SNPs), insertions-deletions, varying 
number of tandem repeats (VNTRs), inversions, and copy number variants 
(Brockmöller and Tzvetkov, 2008). SNPs are the most prevalent class of variants 
amongst individuals.  
Currently, it is estimated that the human genome contains at least between 11 and 12 
million SNPs (Brockmöller and Tzvetkov, 2008). Moreover, approximately 7 
million of these SNPs occur at a minor allele frequency (MAF) greater than 5% and 
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the remaining at a MAF between 1 and 5%. The current opinion is that African 
populations harbour more genetic variation than other populations (Hardy et al., 
2008, Tishkoff et al., 2009). This view is supported when considering the fact that 
the Yoruban genome has 1.25 fold more single-base variants than the Caucasian 
genomes and that a greater percentage is novel, which is reflective of the overall 
increased amount of genome diversity in individuals of African origin (Frazer et al., 
2009). 
Variation in the human genome has a wide variety of medical and health 
implications. The current belief is that the knowledge acquired through human 
genetic studies will have a major impact on medical sciences, and that initially our 
increased understanding of the molecular pathways/mechanisms involved in disease 
will provide new potential drug targets (Frazer et al., 2009, Séguin et al., 2008, Daar 
and Singer, 2005). Subsequently, the expectation is that this increased understanding 
will equip us to predict disease susceptibility, to classify diseases in sub-phenotypes 
from genotypic information, and to improve treatment and expand the use of 
pharmacogenetics (Frazer et al., 2009).  
1.3. Pharmacogenetics/Pharmacogenomics and Individualized/Personalized 
Drug Therapy 
Pharmacogenetics, however, is not a new discipline itself but has been around for 
approximately 50 years (Kalow, 2006). However, advances in genomics, especially 
in methodology, have allowed the merging of pharmacogenetics and 
pharmacogenomics, improving our ability to identify the genetic causes of diseases, 
search for novel drug targets, and to improve drug development (Daar and Singer, 
2005). 
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CHAPTER 1 
Pharmacogenetics is defined as the discipline which uses the patient’s genetic 
information of drug metabolizing enzymes, drug receptors, and drug transporters in 
order to develop and individualized drug therapy that will result in optimal choice 
and dose of the drugs in question (Holm, 2008). The science of pharmacogenetics 
originated from the analysis of a few rare and sometimes unexpectedly found 
extreme reactions (phenotypes) observed in some humans. These phenotypes were 
either inherited diseases or abnormal reactions to drugs or other environmental 
factors (Brockmöller and Tzvetkov, 2008). An important milestone in 
pharmacogenetics occurred when it became clear that drug effects tended to differ 
not only between individuals, but also between human population groups (Kalow, 
2006). 
Pharmacogenomics, on the other hand, is defined as ‘The study of variations of DNA 
and RNA characteristics as related to drug response’ (Bhathena and Spear, 2008). 
Moreover, pharmacogenomics is an approach that has evolved from 
pharmacogenetics and has become a new scope for the pharmaceutical and 
biomedical fields (Khoury et al., 2008). It is widely expected that 
pharmacogenomics will facilitate a trend toward improved patient outcomes by 
increasing our understanding at the molecular level of both the disease and treatment 
response (Bhathena and Spear, 2008, Eichelbaum et al., 2006). Moreover, the 
pharmacogenomics approach has already supplied researchers with a number of 
candidate genes and their translational ramifications on drug response in many 
complex states (McCarthy and Zeggini, 2007). 
Inter-individual difference in the efficacy and the toxicity of medication is common 
amongst patients (Shastry, 2005). This difference in drug response could be due to 
5 
 
 
 
 
 
CHAPTER 1 
age, sex, body weight, nutrition, organ function, infections, co-medication, 
environmental factors, the dose-response curve of a drug (pharmacokinetics and 
pharmacodynamics), and genetic variation (Sadee and Dai, 2005, Shastry, 2005). 
However, when treating individual patients, the focus must be shifted from 
populations, ethnicities or races to the inherent genetic individuality that results from 
mosaics of variable haplotypes (Suarez-Kurtz). Knowledge of an individual’s genetic 
variability in drug response is, therefore, clinically and economically important. This 
type of genetic profiling provides benefits for future medical care by predicting drug 
response or assisting in the development of DNA-based tests. Thus, 
pharmacogenetics and pharmacogenomics are two recent developments to 
investigate inter-individual variations in drug response (Shastry, 2005). 
While the initial focus of pharmacogenetics was on drug-metabolizing pathways 
(pharmacokinetics), the focus of pharmacogenomics is on the genetic basis of the 
individual variation in drug efficacy and toxicity (pharmacodynamics) (Kalow, 2006, 
Urban, 2010). The assumption or expectation of both pharmacogenetics and 
pharmacogenomics is the ability to deliver “personalized medicine”, a broad and 
rapidly advancing field of healthcare that is informed by each patient’s unique, 
clinical, genetic, genomic, and environmental information (Holm, 2008, Limdi and 
Veenstra, 2010). That is, personalized medicine can be used to refine the definition 
of disease, identify disease subtypes, and ultimately define biomarkers capable of 
discriminating between the patients most likely to benefit from a specific treatment 
and those unlikely to respond or likely to experience adverse events (Reitman and 
Schadt, 2007). 
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There are many challenges that must be overcome to apply rapidly accumulating 
genomic information to understand variable drug responses. These include, defining 
candidate genes and pathways; relating disease genes to drug response genes; 
precisely defining drug response phenotypes; and addressing analytic, ethical, and 
technological issues involved in the generation and management of large drug 
response sets (Roden et al., 2006). One of the impediments to the use of 
pharmacogenomics testing is the fact that some prescribing decisions must be made 
emergently, necessitating the availability of pre-emptive genotype results (Relling et 
al., 2010). Furthermore, various pharmacogenomic associated studies have not been 
reproduced and confirmed. In addition, the Genome Wide Association Studies 
(GWAS) that have been performed have been restricted primarily to populations of 
European descent, mostly because biomedical research funding is highest in the 
United States and Western Europe, where European ancestral populations make up 
the majority (Urban, 2010). Furthermore, a great deal of education for the public and 
healthcare professionals in the area is necessary before gaining overall acceptance 
(Avery et al, 2009). 
1.4. Adverse Drug Reactions 
Adverse drug reactions (ADRs) is defined as a response to a drug which is noxious 
and unintended, and occurs at doses normally used in man for the prophalaxis, 
diagnosis, or therapy of disease, or for the modification of physiological function 
(WHO, 2004). The undesirable effects of the drug may lead to any of the following: 
death or a life-threatening event, hospitalization, disability or permanent damage, 
congenital abnormality or birth defect (FDA, 2011). 
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From a clinical perspective, ADRs can be broadly classified as either Type A, which 
are dose-dependent, or Type B (idiosyncratic), where the reaction is not predictable 
from normal drug pharmacology and is generally dose-independent (Daly, 2013). 
Although Type A ADRs are more common, they are frequently mild and often self-
limited. On the other hand, Type B ADRs are less common, but are often more 
severe and are more likely to result in serious morbidity or even mortality. 
ADRs are implicated in a notable number of hospitalizations, and fatal ADRs are 
amongst the leading causes of death in developed nations (Sim and Ingelman-
Sundberg, 2011, Wester et al., 2008). The incidence of severe ADRs internationally 
has been estimated at between 6.2-6.7% in hospitalized patients and the incidence of 
fatal ADRs is estimated to be between 0.15-0.3%. In South Africa, on the other 
hand, ADRs are reported to occur in 14% of hospitalized patients with a five to ten 
times higher fatality rate (Mehta et al., 2008). In recent years, the economic cost of 
ADR-related hospitalizations has reached $136 billion in the USA alone 
(Becquemont, 2009, Bond and Raehl, 2006). 
Genetic susceptibility is an important feature of serious ADRs and there is 
considerable interest in the possibility that development of genetic tests to identify 
all those at risk of adverse events prior to prescription might lead to valuable drugs 
being retained (Daly, 2013). In order to achieve this goal consideration must be 
given to the fact that population differences exist in drug response, including 
susceptibility to ADRs, and that these differences are in part due to genetic 
polymorphisms (Bachtiar and Lee, 2013). Genetic variation frequencies differ 
among different ethnicities, which may be associated with variation of susceptibility 
to ADRs among different populations. 
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1.5. Race, Ethnicity and Genetic Ancestry in Biomedical Research 
The problem of race in scientific research is not a new one, and the issue seems to 
perpetually reappear and remain fundamentally unresolved (Caulfield et al., 2009). 
However, it is a known fact that specific monogenic diseases such as sickle cell 
anemia, Tay-Sachs, and cystic fibrosis for example, differ between populations (Via 
et al., 2009). In order to use genomic knowledge to develop drugs and to improve 
health, we need to consider ethnical differences in different populations (Shastry, 
2005). There exist inter-ethnical differences in polymorphisms of genes encoding 
drug-metabolizing enzymes, transporters and disease-associated proteins (Bachtiar 
and Lee, 2013). Many gene variants differ in frequency between populations or 
subpopulations, but this is often merely due to random fluctuations (called genetic 
drift) and has no true biological meaning (Urban, 2010). With the availability of 
genetic ancestry estimates it is believed that admixed populations represent a 
valuable opportunity to study complex disease and drug response (Via et al., 2009). 
Since admixed populations share varying proportions of different ancestral 
populations their genetic complexity can potentially complicate biomedical research. 
On the other hand, precisely because of this complexity, admixed populations can 
also provide unique opportunity to disentangle the clinical, social, environmental, 
and genetic underpinnings of population differences in health outcomes (Suarez-
Kurtz, 2008). 
The accumulated data reveal that allele, genotype and haplotype frequency of 
polymorphisms of pharmacological relevant genes (pharmacogenes) may differ 
significantly among populations categorized by race, ethnicity, or continental origin 
(Suarez-Kurtz). It is widely accepted that population based pharmacogenetics studies 
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can help in establishing baseline frequency distributions of SNPs of genes important 
in drug metabolism and/or transport. Therefore, recognition of inter-ethnic 
differences in drug response might be useful in the establishment of public health 
policies, the design and interpretation of clinical drug trials, and possibly to guide 
clinicians to prospectively evaluate those patients with the greatest possibility of 
expressing a variant genotype which may be associated with inter-individual 
variation in drug response, efficacy and toxicity (Matimba et al., 2008, Suarez-Kurtz, 
2008). 
1.6. Single-Nucleotide Polymorphisms and Variability in Drug Response 
and Toxicity 
Inter-individual variability in drug response and toxicity is a significant clinical and 
public health problem. This variation can be due to genetic, environmental, 
physiological, and pathophysiological factors (Choi and Song, 2008, Giacomini et 
al., 2010). It is estimated that genetic factors generally account for 15-30% of inter-
individual variation in drug disposition and response, and for certain drugs genetic 
factors can account for up to 95% of the inter-individual variation in drug disposition 
and effects (Avery et al., 2009, Choi and Song, 2008). 
A considerable body of evidence currently exists that suggests that single nucleotide 
polymorphisms (SNPs) in genes encoding drug-metabolizing enzymes, enzymes 
involved in DNA biosynthesis and repair, and drug transporters might determine 
drug efficacy and toxicity (Shastry, 2005). Many drug-metabolizing enzymes and 
drug transport proteins have consistently replicated associations between genetic 
variants and the clinical pharmacokinetics of at least one drug (Bhathena and Spear, 
2008). Genetic polymorphisms in membrane transporter genes are increasingly been 
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recognized as a possible mechanism for explaining variation in drug response 
(Leabman et al., 2003, Yan Shu et al., 2007). 
1.7. Membrane Transporters 
Membrane transporters are specialized integral proteins that span cell membrane 
bilayers and play a critical role in the translocation of chemicals into and out of cells 
using active and passive mechanisms (Klaassen and Aleksunes, 2010). They are 
responsible for maintaining cellular and organismal homeostasis by importing 
nutrients essential for cellular respiration and exporting metabolic waste products 
and xenobiotics (Leabman et al., 2003). These transporters are located in the 
epithelial membrane of the liver, kidney, intestine, and target organs and are now 
widely acknowledged as important determinants governing drug absorption, 
excretion, and, in many cases, extent of drug entry into target organs (Choi and 
Song, 2008, DeGorter et al., 2012). 
Inter-individual variation in transporter activity can arise from numerous factors, 
including genetic heterogeneity, certain disease processes, concomitant medications, 
and herbal and dietary constituents that may inhibit or induce transporter expression 
or activity (DeGorter et al., 2012, Giacomini et al., 2010). Numerous studies have 
suggested that membrane transporters play a part in vivo in drug disposition, 
therapeutic efficacy, and adverse drug reactions. Moreover, genetic polymorphisms 
in membrane transporter genes have increasingly been recognized as a possible 
mechanism accounting for variation in drug response (Leabman et al., 2003, Yan 
Shu et al., 2007).  
During the last decade, a greater focus has been given to the impact of genetic 
variations in membrane transporters on the pharmacokinetics and toxicity of 
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numerous therapeutic drugs (Hediger et al., 2004). However, while the majority of 
transporter-related pharmacogenetic research has been in regards to classic genes 
encoding the outward-directed ATP-binding cassette (ABC) transporters, more 
studies have been conducted in recent years evaluating genes encoding solute carrier 
(SLC) transporters that mediate the cellular uptake, distribution and elimination of 
clinically important drugs (Franke et al., 2010). 
1.8. Solute Carrier Transporters 
The solute carrier transporter (SLC) superfamily is a large family of membrane-
bound proteins that share 20-25% of sequence homology (Hediger et al., 2004). This 
major facilitator family consists of more than 300 members grouped into 51 classes. 
SLC transporters typically use secondary and tertiary active transport to move 
chemicals over biological membranes (Klaassen and Aleksunes, 2010). They are 
trans-membrane proteins which typically have a predicted membrane topology that 
consists of 12 α-helical transmembrane helices (TMHs), an intracellular N-terminus, 
a large glycosylated extracellular loop between TMHs 1 and 2, a large intracellular 
loop with phosphorylation sites between TMHs 6 and 7, and an intracellular C-
terminus (Koepsell et al., 2007). SLCs are expressed in most tissues. However, these 
proteins are expressed most abundantly in the liver, kidney, and intestine where they 
are either located at the basolateral or apical plasma membranes of polarized cells 
(Wojtal et al., 2009). Today it is known that members of the SLC family are 
involved in the facilitated transport of a variety of substances including drugs, 
environmental toxins, xenobiotics, and endogenous metabolites across plasma 
membranes (Hediger et al., 2004, Koepsell et al., 2007). Moreover, these SLC 
transporters play a critical role in the absorption and excretion of drugs in the 
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kidneys, liver, and intestine, thus, influencing the pharmacodynamic and 
pharmacokinetic characteristics of these drugs (Meier et al., 2007). 
The SLC family can be divided into three subgroups based on substrate specificity 
and function: organic cation transporters (OCTs), the organic cation/zwitterion 
transporters (OCTNs), and the organic anion transporters (OATs) (Koepsell et al., 
2007). The OCT subgroup contains three subtypes of facilitated transporters called 
hOCT1 (encoded by the SLC22A1 gene), OCT2 (SLC22A2), and OCT3 (SLC22A3). 
The genes encoding the three OCT isoforms are clustered together on the long arm 
of chromosome 6 (Tzvetkov et al., 2009, Koehler et al., 1997). Based on their 
substrate properties and tissue distributions, hOCT1, hOCT2, and hOCT3 are 
thought to play important roles in the biliary and renal excretion of their substrates 
and the distribution of organic cationic drugs in the liver, kidney, heart, and brain 
(Jonker and Schinkel, 2004, Koepsell et al., 2007). Moreover, there are several 
members of the SLC family for which the substrate specificity and/or function have 
not been elucidated yet. 
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Figure 1.1 - Multiple protein sequence alignment of OCTs from four animal species 
showing a high degree of evolutionary conservation. 
  
10 20 30 40 50 60 70 80 90 100
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
human  OCT1 MP-TVDDILEQVGESGWFQKQAFLILCLLSAAFAPICVGIVFLGFTPDHH-CQSPGVAELSQRCGWSPAEELNYTVPGLGPAGEA-FLGQCRRYEVDWNQ
rabbit OCT1 MP-TVDDVLEQVGEFGWFQKRTFLFLCLISAILAPIYLGIVFLGFTPDHR-CRSPGVDELSQRCGWSPEEELNYTVPGLG-ATDGAFVRQCMRYEVDWNQ
mouse  OCT1 MP-TVDDVLEHVGEFGWFQKQAFLLLCLISASLAPIYVGIVFLGFTPDHH-CRSPGVAELSQRCGWSPAEELNYTVPGLGSAGEASFLSQCMKYEVDWNQ
rat    OCT1 MP-TVDDVLEQVGEFGWFQKQAFLLLCLISASLAPIYVGIVFLGFTPGHY-CQNPGVAELSQRCGWSQAEELNYTVPGLGPSDEASFLSQCMRYEVDWNQ
human  OCT2 MPTTVDDVLEHGGEFHFFQKQMFFLLALLSATFAPIYVGIVFLGFTPDHR-CRSPGVAELSLRCGWSPAEELNYTVPGPGPAGEAS-PRQCRRYEVDWNQ
rabbit OCT2 MP-TVDDILEQVGHFHFFQKQTFFLLALISAAFTPIYVGIVFLGFTPDHR-CRSPGVAELSQRCGWSPGEELNYTVPGLG-AADGAFARQCMRYEVDWNQ
mouse  OCT2 MP-TVDDILEHIGEFHLFQKQTFFLLALLSGAFTPIYVGIVFLGFTPNHH-CRSPGVAELSQRCGWSPAEELNYTVPGLGSAGEVSFLSQCMRYEVDWNQ
rat    OCT2 MS-TVDDILEHIGEFHLFQKQTFFLLALLSGAFTPIYVGIVFLGFTPDHH-CWSPGAAKLSQRCGWSQAEELNYTVPGLGPSDEASFLSQCMRYEVDWNQ
human  OCT3 MP-SFDEALQRVGEFGRFQRRVFLLLCLTGVTFAFLFVGVVFLGTQPDHYWCRGPSAAALAERCGWSPEEEWNRTAPASRGPEPPERRGRCQRYLLEAAN
rabbit OCT3 ----------------------------------------------------------------------------------------------------
mouse  OCT3 MP-TFDQALRKAGEFGRFQRRVFLLLCLTGVTFAFLFVGVVFLGSQPDYYWCRGPRATALAERCAWSPEEEWNLTTPELHVPAERRGQGHCHRYLLEATN
rat    OCT3 MP-TFDQALRKAGEFGRFQRRVFLLLCLTGVTFAFLFVGVVFLGSQPDYYWCRGPRATALAERCAWSPEEEWNLTTPELHVPAERRGQGHCHRYLLEDTN
110 120 130 140 150 160 170 180 190 200
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
human  OCT1 SA------LSCVDPLASLATNRSHLPLGPCQDGWVYDTPGSSIVTEFNLVCADSWKLDLFQSCLNAGFLFGSLGVGYFADRFGRKLCLLGTVLVNAVSGV
rabbit OCT1 SS------LGCVDPLASLAPNRSHLPLGPCQHGWVYDTPGSSIVTEFNLVCADAWKVDLFQSCVNLGFFLGSLGVGYIADRFGRKLCLLLTTLINAVSGV
mouse  OCT1 ST------LDCVDPLSSLAANRSHLPLSPCEHGWVYDTPGSSIVTEFNLVCGDAWKVDLFQSCVNLGFFLGSLVVGYIADRFGRKLCLLVTTLVTSLSGV
rat    OCT1 ST------LDCVDPLSSLVANRSQLPLGPCEHGWVYDTPGSSIVTEFNLVCGDAWKVDLFQSCVNLGFFLGSLVVGYIADRFGRKLCLLVTTLVTSVSGV
human  OCT2 ST------FDCVDPLASLDTNRSRLPLGPCRDGWVYETPGSSIVTEFNLVCANSWMLDLFQSSVNVGFFIGSMSIGYIADRFGRKLCLLTTVLINAAAGV
rabbit OCT2 SS------PGCVDPLASLAPNRSHLPLGPCQHGWVYDTPGSSIVTEFNLVCARSWMLDLFQSAVNIGFFIGSVGIGYLADRFGRKLCLLVTILINAAAGV
mouse  OCT2 ST------LDCVDPLSSLAANRSHLPLSPCEHGWVYDTPGSSIVTEFNLVCAHSWMLDLFQSLVNVGFFIGAVGIGYLADRFGRKFCLLVTILINAISGV
rat    OCT2 ST------LDCVDPLSSLAADRNQLPLGPCEHGWVYNTPGSSIVTEFNLVCAHSWMLDLFQSVVNVGFFIGAMMIGYLADRFGRKFCLLVTILINAISGA
human  OCT3 DSASATSALSCADPLAAFP-NRS-APLVPCRGGWRYAQAHSTIVSEFDLVCVNAWMLDLTQAILNLGFLTGAFTLGYAADRYGRIVIYLLSCLGVGVTGV
rabbit OCT3 -------------------------------------------------------MLDLTQAILNLGFLAGAFTLGYAVDRYGRRVTYLISCLGVGITGV
mouse  OCT3 TSSELS-----CDPLTAFP-NRS-APLVSCSGDWRYVETHSTIVSQFDLVCSNAWMLDLTQAILNLGFLAGAFTLGYAADRYGRLIIYLISCFGVGITGV
rat    OCT3 TSSELS-----CDPLAAFP-NRS-APLVPCSGDWRYVETHSTIVSQFDLVCGNAWMLDLTQAILNLGFLAGAFTLGYAADRYGRLIVYLISCFGVGITGV
210 220 230 240 250 260 270 280 290 300
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
human  OCT1 LMAFSPNYMSMLLFRLLQGLVSKGNWMAGYTLITEFVGSGSRRTVAIMYQMAFTVGLVALTGLAYALPHWRWLQLAVSLPTFLFLLYYWCVPESPRWLLS
rabbit OCT1 LTAVAPDYTSMLLFRLLQGLVSKGSWMSGYTLITEFVGSGYRRTVAILYQVAFSVGLVALSGVAYAIPNWRWLQLTVSLPTFLCLFYYWCVPESPRWLLS
mouse  OCT1 LTAVAPDYTSMLLFRLLQGMVSKGSWVSGYTLITEFVGSGYRRTTAILYQVAFTVGLVGLAGVAYAIPDWRWLQLAVSLPTFLFLLYYWFVPESPRWLLS
rat    OCT1 LTAVAPDYTSMLLFRLLQGMVSKGSWVSGYTLITEFVGSGYRRTTAILYQMAFTVGLVGLAGVAYAIPDWRWLQLAVSLPTFLFLLYYWFVPESPRWLLS
human  OCT2 LMAISPTYTWMLIFRLIQGLVSKAGWLIGYILITEFVGRRYRRTVGIFYQVAYTVGLLVLAGVAYALPHWRWLQFTVSLPNFFFLLYYWCIPESPRWLIS
rabbit OCT2 LMAVSPNYTWMLIFRLIQGLVSKAGWLIGYILITEFVGLNYRRTVGILYQVAFTVGLLVLAGVAYALPRWRWLQLTVTLPYFCFLLYYWCIPESPRWLIS
mouse  OCT2 LMAISPNYAWMLVFRFLQGLVSKAGWLIGYILITEFVGLGYRRTVGICYQIAFTVGLLILAGVAYALPNWRWLQFAVTLPNFCFLLYFWCIPESPRWLIS
rat    OCT2 LMAISPNYAWMLVFRFLQGLVSKAGWLIGYILITEFVGLGYRRMVGICYQIAFTVGLLILAGVAYVIPNWRWLQFAVTLPNFCFLLYFWCIPESPRWLIS
human  OCT3 VVAFAPNFPVFVIFRFLQGVFGKGTWMTCYVIVTEIVGSKQRRIVGIVIQMFFTLGIIILPGIAYFIPNWQGIQLAITLPSFLFLLYYWVVPESPRWLIT
rabbit OCT3 VVAFAPNFPVFAVFRFLQGVFGKGTWMTCYVIVTEIVGSKQRRIVGIVIQMFFTLGIIILPGIAYFIPSWQGIQLAVTLPNFLFLLYYWVVPESPRWLIT
mouse  OCT3 VVAFAPNFSVFVIFRFLQGVFGKGAWMTCFVIVTEIVGSKQRRIVGIVIQMFFTLGIIILPGIAYFTPSWQGIQLAISLPSFLFLLYYWVVPESPRWLIT
rat    OCT3 VVAFAPNFSVFVIFRFLQGVFGKGAWMTCFVIVTEIVGSKQRRIVGIVIQMFFTLGIIILPGIAYFTPSWQGIQLAISLPSFLFLLYYWVVPESPRWLIT
310 320 330 340 350 360 370 380 390 400
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
human  OCT1 QKRNTEAIKIMDHIAQKNGKLPPADLKMLSLEEDVTEKLSPSFADLFRTPRLRKRTFILMYLWFTDSVLYQGLILHMGATSGNLYLDFLYSALVEIPGAF
rabbit OCT1 QKRNTDAVKIMDNIAQKNGKLPPADLKMLSLDEDVTEKLSPSLADLFRTPNLRKHTFILMFLWFTCSVLYQGLILHMGATGGNVYLDFFYSSLVEFPAAF
mouse  OCT1 QKRTTQAVRIMEQIAQKNRKVPPADLKMMCLEEDASERRSPSFADLFRTPSLRKHTLILMYLWFSCAVLYQGLIMHVGATGANLYLDFFYSSLVEFPAAF
rat    OCT1 QKRTTRAVRIMEQIAQKNGKVPPADLKMLCLEEDASEKRSPSFADLFRTPNLRKHTVILMYLWFSCAVLYQGLIMHVGATGANLYLDFFYSSLVEFPAAF
human  OCT2 QNKNAEAMRIIKHIAKKNGKSLPASLQRLRLEEETGKKLNPSFLDLVRTPQIRKHTMILMYNWFTSSVLYQGLIMHMGLAGDNIYLDFFYSALVEFPAAF
rabbit OCT2 QNKNAKAMRIMEHIAKKNGKSLPVSLQSLRAAEDVGEKLNPSFLDLVRTPQIRKHTCILMYNWFTSSVLYQGLIMHLGLAGGDIYLDFFYSALVEFPAAF
mouse  OCT2 QNKNAKAMKIIKHIAKKNGKSVPVSLQSLTADEDTGMKLNPSFLDLVRTPQIRKHTLILMYNWFTSSVLYQGLIMHMGLAGDNIYLDFFYSALVEFPAAF
rat    OCT2 QNKIVKAMKIIKHIAKKNGKSVPVSLQNLTPDEDAGKKLKPSILDLVRTPQIRKHTLILMYNWFTSSVLYQGLIMHMGLAGDNIYLDFFYSALVEFPAAF
human  OCT3 RKKGDKALQILRRIAKCNGKYLSSNYSEITVTDEEVS--NPSFLDLVRTPQMRKCTLILMFAWFTSAVVYQGLVMRLGIIGGNLYIDFFISGVVELPGAL
rabbit OCT3 RKEGDEALKILRKIAKCNGKYLSPNYSEITVTDEEVS--NPSFLDLVRTPQMRKCTLILMFAWFTSAVVYQGLVMRLGIIGGNLYIDFFISGVVELPGAL
mouse  OCT3 RKQGEKALQILRRVAKCNGKHLSSNYSEITVTDEEVS--NPSCLDLVRTPQMRKCTLILMFAWFTSAVVYQGLVMRLGLIGGNLYIDFFISGLVELPGAL
rat    OCT3 RKQGEKALQILRRVAKCNGKHLSSNYSEITVTDEEVS--NPSCLDLVRTPQMRKCTLILMFAWFTSAVVYQGLVMRLGLIGGNLYMDFFISGLVELPGAL
410 420 430 440 450 460 470 480 490 500
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
human  OCT1 IALITIDRVGRIYPMAMSNLLAGAACLVMIFISPDLHWLNIIIMCVGRMGITIAIQMICLVNAELYPTFVRNLGVMVCSSLCDIGGIITPFIVFRLREVW
rabbit OCT1 VILVTIDRVGRIYPMAASNLAAGVASVILIFVPQDLHWLTIVLSCVGRMGATIVLQMICLVNAELYPTFVRNLGVMVCSALCDVGGIITPFMVFRLMEVW
mouse  OCT1 IILVTIDRIGRIYPIAASNLVAGAACLLMIFIPHELHWLNVTLACLGRMGATIVLQMVCLVNAELYPTFIRNLGMMVCSALCDLGGIFTPFMVFRLMEVW
rat    OCT1 IILVTIDRIGRIYPIAASNLVTGAACLLMIFIPHELHWLNVTLACLGRMGATIVLQMVCLVNAELYPTFIRNLGMMVCSALCDLGGIFTPFMVFRLMEVW
human  OCT2 MIILTIDRIGRRYPWAASNMVAGAACLASVFIPGDLQWLKIIISCLGRMGITMAYEIVCLVNAELYPTFIRNLGVHICSSMCDIGGIITPFLVYRLTNIW
rabbit OCT2 LIIATIDRVGRRYPWAVSNMVAGAACLASVFVPDDLQGLRITVACLGRMGITMAYEMVCLVNAELYPTFIRNLGVLVCSSLCDVGGIVTPFLVYRLTAIW
mouse  OCT2 IIILTIDRIGRRYPWAVSNMVAGAACLASVFIPDDLQWLKITVACLGRMGITIAYEMVCLVNAELYPTYIRNLAVLVCSSMCDIGGIVTPFLVYRLTDIW
rat    OCT2 IIILTIDRVGRRYPWAVSNMVAGAACLASVFIPDDLQWLKITIACLGRMGITMAYEMVCLVNAELYPTYIRNLGVLVCSSMCDIGGIITPFLVYRLTDIW
human  OCT3 LILLTIERLGRRLPFAASNIVAGVACLVTAFLPEGIAWLRTTVATLGRLGITMAFEIVYLVNSELYPTTLRNFGVSLCSGLCDFGGIIAPFLLFRLAAVW
rabbit OCT3 LILLTIERLGRRLPFAASNMMAGVACLVTAFLPEGVPWLRTTVATLGRLGITMAFEIVYLVNSELYPTTLRNFGVSLCSGLCDFGGIIAPFLLFRLAAVW
mouse  OCT3 LILLTIERLGRRLPFAASNIVAGVSCLVTAFLPEGIPWLRTTVATLGRLGITMAFEIVYLVNSELYPTTLRNFGVSLCSGLCDFGGIIAPFLLFRLAAIW
rat    OCT3 LILLTIERLGRRLPFAASNIVAGVSCLVTAFLPEGIPWLRTTVATLGRLGITMAFEIVYLVNSELYPTTLRNFGVSLCSGLCDFGGIIAPFLLFRLAAIW
510 520 530 540 550 560 570 580 590 600
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
human  OCT1 QALPLILFAVLGLLAAGVTLLLPETKGVALPETMKDAENL-GRKAKPKE--------NTIYLKVQTSE----------------PSGT------------
rabbit OCT1 QPLPLIVFGVLGLLAGGMTLLLPETKGVALPETIEDAENL-RRKAKPKE--------SKIYLQVQTSE----------------LKGP------------
mouse  OCT1 QALPLILFGVLGLSAGAVTLLLPETKGVALPETIEEAENLGRRKSKAKE--------NTIYLQVQTGK----------------SPHT------------
rat    OCT1 QALPLILFGVLGLTAGAMTLLLPETKGVALPETIEEAENLGRRKSKAKE--------NTIYLQVQTGK----------------SSST------------
human  OCT2 LELPLMVFGVLGLVAGGLVLLLPETKGKALPETIEEAENMQRPRKNKEK---------MIYLQVQKLD----------------IPLN------------
rabbit OCT2 LQLPLVVFAVVGLVAGGLVLMLPETKGRTLPETIEEAENLQRPRKNREK---------VIYVHVRKAD----------------GPLT------------
mouse  OCT2 LEFPLVVFAVVGLVAGGLVLLLPETKGKALPETIEDAEKMQRPRKKKEK---------RIYLQVKK------------------AELS------------
rat    OCT2 MEFPLVVFAVVGLVAGALVLLLPETKGKALPETIEDAENMQRPRKKERKENLPPSQASRPSAKLKRKGIIAAGADFALSEARDGASLSPPPKPTQTNLTY
human  OCT3 LELPLIIFGILASICGGLVMLLPETKGIALPETVDDVEKLGSPHSCKCG--------RNKKTPVSRSHL-------------------------------
rabbit OCT3 LELPLIIFGVLASVCGGLVMLLPETKGIALPETVDDVENLGSPHSFRCR--------RKKKSPVCSSHL-------------------------------
mouse  OCT3 LELPLIIFGILASVCGGLVMLLPETKGIALPETVEDVEKLGSSQLHQCG--------RKKKTQVSTSDV-------------------------------
rat    OCT3 LELPLIIFGILASVCGGLVMLLPETKGIALPETVEDVEKLGSSQLHQCG--------RKKKTQVSTSNV-------------------------------
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1.8.1. Organic Cation Transporters 
1.8.1.1. Structure 
Members of the OCT family are highly conserved among species and generally 550-
560 amino acids in length and share common structural features, including a 
characteristic membrane topology, depicted in Figures 1.1 and 1.2, of 12 putative 
transmembrane spanning α-helices (TMHs), intracellular COOH and NH2 termini, an 
intracellular loop with phosphorylation sites between the sixth and the seventh 
TMHs and a large extracellular loop between the first and second TMHs containing 
glycosylation sites (Burckhardt and Wolff, 2000, Ciarimboli, 2008, Koepsell et al., 
2007). 
 
Figure 1.2 - Predicted membrane topology of OCTs as represented by human OCT1 
(Shu et al., 2003). 
1.8.1.2. Substrate Specificity 
OCTs are defined as polyspecific transporters and function as uniporters that play a 
role in facilitated diffusion in either direction and are involved in translocation of 
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organic cations, endogenous amines, therapeutic drugs and cationic xenobiotics with 
different molecular structures (Tables 1.1-1.3 and Figures 1.3 & 1.4) (Jonker and 
Schinkel, 2004, Koepsell et al., 2007). There is extensive overlap of substrate and 
inhibitor specificities among hOCT1-3 from different species. Oct1/hOCT1 
orthologs from four species (rat, mouse, rabbit, and human) all transport 
tetraethylammonium. However, the affinity and transport rates differ between the 
four species. Oct1/hOCT1 substrates (Table 1.1) include pharmaceuticals such as the 
antidiabetic drug metformin (Kimura et al., 2005a, Wang et al., 2002), the antiviral 
drugs acyclovir and zalcitabine (Jung et al., 2008, Takeda et al., 2002), the 
antineoplastic cisplatin (Ciarimboli et al., 2005b, Ciarimboli et al., 2010), the N-
methyl-D-aspartate-receptor antagonist memantine, and the histamine H2-receptor 
antagonist ranitidine. In addition, OCTs are also responsible for the transport of 
biogenic amine neurotransmitters (Table 1.2 and Figure 1.3) such as dopamine, 
epinephrine, norepinephrine, and histamine (Klaassen and Aleksunes, 2010). 
 
Figure 1.3 - Chemical structures of 4 platinum agents which are substrates of 
hOCTs and hMATEs (Yokoo et al., 2007). 
 
17 
 
 
 
 
 
CHAPTER 1 
Table 1.1 - Selected drugs transported by hOCTs and hMATEs. 
Drug Category Typical Drug Pharmacological Action References 
    
Anthraquinones Mitoxantrone Antineoplastic (Koepsell et al., 2007) 
Aromatic diamidines Furamidine Anti-parasitic (Ming et al., 2009) 
Biguanides Metformin Antidiabetic (Shikata et al., 2007, Takane et al., 2008) 
Camptothecin analogs Irinotecan Antineoplastic (Gupta et al., 2012) 
Cationic steroids Rocuronium Neuromuscular blocking (Van Montfoort et al., 2001) 
Dopamine agonists Pramipexole Anti-Parkinsonian (Diao et al., 2010) 
Dopamine antagonists Sulpiride Antidepressant (Koepsell et al., 2007) 
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Table 1.1 Continued - Selected drugs transported by hOCTs and hMATEs. 
    
Fluoroquinolones Ciprofloxacin Antimicrobials (Ciarimboli et al., 2013) 
Histamine Antagonists Cimetidine Antigastric ulcers (Tahara et al., 2005, Zhang et al., 1998) 
NMDA receptor antagonists Memantine Anti-Parkinsonian (Amphoux et al., 2006) 
Nucleoside analogs Lamividine Antivirals (Jung et al., 2008, Takeda et al., 2002) 
Opioids O-Desmethyltramadol Analgesic (Tzvetkov et al., 2011) 
Psychostimulant D-Amphetamine  (Amphoux et al., 2006) 
Tyrosine kinase inhibitor Imatinib Antineoplastic (Herraez et al., 2013, Schmidt-Lauber et al., 2012, Thomas et al., 2004) 
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Table 1.2 - Endogenous compounds transported by hOCTs and hMATEs. 
Category Compound References 
   
Biogenic monoamines Histamine (Amphoux et al., 2006, Busch et al., 1998, Koepsell et al., 2007) Serotonin 
   
Biogenic polyamines 
Agmatine 
(Gründemann et al., 2003, Sala-Rabanal et al., 2013) Putrescine 
Spermidine 
   
Cathecolamines 
Dopamine 
(Amphoux et al., 2006) Epinephrine 
Norepinephrine 
   
Ethanolamines Choline (Koepsell et al., 2007) 
   
Prostaglandins Prostaglandin E2 (Kimura et al., 2002) Prostaglandin F2α 
   
Vitamins N-methylnicotinamide (Chen et al., 2014, Gorboulev et al., 1997, Lemos et al., 2012) Thiamine 
   
Other metabolites Creatinine (Masuda et al., 2006) L-carnitine 
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Table 1.3 - Xenobiotics transported by OCTs and MATEs in vitro. 
Category Xenobiotic Reference 
   
Quaternary ammonium 
compounds Tetraethylammonium (Iwai et al., 2009, Zhang et al., 1998) 
   
Herbicides Paraquat (Chen et al., 2007) 
   
Neurotoxins 
1-Methyl-4-phenylpyridinium (MPP+) 
(Gorboulev et al., 1997, Yang et al., 2001) 
1-Methyl-4-phenyl-tetrahydropyridine (MPTP) 
   
Alkaloids 
APD-ajmalinium 
(Kim and Shim, 2006, Nies et al., 2008, Van Montfoort 
et al., 2001) Berberine 
Nicotine 
   
Fluorescent Dyes 
4′,6-diamidino-2-phenylindole (DAPI) 
(Ahlin et al., 2008, Bednarczyk et al., 2000, Kim and 
Shim, 2006, Lee et al., 2009, Mehrens et al., 2000, 
Yasujima et al., 2011) 
4-(4-(dimethylamino)-styryl)-N-methylpyridinium (ASP) 
[2-(4-nitro-2,1,3-benzooxadiazole-7-yl)aminoethyl]trimethylammonium 
Ethidium 
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1.8.1.3. Tissue Distribution and Localization 
The tissue distribution of the OCT subgroup is quite distinctive, with hOCT1 being 
primarily expressed in the basolateral or sinusoidal membrane of hepatocytes and 
also being present in the epithelial membrane of the intestine at low levels 
(Gorboulev et al., 1997, Zhang et al., 1997). Thus, hOCT1 is thought to play a 
fundamental role in the uptake of substrates into the hepatocytes. On the other hand, 
hOCT2 is predominantly expressed at the basolateral membrane of the proximal 
renal tubules and facilitates uptake of substrates from the circulation into renal 
epithelial cells (Gorboulev et al., 1997, Motohashi et al., 2002). hOCT3, on the other 
hand, shows a widespread tissue distribution, including the brain, heart, skeletal 
muscle, blood vessels, placenta, and liver (Koepsell et al., 2007). 
 
Figure 1.4 - Chemical structures of selected bio-amine substrates of hOCTs (Chen et 
al., 2010a). 
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1.8.1.4. Expression and Regulation of OCTs 
The regulation of OCTs has great physiological and even clinical importance 
because they can ultimately change the mRNA or protein levels of OCTs, and as a 
result, alter the absorption, secretion and tissue distribution of endogenous 
metabolites, drugs, and xenobiotics (Choi and Song, 2008, Ciarimboli et al., 2005a). 
These regulatory mechanisms are important because stimulation of OCT expression 
can accelerate detoxification, whereas inhibition can prolong exposure of the body to 
dangerous substances. However, the regulation of OCTS is complex and may occur 
at the transcription, message stability, translation, and various posttranslational 
modification levels (Koepsell et al., 2007). 
 
Figure 1.5 - Schematic representation of transcriptional and post-translational 
regulation of hOCT1 (A) and hOCT2 (B) (Choi and Song, 2008). 
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1.8.1.4.1. Short-Term Regulation 
Mechanisms of post-translational activation of hOCT1 by its phosphorylation status 
have been proposed (Ciarimboli et al., 2004, Ciarimboli and Schlatter, 2005).  There 
are multiple potential phosphorylation sites that are conserved among OCTs, which 
provide target sequences for functional regulation by kinases and phosphatases. 
hOCT1 and hOCT2 share common regulatory mechanisms involving protein kinase 
A (PKA) and calmodulin (CAM). hOCT1 is activated by Src-like p53lck tyrosine 
kinase (Ciarimboli et al., 2004). However, PKC activation decreases the affinity of 
hOCT1 for prototypical substrates (Ciarimboli and Schlatter, 2005). Expression 
levels of hOCT1 were unchanged by a PKA activator, whereas OCT2 was down-
regulated by the PKC activator 1,2-diocanoyl-sn-glycerol (DOG). 
Çetinkaya et al. (2003) demonstrated that hOCT2 is inhibited by PKA and 
phosphatidylinositol 3-kinase (PI3K) and activated by a CAM-dependent signalling 
pathway, probably through a change in substrate affinity (Cetinkaya et al., 2003). 
Furthermore, in a subsequent study Biermann et al. (2006) showed that inhibition of 
the Ca2+/CAM complex by calmidazolium causes changes in transport capacity due 
to reduced hOCT2 trafficking/localization to the plasma membrane (Biermann et al., 
2006). 
1.8.1.4.2. Long-Term Regulation 
Transcription factors may be responsible for the constitutive expression of SLC22A1. 
In a study by Saborowski et al. (2006) it was demonstrated that transcriptional 
activation of SLC22A1 can be mediated by the binding of  hepatocyte nuclear factor 
4α (HNF-4α) to DNA response elements (DR-2) adjacent to the gene and suppressed 
by bile acids via the bile acid-inducible transcriptional repressor, small heterodimer 
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partner (SHP) (Saborowski et al., 2006). Furthermore, Rulcova et al. (2013) in a 
recent study showed that SLC22A1 expression is indirectly induced by 
glucocorticoid activation through the upregulation of HNF4-α in primary 
hepatocytes (Rulcova et al., 2013). Moreover, Asaka et al. (2007) demonstrated that 
basal transcription of SLC22A2 was stimulated by binding of the ubiquitously 
expressed and constitutively active upstream stimulating factor (USF) 1 to the 
proximal promoter region (Asaka et al., 2007). In a recent study O’Brien et al 
showed through electrophoretic mobility shift and chromatin immunoprecipitation 
assays that the expression of hOCT1 is regulated by HNF1 through binding to an 
evolutionary conserved region in intron 1 of SLC22A1 (O’Brien et al., 
2013).Epigenetic gene silencing may also provide a mechanism of organic cation 
transporter gene regulation. Recent studies have shown that DNA methylation of 
SLC22A1 in hepatocellular carcinoma (HCC) (Schaeffeler et al., 2011) and SLC22A3 
in prostate cancer (Chen et al., 2013) is associated with reduced expression of these 
genes. 
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Figure 1.6 - Multiple protein sequence alignment of MATE protein sequences from 
four different animal species. 
  
10 20 30 40 50 60 70 80 90 100
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
human  MATE1 MEAPEE-PAPVRGGPEATLEVRGS-RCLRL-------SAFREELRALLVLAGPAFLVQLMVFLISFISSVFCGHLGKLELDAVTLAIAVINVTGVSVGFG
rabbit MATE1 MEAPVE-LGP--GGRQASPERRHWLRCLVL-------SDFREELRALLVLACPAFLAQLMVFLISFVSSVFCGHLSKLELNAVTLAIAVINVMGVSVGFG
mouse  MATE1 MERTEE-SAPGPGGADAASERRGL-RCLLL-------PGFLEELRALLVLAGPAFLAQLMMFLISFISSVFCGHLGKLELDAVTLAIAVINVTGISVGHG
rat    MATE1 MEVLEE-PAPGPGGADAA-ERRGL-RRLLL-------SGFQEELRALLVLAGPAFLAQLMMFLISFISSVFCGHLGKLELDAVTLAIAVINVTGISVGHG
human  MATE2 isoform 1 MDSLQDTVALDHGGCCPALSRLVP-------------RGFGTEMWTLFALSGPLFLFQVLTFMIYIVSTVFCGHLGKVELASVTLAVAFVNVCGVSVGVG
human  MATE2 isoform 3 MDSLQDTVALDHGGCCPALSRLVP-------------RGFGTEMWTLFALSGPLFLFQVLTFMIYIVSTVFCGHLGKVELASVTLAVAFVNVCGVSVGVG
human  MATE2 isoform 2 MDSLQDTVALDHGGCCPALSRLVP-------------RGFGTEMWTLFALSGPLFLFQVLTFMIYIVSTVFCGHLGKVELASVTLAVAFVNVCGVSVGVG
rabbit MATE2 MDSQQDVVNLDQGGCCPALRKLLP-------------RGFWDEARALFVLSGPLFLFQVLNFLTYVVGTVFCGHLGKVELASVTLGVAFVNVCGVSVGAG
mouse  MATE2 MEPAEDSLGATIQPPELVRVPRGRSLRILLGLRGALSPDVRREAAALVALAGPVFLAQLMIFLISIVSSIFCGHLGKVELDAVTLAVSVVNVTGISVGTG
110 120 130 140 150 160 170 180 190 200
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
human  MATE1 LSSACDTLISQTYGSQNLKHVGVILQRSALVLLLCCFPCWALFLNTQHILLLFRQDPDVSRLTQTYVTIFIPALPATFLYMLQVKYLLNQ----------
rabbit MATE1 LSSACDTLISQTYGSRNLKHVGVILQRGSLILLLCCLPCWALFLNTQHILLLFRQDPAVSRLTQTYVTIFIPALPATFLYTLQVKYLLNQ----------
mouse  MATE1 LSSACDTLISQTYGSQNLKHVGVILQRGTLILLLCCFPCWALFINTEQILLLFRQDPDVSRLTQTYVMIFIPALPAAFLYTLQVKYLLNQ----------
rat    MATE1 LSSACDTLISQTYGSQNLKHVGVILQRGTLILLLCCFPCWALFINTEQILLLFRQDPDVSRLTQTYVMVFIPALPAAFLYTLQVKYLLNQ----------
human  MATE2 isoform 1 LSSACDTLMSQSFGSPNKKHVGVILQRGALVLLLCCLPCWALFLNTQHILLLFRQDPDVSRLTQDYVMIFIPGLPVIFLYNLLAKYLQNQGWLKGQEEES
human  MATE2 isoform 3 LSSACDTLMSQSFGSPNKKHVGVILQRGALVLLLCCLPCWALFLNTQHILLLFRQDPDVSRLTQDYVMIFIPGLPVIFLYNLLAKYLQNQ----------
human  MATE2 isoform 2 LSSACDTLMSQSFGSPNKKHVGVILQRGALVLLLCCLPCWALFLNTQHILLLFRQDPDVSRLTQDYVMIFIPGLPVIFLYNLLAKYLQNQ----------
rabbit MATE2 LSSACDTLMSQSFGSPNKKHVGVILQRGSLILLLCCLPCWALFLNTQHILLLFRQDPAVSRLTQDYAMIFIPGLPAIFLYSLLAKYLQNQ----------
mouse  MATE2 LASACDTLMSQSFGGKNLKRVGVILQRGILILLLCCFPCWAIFLNTERLLLLLRQDPDVARLAQVYVMICIPALPAAFLFQLQTRYLQSQ----------
210 220 230 240 250 260 270 280 290 300
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
human  MATE1 --------------------------GIVLPQIVTGVAANLVNALANYLFLHQLHLGVIGSALANLISQYTLALLLFLYILGKKLHQATWGGWSLECLQD
rabbit MATE1 --------------------------GIVLPQVVTGVAANLVNALANYLFVYQLHLGVMGSALANTVAQFTLALLLFLYILRSKVYQATWGGWSLECLQD
mouse  MATE1 --------------------------GIVLPQIMTGIAANLVNALANYVFLYHLHLGVMGSALANTISQFALAIFLFLYILWRRLHQATWGGWSWECLQD
rat    MATE1 --------------------------GIVLPQVITGIAANLVNALANYLFLHQLHLGVMGSALANTISQFALAIFLFLYILWRKLHHATWGGWSWECLQD
human  MATE2 isoform 1 PFQTPGLSILHPSHSHLSRASFHLFQKITWPQVLSGVVGNCVNGVANYALVSVLNLGVRGSAYANIISQFAQTVFLLLYIVLKKLHLETWAGWSSQCLQD
human  MATE2 isoform 3 --------------------------KITWPQVLSGVVGNCVNGVANYALVSVLNLGVRGSAYANIISQFAQTVFLLLYIVLKKLHLETWAGWSSQCLQD
human  MATE2 isoform 2 --------------------------KITWPQVLSGVVGNCVNGVANYALVSVLNLGVRGSAYANIISQFAQTVFLLLYIVLKKLHLETWAGWSSQCLQD
rabbit MATE2 --------------------------GIVWPQVLSGVVGNCVNGVANYALVSVLNLGVRGSAYANTISQFVQAAFLFLHIVLKKLHLETWEGWSSQCLRD
mouse  MATE2 --------------------------GIIMPQVIVGIAANVVNVGMNAFLLYALDLGVVGSAWANTTSQFFLSALLFLYVWWKRIHIHTWGGWTRECFQE
310 320 330 340 350 360 370 380 390 400
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
human  MATE1 WASFLRLAIPSMLMLCMEWWAYEVGSFLSGILGMVELGAQSIVYELAIIVYM--------------VPAGFSVAASVRVGNALGAGDMEQARKSSTVSLL
rabbit MATE1 WASFFRLAIPSMLMLCMEWWAYEIGSFLSGILGMVELGAQSVTYELAVIVYM--------------IPMGLSVAVNVRVGNALGAGNIEQAKKSSAVALL
mouse  MATE1 WASFLRLAIPSMLMLCIEWWAYEVGSFLSGILGMVELGAQSITYELAIIVYM--------------IPSGFSVAANVRVGNALGAGNIDQAKKSSAISLI
rat    MATE1 WASFLQLAIPSMLMLCIEWWAYEVGSFLSGILGMVELGAQSITYELAIIVYM--------------IPAGFSVAANVRVGNALGAGNIDQAKKSSAISLI
human  MATE2 isoform 1 WGPFFSLAVPSMLMICVEWWAYEIGSFLMGLLSVVDLSAQAVIYEVATVTYM--------------IPLGLSIGVCVRVGMALGAADTVQAKRSAVSGVL
human  MATE2 isoform 3 WGPFFSLAVPSMLMICVEWWAYEIGSFLMGLLSVVDLSAQAVIYEVATVTYMRHSHRLAYAAHVTRIPLGLSIGVCVRVGMALGAADTVQAKRSAVSGVL
human  MATE2 isoform 2 WGPFFSLAVPSMLMICVEWWAYEIGSFLMGLLSVVDLSAQAVIYEVATVTYM--------------IPLGLSIGVCVRVGMALGAADTVQAKRSAVSGVL
rabbit MATE2 WGPFLSLAIPSMLMMCVEWWAYEIGSFLMGLLGVVDLSGQAIIYEVATVVYM--------------IPMGLGMAVCVRVGTALGAADTLQAKRSAVSGLL
mouse  MATE2 WSSYTRLAIPSMFMVCIEWWTFEIGTFLAGLVNVTELGAQAVIYELASVAYM--------------VPFGFGVAASVRVGNALGAGNADQARCSCTTVLL
410 420 430 440 450 460 470 480 490 500
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
human  MATE1 ITVLFAVAFSVLLLSCKDHVGYIFTTDRDIINLVAQVVPIYAVSHLFEALACTSGGVLRGSGNQKVGAIVNTIGYYVVGLPIGIALMFATTLGVMGLWSG
rabbit MATE1 VTELIAVVFCVMLLSCKDLVGYIFTSDRDIIALVAQVTPIYAVSHLFESLAGTSGGILRGSGNQKFGAIVNAIGYYVVGLPIGIALMFAAKLGVIGLWLG
mouse  MATE1 VTELFAVTFCVLLLGCKDLVGYIFTTDRDIVALVAQVIPIYAVSHLFEGLACTCGGILRGTGNQKVGAIVNAIGYYVIGLPIGIALMFAAKLGVIGLWSG
rat    MATE1 VTELFAVTFCVLLLGCKDLVGYIFTTDWDIVALVAQVVPIYAVSHLFEALACTCGGVLRGTGNQKVGAIVNAIGYYVIGLPIGISLMFVAKLGVIGLWSG
human  MATE2 isoform 1 SIVGISLVLGTLISILKNQLGHIFTNDEDVIALVSQVLPVYSVFHVFEAICCVYGGVLRGTGKQAFGAAVNAITYYIIGLPLGILLTFVVRMRIMGLWLG
human  MATE2 isoform 3 SIVGISLVLGTLISILKNQLGHIFTNDEDVIALVSQVLPVYSVFHVFEAICCVYGGVLRGTGKQAFGAAVNAITYYIIGLPLGILLTFVVRMRIMGLWLG
human  MATE2 isoform 2 SIVGISLVLGTLISILKNQLGHIFTNDEDVIALVSQVLPVYSVFHVFEAICCVYGGVLRGTGKQAFGAAVNAITYYIIGLPLGILLTFVVRMRIMGLWLG
rabbit MATE2 CTAGTSLVVGTLLGLLNSQLGYIFTSDEEVIALVNQVLPIYIVFQLVEAVCCVFGGVLRGTGKQAFGAIVNAIMYYIVGLPLGIVLTFVVGMRIMGLWLG
mouse  MATE2 CAGVCALLVGILLAALKDVVAYIFTNDKDIISLVSQVMPIFAPFHLFDALAGTCGGVLRGTGKQKIGAVLNTIGYYGFGFPIGVSLMFAAKLGIIGLWAG
510 520 530 540 550 560 570 580 590 600
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
human  MATE1 IIICTVFQAVCFLGFIIQLNWKKACQQAQVHANLKVNNV-------PRSGNSALPQDPLHPGCP-ENLEGILTNDVGKTGEPQSDQQMRQEEPLPEHPQD
rabbit MATE1 IVVCAVSQAVCFLGFIARLNWTKACQQARVHANLTVN-T-------ASNGNSAVLPDQPHPVGP-DSHGGIVLRDADRKEGAELNEQVHPELPLPVRPED
mouse  MATE1 IIICTTCQTTCFLAFIARLNWKRACQQAQVHANLKVN----------VALNSAVSHEPAHPVCP-ESHGEIMMTDLEKKDETQLDQPMNQQQALPIRPKD
rat    MATE1 IIICSVCQTSCFLVFIARLNWKLACQQAQVHANLKVN----------VALNSAVSQEPAHPVGP-ESHGEIMMTDLEKKDEIQLDQQMNQQQALPVHPKD
human  MATE2 isoform 1 MLACVFLATAAFVAYTARLDWKLAAEEAKKHSGRQQQQR------AESTATRPGPEKAVLSSVATGSSPGITLTTYSRS-ECHVDFFRTPEEAHALSAPT
human  MATE2 isoform 3 MLACVFLATAAFVAYTARLDWKLAAEEAKKHSGRQQQQR------AESTATRPGPEKAVLSSVATGSSPGITLTTYSRS-ECHVDFFRTPEEAHALSAPT
human  MATE2 isoform 2 MLACVFLATAAFVAYTARLDWKLAAEEAKKHSGRQQQQR------AESTATRPGPEKAVLSSVATGSSPGITLTTYSRS-ECHVDFFRTPEEAHALSAPT
rabbit MATE2 MLTCIFLAAVTFVVYAVQLDWKLAAEEAQKHAGLQQQQQQQQQQGAECTAPSPGPDKAVVSSVATGCNPGIALTMYSRP-GCHVDFYGRPEAAPAPAAPA
mouse  MATE2 LIVCVSFQAFSYLIYILRTNWSRVAEQAQVRAGLKST-------------KELIPTPADLPILEREVMDGVILPDIIRP-ESQTGQLVVEENSQCAVPTV
610 620 630
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . .
human  MATE1 GAKLSRKQLVLRRGLLLLGVFLILLVGILVRFYVRIQ
rabbit MATE1 SAHLSGKQLALRRGLLLLGVILVLLAGILVKVYVRTQ
mouse  MATE1 SNKLSGKQLALRRGLLLLGVVLVLVGGILVRVYIRIE
rat    MATE1 SNKLSGKQLALRRGLLFLGVVLVLVGGILVRVYIRTE
human  MATE2 isoform 1 S-RLSVKQLVIRRGAALGAASATLMVGLTVRILATRH
human  MATE2 isoform 3 S-RLSVKQLVIRRGAALGAASATLMVGLTVRILATRH
human  MATE2 isoform 2 S-RLSVKQLVIRRGAALGAASATLMVGLTVRILATRH
rabbit MATE2 S-RLSVRQLLFRRGAALAASVAVLMAGLLVRVLTTGY
mouse  MATE2 GEVLTGRQLVFYRGMALTVSVAVLIAGIVVRVFNDRG
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1.8.2. Multidrug and Toxin Extrusion 1 (MATE-1) 
1.8.2.1. Structure 
hMATE1 and the kidney-specific hMATE2-K are orthologs of the multidrug and 
toxin extrusion (MATE) family of bacteria. hMATE1 is encoded by the SLC47A1 
gene located at 17p11.2 with gene organization as depicted in Figure 1.7 (Otsuka et 
al., 2005, Terada and Inui, 2008). MATEs are highly conserved among species as 
shown in Figure 1.6 with human, mouse, rat, and rabbit MATE1 being 570, 532, 
566, and 568 amino acid residues in length, respectively (Otsuka et al., 2005, Terada 
et al., 2006). While the prokaryotic, fungal, and plant MATE family members share 
a predicted membrane topology of 12 TMHs, Zhang and Wright’s study has shown 
that hMATE1and hMATE2-K appear to have an additional COOH-terminal helix 
(Zhang and Wright, 2009). 
Initial studies using rat renal brush-border membranes vesicles have indicated that 
cysteine and histidine residues are critical for H+/organic cation antiporter activity 
(Hori et al., 1987, Hori et al., 1989). Subsequently, Matsumoto et al. (2009) showed 
that when the conserved Glu-273, Glu-278, Glu-300, and Glu-389 residues of 
hMATE1 were substituted with alanine or aspartate transport activity was reduced, 
suggesting an important role in the transport function of the MATE family 
(Matsumoto et al., 2008). 
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Figure 1.7 - A schematic representation of the gene organization and the primary 
protein structure of human (A) SLC47A1 (hMATE1) and (B) SLC47A2 (hMATE2-
K). The diagram depicts exons (numbered 1-17) and introns of both genes together 
with the arrangement of transmembrane helices (TMHs) (numbered 1-13) of 
encoded proteins (Staud et al., 2013). 
1.8.2.2. Tissue Distribution, Membrane Localization and Substrate 
Specificity 
hMATE1 is predominantly expressed at the luminal membranes of the renal 
proximal tubules (kidney) and the bile canaliculi (liver) and mediates the secretion of 
organic cations by using an oppositely directed H+ gradient as a driving force 
(Masuda et al., 2006, Otsuka et al., 2005, Tsuda et al., 2009b). On the hand, 
28 
 
 
 
 
 
CHAPTER 1 
hMATE2-K is primarily expressed in the brush-border membrane of renal proximal 
tubules (Masuda et al., 2006). 
hMATE1 and hMATE2-K mediates the H+-coupled electroneutral exchange of 
tetraethylammonium (TEA) and 1-methyl-4-phenylpyridinium (MMP+), two 
prototypical organic cation substrates of renal and hepatic H+-coupled organic cation 
antiporters (Koepsell et al., 2007, Tanihara et al., 2007). In addition, MATEs are 
also involved in the transport of clinically important drugs such as metformin, 
cimetidine, and procainamide (Tanihara et al., 2007). Km values of cationic drugs for 
hMATE1 and hMATE2-K are similar and higher than the plasma concentrations in 
clinical use. As a key element in the renal (and hepatic) secretion of cationic drugs, 
the human MATEs are likely targets for unwanted drug-drug interactions, as well as 
principal arbiters of the pharmacodynamics and pharmacokinetics of many clinically 
important agents (Zhang et al., 2012). Although MATEs recognize substrates similar 
to the OCT family, MATEs can transport zwitterions and anionic compounds in 
addition to cationic drugs.  In spite of having overlapping substrate spectra, MATE1 
and MATE2-K do differ in substrate specificity and affinity. 
1.8.2.3. Regulation of MATEs 
In contrast to OCTs, little information is available on the regulation of MATEs. The 
proximal promoter region of human, murine, and rat SLC47A1 genes lacked a 
canonical TATA-box but contained two conserved Sp1-binding consensus 
sequences. Moreover, disruption of Sp1 binding through mutagenesis affected 
hMATE1 activity that lead to an approximate 50% reduction relative to the control. 
In a study by Lickteig et al (2008) the pharmacological induction of MATEs in the 
liver by the activation of known transcription factors was investigated (Lickteig et 
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al., 2008). Their study suggested that none of Aryl hydrocarbon receptor (AhR), 
constitutive androstane receptor (CAR), pregnane x receptor (PXR), peroxisome 
proliferator-activated receptor α (PPARα), and NF-E2-related factor 2 (NrF2) were 
able to alter hMATE1 or hMATE2 function. 
1.9. Clinical association between OCT and MATE variant alleles and drug 
disposition, response and toxicity 
1.9.1. Metformin and type-2 diabetes 
Metformin is a biguanide organic cationic (pKa 12.4) drug that is routinely 
prescribed as the preferred first-line therapeutic drug in the treatment of type-2 
diabetes mellitus (Kirpichnikov et al., 2002, Nathan et al., 2009). It improves insulin 
sensitivity and thus decreases the insulin resistance that is prevalent in type-2 
diabetes mellitus. Metformin is not metabolized and is excreted unchanged by active 
tubular secretion and glomerular filtration into the urine. 
Although, the exact mechanistic pathway for metformin action is currently only 
partially understood, it is widely believed to activate adenosine monophosphate 
(AMP)-activated protein kinase (AMPK) by inhibition of the mitochondrial 
respiratory chain (Owen et al., 2000, Zhou et al., 2001). Moreover, this activation of 
AMPK by metformin requires the phosphorylation of AMPK by a serine-threonine 
kinase, LKB1 (Shaw et al., 2005). This results in an increase in cellular AMP levels 
which in turn lead to insulin suppression of glucose production via gluconeogenesis 
and increased peripheral glucose uptake (Hawley et al., 2010, Hundal et al., 2000, 
Zhou et al., 2001). However, evidence exists which suggests that metformin also 
exerts its metabolic effects via AMPK-independent mechanisms. 
30 
 
 
 
 
 
CHAPTER 1 
In addition to its favorable effect on hyperglycemia, metformin also has other 
beneficial effects. Firstly, metformin is able to exert its glucose-lowering actions 
with a low risk of hypoglyceamia. Secondly, it reduces the likelihood of developing 
macrovascular (hypertension and atheroscelorosis) and microvascular (neuropathy, 
retinopathy, and nephropathy) complications. Thirdly, it is weight neutral, that is, it 
does not affect body mass index (BMI) or decrease body weight in obese patients 
with or without diabetes. 
However, approximately 30-40% of patients using metformin as an anti-diabetic 
therapeutic experience adverse events such as diarrhea and nausea; or a more serious 
but rare side effect, lactic acidosis (Reitman and Schadt, 2007, Takane et al., 2008, 
Wang et al., 2002). Moreover, approximately 38% of metformin users did not 
achieve acceptable control of fasting glucose levels and showed a variable glycemic 
response (Reitman and Schadt, 2007). This variation in glycemic response to 
metformin was attributed to the uptake of the drug either at the hepatic level or the 
elimination of the drug at the renal level. Furthermore, it was established that genetic 
variations in solute carrier transporter (SLC) genes, specifically hOCT1 (hepatic 
level) and hOCT2 (renal level), are involved in this varied response to the drug 
(Figure 1.8) (Kimura et al., 2005a, Wang et al., 2002). In addition, genetic variation 
in another SLC, hMATE1 transporter protein was also implicated in the glucose 
lowering effect of metformin (Matthijs L Becker et al., 2009). 
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Figure 1.8 - Pharmacokinetics pathway of metformin (Gong et al., 2012). 
1.9.2. Implication of the Genetic Polymorphisms in OCTs on the 
Pharmacokinetic and/or Pharmacodynamic Profiles of Metformin in 
Humans 
Recent studies suggest that inter-patient variability in response to metformin therapy 
could be related to polymorphisms in the organic cation transporter (OCT) genes 
and/or the multidrug and toxin extrusion (MATE) genes.  
Shikata et al. (2007) and Shu et al. (2007) showed in their respective studies that 
hOCT1 is an important determinant of the therapeutic action of metformin and that 
genetic variation in the SLC22A1 gene may contribute to variation in therapeutic 
response to the drug, presumably by decreasing the hepatic uptake of the drug 
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(Shikata et al., 2007, Y Shu et al., 2007). Furthermore, Shu et al showed that 
deletion of Slc22a1 in mouse liver reduced metformin effects on 5’ adenosine 
monophosphate-activated protein kinase (AMPK) phosphorylation and 
gluconeogenesis; as a consequence, the glucose-lowering effect of metformin was 
abolished. In addition, they demonstrated that four loss-of-function polymorphisms 
in SLC22A1 in a study of 20 normal glucose-tolerant individuals resulted in a 
reduction of the effect of metformin on response to oral glucose (Y Shu et al., 2007). 
Subsequently, it was shown that individuals carrying the loss-of-function hOCT1 
polymorphisms had higher serum metformin concentrations, suggesting that this 
may be due to reduced hepatic uptake of the drug (Shu et al, 2008). 
Non-synonymous genetic variants in hOCT1, implicated in reduced activity in 
assays done in vitro, have been identified largely in populations of European 
ancestry. However, hOCT1 is highly polymorphic in ethnically diverse populations. 
Tzvetkov et al. (2009) found in their study an increase in renal metformin excretion 
in individuals with amino acid variants of hOCT1 with low or missing transport 
which is in apparent contradiction to the findings of Shu et al (Shu et al., 2008). 
Genetic variations in SLC22A2 are associated with decreased renal excretion and 
increased plasma concentrations of metformin (Shikata et al., 2007, Song et al., 
2008a, Song et al., 2008b, Wang et al., 2008). Furthermore, it was shown that 
coadministration of cimetidine resulted in the inhibition of renal tubular secretion of 
metformin and a concomitant increase in plasma levels of metformin. In addition, it 
was also demonstrated that drug-drug interactions between metformin and 
cimetidine depend on genetic polymorphisms in the hOCT2 gene. However, in 
contrast Tzvetkov et al. (2009) concluded in their study that there was not a 
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statistically significant association of genetic variants in hOCT2 with the renal 
elimination of metformin (Tzvetkov et al., 2009). This was consistent with the 
findings of previous studies which did not find any relationship between non-
synonymous variations of hOCT2 and metformin uptake in vitro or the glucose-
lowering effect of metformin (Leabman et al., 2002, Shikata et al., 2007). Moreover, 
Leabman et al (2002) concluded that selection has acted against amino acid changes 
in hOCT2, suggesting that hOCT2 is relatively intolerant of non-synonymous 
changes (Leabman et al., 2002). 
Metformin has also been identified as a good substrate of hMATE1 and hMATE2-K 
proteins. The hMATE1 protein is expressed in the bile canalicular membrane of 
hepatocytes and in the renal epithelium, whereas hMATE2-K is expressed primarily 
in the renal epithelium. Based on the tissue distributions of these proteins it is 
believed that they play an important role in the elimination of metformin into the bile 
(hMATE1) and urine (hMATE1 and hMATE2-K). Moreover, hMATE1 is 
considered to play an important role in the pharmacokinetics and pharmacodynamics 
of metformin (ML Becker et al., 2009). Furthermore, polymorphisms in the 
SLC47A1 gene were associated with a reduction in A1C level, consistent with a 
reduction in hMATE1 transporter activity (Matthijs L Becker et al., 2009). In 
addition, zu Schwabedissen et al showed that coordinate function of hMATE1 with 
hOCT2 likely contributes to the vectorial renal elimination of organic cationic drugs 
and that altered activity of hMATE1, whether by drugs or polymorphisms, should be 
considered as an important determinant of renal cationic drug elimination (zu 
Schwabedissen et al., 2010). 
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1.9.3. hOCT1 transcript levels and SNPs as predictors of response to imatinib 
in CML 
Chronic myeloid leukemia (CML) is a hematopoietic stem cell disorder, 
characterized by the presence of the Philadelphia (Ph) chromosome that results from 
a balanced reciprocal translocation between chromosomes 9 and 22 (Singh et al., 
2012). Functionally, this translocation results in the formation of the BCR-ABL gene 
which is then translated into the BCR-ABL a protein with intrinsic tyrosine kinase 
activity that is critical to the development of CML (Rowly, 1973). Imatinib mesylate, 
a tyrosine kinase inhibitor (TKI), is now the first-line therapeutic for the treatment of 
chronic phase CML (White et al., 2010). However, 30-40% of patients with CML 
are resistant to imatinib treatment and do not achieve a complete cytogenic response 
(CCR) (Druker et al., 2006, Hochhaus et al., 2009). 
This heterogeneity in imatinib response could be attributed to the presence of SNPs 
in the SLC22A1 gene which codes for the hOCT1 transporter protein (Giannoudis et 
al., 2013). hOCT1 is an influx organic cation transporter that mediates the uptake of 
imatinib, a selective inhibitor of the oncogenic protein Bcr/Abl, into CML cells 
(Crossman et al., 2005, Thomas et al., 2004). In a recent study by Giannoudis et al. 
(2013), the effect of polymorphisms rs628031 (M408V) and rs35191146 (M420del) 
on imatinib uptake and clinical efficacy was investigated (Giannoudis et al., 2013). 
In CML cell lines transfected with the M420del variant and/or M408V variant, 
M420del significantly decreased imatinib uptake. However, this effect was 
countered if the M408V SNP was also present. Giannoudis et al. (2013) concluded 
that the only SNP associated with imatinib treatment outcome was M420del 
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(rs35191146), with patients with the M420del genotype demonstrating an increased 
probability of imatinib treatment failure (Giannoudis et al., 2013). 
However, the role of hOCT1 in the uptake of imatinib is controversial. In a recent 
study, Nies et al. (2014) challenged the role of hOCT1 in imatinib uptake, and 
showed through transport and inhibition studies that overexpression of functional 
hOCT1 did not lead to increased accumulation of imatinib (Nies et al., 2014). They 
concluded that cellular uptake of imatinib is independent of hOCT1 and as such 
hOCT1 is not a valid biomarker for imatinib resistance. 
1.10. OCTs and MATEs in drug-drug interactions 
OCTs and MATEs play an important role in the uptake, distribution, and elimination 
of commonly used clinical drugs. Since more than 30% of clinically used drugs are 
organic cations, drug-drug interaction (DDI) by inhibition of OCT and/or MATE 
transporters may be clinically relevant. DDIs involving the inhibition of metabolism 
and/or excretion prolong the plasma elimination half-lives, leading to the 
accumulation of victim drugs in the body, and consequently potentiate 
pharmacological/adverse effects (Ito et al., 2012). 
Apical efflux by the MATE family is considered one of the sites of DDI in addition 
to OCTs at the basolateral membrane (Tsuda et al., 2009b). The anti-histamine 
cimetidine is known to cause DDIs with OCs in the kidney, and a previous study 
showed that the coadministration of cimetidine with fexofenadine (FEX), for 
example, decreases the renal clearance of the drug.  Previously hOCT2 was 
implicated in DDIs which involved the antihistamine cimetidine. In a study by 
Matsushima et al. (2009) it was suggested that the DDI with cimetidine and FEX 
was mainly caused by the inhibition of hMATE1-mediated efflux of FEX rather than 
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the inhibition of its renal uptake process (Matsushima et al., 2009).  Moreover, a 
recent study by Ito et al. (2012) supported this observation and showed that it is in 
fact the competitive inhibition of the luminal efflux by hMATE1, and not the 
basolateral uptake by hOCT2, which is the likely mechanism underlying the 
pharmacokinetic DDIs caused by cimetidine in the kidney (Ito et al., 2012). 
Inhibitors that preferentially interact with and impair the function of MATEs, may 
not only result in decreased clearance but may also lead to nephrotoxicity. 
Minematsu et al. (2011) investigated the inhibitory effect of 8 tyrosine kinase 
inhibitors on metformin transport activity by human hOCT1, hOCT2, hOCT3, 
hMATE1 and hMATE2-K (Minematsu et al., 2010). They found that imatinib, 
nilotinib, gefitinib, and erlotinib exerted selectively potent inhibitory effects on 
hMATE1, hOCT3, hMATE2-K, and hOCT1, respectively. Furthermore, they found 
that compared to the reference hOCT1, the M420del variant was more sensitive to 
drug inhibition erlotinib. 
1.11. OCTs and Cancer 
OCTs may play an important role in the treatment of malignant tumours. For 
example, hOCT1 is responsible for the active uptake of the charged hydrophilic anti-
cancer agents imatinib, cisplatin, oxaliplatin, picoplatin, irinotecan, and paclitaxel, 
thus contributing to the susceptibility of cancer cells to these antineoplastic drugs 
(Gupta et al., 2012). hOCT1 activity was reported to correlate well with the 
sensitivity of tyrosine kinase inhibitors (TKIs) such as imatinib in patients with 
chronic myeloid leukemia (CML). 
Yokoo et al. (2008) investigated whether hOCT3 was significantly involved in the 
oxaliplatin-induced cytotoxicity and accumulation of platinum in colorectal cancer 
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(Yokoo et al., 2008). They found that SLC22A3 expression was higher in colon and 
rectal cancerous tissues compared to normal tissues in Caucasian patients. Moreover, 
they found that the cytotoxicity and accumulation of platinum caused by the 
treatment of oxaliplatin but not cisplatin depended on SLC22A3 expression. Li et al. 
(2012) in a recent study investigated whether drug transporters played a role in 
determination of cisplatin resistance in cervical cancer cells (Li et al., 2012). They 
found that hOCT3 partially contributed to the sensitivity of adenocarcinoma cells to 
cisplatin cytotoxicity. Based on their data they suggested that down-regulation of 
SLC22A3 as a mechanism responsible for cisplatin accumulation in cervical 
adenocarcinoma cells. Expression of hOCT3 in kidney carcinoma cell lines increases 
chemosensitivity to the antineoplastics melphalan, irinotecan, and vincristine 
(Shnitsar et al., 2009). 
In a recent study, Heise et al. (2012) investigated the impact of OCT expression on 
hepatocellular carcinoma (HCC) and patient survival (Heise et al., 2012). They 
found that down-regulation of SLC22A1 expression in HCC is associated with 
advance tumour stages and a worse patient survival rate. Down-regulation of 
SLC22A1 expression was also associated with tumor progression and reduced patient 
survival in human cholangiocellular carcinoma (CCA) (Lautem et al., 2013). 
Moreover, the down-regulation of SLC22A1 was significantly associated with 
advanced CCA stages. These findings could be important in future treatment 
strategies for these diseases. 
Mohelnikova-Duchonova et al. (2013) investigated the association between the 
expression of solute carrier transporters and the prognosis of pancreatic cancer 
(Mohelnikova-Duchonova et al., 2013). They found that expression of some SLCs 
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predicted the outcome of PDAC patients regardless of chemotherapy and that there is 
considerable variability in the expression in SLC transporters between tumor and 
normal human pancreas tissues which may modify the outcomes of patients treated 
with nucleoside analogs- and platinum containing regimens. 
A common variant in 6q26-q27 is associated with distal colon cancer in a Japanese 
population (Cui et al., 2011).  However, Zhu et al. (2013) found that the genetic 
variant rs7758229 in 6q26-27 was not associated with colorectal cancer risk in a 
Chinese population (Zhu et al., 2013). Genetic and functional analysis have 
implicate the SLC22A3 gene together with 2 other genes in prostate cancer 
pathogenesis (Grisanzio et al., 2012). 
1.12. Genomic Diversity and Personalized Medicine: The African Perspective 
Although controversial, the concepts of race, ethnicity, and ancestry, have for a long 
time been recognized as having a strong influence on pharmacogenetic discovery, 
and our understanding of population differences in drug efficacy and toxicity (Urban, 
2010). 
Most dosing regimens are recommended on the basis of clinical trials that have been 
conducted in Caucasian or Asian populations which may not be appropriate for 
African populations (Masimirembwa and Hasler, 2013). 
Pharmacogenomic/pharmacogenetic applications hold the promise of using genome-
based technologies to improve health by the prevention or effective treatment of 
disease. The current belief is that even developing nations, such as those in sub-
Saharan Africa, can benefit from pharmacogenomics in order to inform public health 
policies, designing and interpreting clinical trials, and possibly to help guide 
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clinicians to prospectively evaluate those patients with the greatest probability of 
expressing a variant genotype (Suarez-Kurtz, 2008, Daar and Singer, 2005). 
The South African health system, both private and public, faces a high burden of 
communicable and non-communicable diseases, high maternal and child mortality, 
as well as injury and violent related deaths (Coovadia et al., 2009, Mayosi et al., 
2012). This high burden of infectious and chronic diseases results in a health system 
that is continuously under-resourced. Although South Africa’s per capita health 
expenditure is the highest of any middle-income country in the world its health 
outcomes are often worse than that of lower-income countries (Coovadia et al., 
2009, Warnich et al., 2011). The current challenge in 
pharmacogenomics/pharmacogenetics in sub-Saharan Africa, and for that matter 
South Africa, is to ascertain the extent of the genomic diversity in our under-studied 
populations, to understand genotype-environment interactions, and to translate this 
knowledge into clinical applications that can be utilized in public health care (Hardy 
et al., 2008). 
1.13. Summary and Main Objectives of the Project 
The past decade has seen remarkable progress in the field of membrane transporters, 
not only in terms of functional characterization and substrate specificity but also in 
elucidating the important role that transporters play in diseases such as cancer and in 
the disposition and efficacy of drugs in clinical use. To date 48 members of the ABC 
and over 325 members of the SLC families of membrane transporters have been 
identified. These transporters are ubiquitously expressed and play a critical role in 
maintaining cellular and organismal homeostasis by importing nutrients essential for 
cellular metabolism and eliminating metabolic by-products and toxic xenobiotics. 
40 
 
 
 
 
 
CHAPTER 1 
Whereas most membrane transporters are oligospecific (specialized for the 
translocation of specific metabolic or nutritional compounds), polyspecific 
transporters accept compounds with different sizes and molecular structures. These 
polyspecific transporters exhibit large variations in affinity and turnover for different 
compounds and may have specific physiological roles. Given the fact that 40% of 
clinically used drugs exist as organic cations at physiological pH, the polyspecific 
OCT and MATE families of SLCs have attracted a significant amount of interest. 
The genes encoding these transporters are also being investigated as potential risk 
loci for cancer, and SNPs in these genes have been associated with imatinib 
treatment failure in CML patients. Moreover, genetic variations in these transporters 
are increasingly being recognized as a possible mechanism that can explain the inter-
individual variability in drug efficacy and toxicity. However, the majority of these 
studies were conducted in Caucasian and Asian populations and were based on 
genetic variants that are specific to these populations. The findings of these studies 
are often extrapolated for use and interpretation in other populations. This is in spite 
of the fact that the population frequency of variant alleles can differ markedly 
between populations. In addition, ethnic-specific variants exist in non-Caucasian and 
non-Asian populations which may be more predictive of treatment outcome or 
disease progression for a specific ethnic group. However, the allelic distribution and 
role of genetic variants of OCT and MATE transporters in drug efficacy and toxicity 
and disease progression in indigenous South African populations have not received 
the necessary priority. 
Inter-individual variability in drug response is a significant clinical problem which 
has attracted a fair amount of research interest. It is estimated that genetic factors can 
account for approximately 15-30% of inter-individual variability in drug response 
41 
 
 
 
 
 
CHAPTER 1 
and efficacy. Initially the focus has been on drug metabolizing enzymes, however 
membrane transporter belonging to the SLC family are increasingly being 
recognized as a possible mechanism explaining this variability in drug response and 
efficacy. Given that 40% of therapeutic drugs exist as OCs at physiological pH, the 
OCTs and MATEs of the SLC family is receiving a greater amount of attention. 
Reduced-function variants have been identified, primarily in American and European 
Caucasians, which affect the pharmacokinetics of OCT and MATE substrate drugs 
such as metformin for example. Although African populations are considered to 
harbour more genomic diversity than Caucasian populations, this diversity is 
however under-studied. Thus, little or no information is available on the extent of 
genetic variation in OCT and MATE genes within African populations. Although 
several populations from West, East, and Central Africa are included in the 1000 
Genomes and HapMap projects, these groups cannot represent the genomic diversity 
of the entire continent. Therefore, in order to bridge the gap that exist with regards to 
information on the pharmacogenetic relevant OCT and MATE genes, especially in 
indigenous southern African populations, this study prioritized the genotyping of 78 
SNPs in four genes, known to affect drug disposition and efficacy, in the Xhosa 
population of South Africa. 
We have developed and optimized eight SNaPshot™ multiplex genotyping systems 
covering the 78 previously identified SNPs in SLC22A1-3, and SLC47A1. The 
SLC22A1 systems were subsequently used to genotype 148 Xhosa individuals, which 
is described in Chapter 2. The allele and genotype frequencies obtained were then 
compared to other populations to assess the amount of variation between the Xhosa 
population and two other African populations, the Yoruba of Nigeria and Luhya of 
Kenya, African Americans, Caucasians, and Asians. In addition, the genotypic 
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information was used to establish haplotype structures for the Xhosa population in 
the SLC22A1 gene which can potentially be used in future pharmacogenetic studies. 
In Chapter 3 we expanded the study to investigate genotype and allele frequency 
distributions of 20 nonsynonymous SNPs of SLC47A1, the gene that codes for the 
H+/organic cation efflux transporter hMATE1, which is co-localized with the uptake 
OCTs hOCT1 (liver) and hOCT2 (kidney) and facilitates the elimination of cationic 
drugs and other xenobiotics from the kidney into the urine. Chapter 4 describes the 
genotyping of 20 nonsynonymous SNPs of SLC22A2, the gene coding for the 
kidney-specific hOCT2 which is a hOCT1 paralogue and a known site of DDIs. The 
hOCT1 and hOCT2 paralogue hOCT3 has been identified as a biomarker in several 
cancers and is also involved in the transport of various antineoplastics. The extent of 
genetic variation within the SLC22A3 gene, encoding hOCT3, was assessed by 
genotyping previously identified 18 nonsynonomous as described in Chapter 5. In 
order to determine whether the Xhosa participants harboured any novel genetic 
polymorphisms, we embarked on sequencing approximately 500bp of the proximal 
promoter region and all 11 exons plus flanking regions of SLC22A2 in 96 individuals 
as described in Chapter 6. The main conclusions of the project were summarized in 
Chapter 7, and few prospects for the pharmacogenetics of OCTs and MATEs in the 
indigenous African populations residing in South Africa were also presented. 
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CHAPTER 2 
Genetic Polymorphisms and Haplotype Structure of SLC22A1 in the Xhosa 
Population 
2.1. Abstract 
Human organic cation transporter 1 is primarily expressed in hepatocytes and 
mediates the electrogenic transport of various endogenous and exogenous 
compounds, including clinically important drugs. Genetic polymorphisms in the 
gene coding for human organic cation transporter 1, SLC22A1, are increasingly 
being recognized as a possible mechanism explaining the variable response to 
clinical drugs, which are substrates for this transporter. The genotypic and allelic 
distributions of nineteen nonsynonymous and one intronic SLC22A1 single 
nucleotide polymorphisms were determined in 148 healthy Xhosa participants from 
South Africa, using a SNAPshot™ multiplex assay. In addition, haplotype structure 
for SLC22A1 was inferred from the genotypic data. The minor allele frequencies for 
S14F (rs34447885), P341L (rs2282143), V519F (rs78899680), and the intronic 
variant rs622342 were 1.7%, 8.4%, 3.0%, and 21.6%, respectively. None of the 
participants carried the variant allele for R61C (rs12208357), C88R (rs55918055), 
S189L (rs34104736), G220V (rs36103319), P283L (rs4646277), R287G 
(rs4646278), G401S (rs34130495), M440I (rs35956182), or G465R (rs34059508). In 
addition, no variant alleles were observed for A306T, A413V (rs144322387), 
M420V (rs142448543), I421F, C436F (rs139512541), V501E, or I542V 
(rs137928512) in the population. Eight haplotypes were inferred from the genotypic 
data. This study reports important genetic data that could be useful for future 
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pharmacogenetic studies of drug transporters in the indigenous Sub-Saharan African 
populations.  
2.2. Introduction 
Membrane transporters play an important role in the metabolism of clinical drugs 
and endogenous compounds. Single nucleotide polymorphisms (SNPs) in ATP-
binding cassette (ABC) and solute carrier transporter (SLC) genes have been 
increasingly recognized as a possible mechanism accounting for altered transport 
activity, which may have profound clinical implications (Leabman et al., 2003). In 
general, genetic factors are estimated to account for 15-20% of inter-individual 
variations in drug disposition and responses (Choi and Song, 2008, Evans and 
Relling, 1999, Eichelbaum et al., 2006). However, for certain drugs genetic factors 
can account for up to 95% of inter-individual variability in drug disposition and 
effect (Eichelbaum et al., 2006, Evans and Relling, 2004). 
Polyspecifc organic cation transporters (OCTs) are involved in the sodium-
independent electrogenic transport of small organic cations (OCs) with different 
molecular structures (Koepsell et al., 2007). These organic cations include clinically 
important drugs (metformin, cimetidine, procainamide), endogenous compounds 
(dopamine, norephinephrine, and toxic substrates (tetra-ethylammonium, 
haloperidol-derived pyridinium metabolite, 1-methyl-4-phenylpyridinium) 
(Gorboulev et al., 1997). Based on their substrate properties and tissue distributions, 
human OCT1-3 are thought to play important roles in the biliary and renal excretion 
of their substrates and the distribution of organic cationic drugs in the liver, kidney, 
heart, and brain (Jonker and Schinkel, 2004). 
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The uptake transporter hOCT1 is encoded by the SLC22A1 gene which is located on 
chromosome 6q26, and consists of 11 exons spanning approximately 37kb 
(Gorboulev et al., 1997, Koehler et al., 1997, Koepsell et al., 2007). hOCT1 is 
primarily expressed in the sinusoidal or basolateral membrane of hepatocytes and is 
thought to play an important role in the hepatic uptake, distribution and excretion of 
clinically important drugs (Gorboulev et al., 1997, Zhang et al., 1997). 
The role of hOCT1 in the clinical pharmacology of clinical therapeutics such as the 
anti-diabetic drug metformin, the anti-neoplastic imatinib, the anti-HIV drug 
lamivudine, and the serotonin receptor type antogonists tropisetron and ondansetron 
has been extensively researched (Yan Shu et al., 2007, Shu et al., 2008, Tzvetkov et 
al., 2009). Moreover, a number of SLC22A1 variants have been associated with 
functional changes in protein activity, as well as drug disposition, response, and 
toxicity. For example, Bazeos et al. (2010) found that SLC22A1 transcript levels and 
SNPs can be predictive factors for response to imatinib in chronic myeloid leukemia 
(CML) (Bazeos et al., 2010). Previous studies have shown that hOCT1 is highly 
polymorphic in ethnically diverse populations (Sakata et al., 2004, Shu et al., 2003, 
Kang et al., 2007). 
These aforementioned reduced-function genetic variants were however primarily 
found in studies with European participants and have not been consistently replicated 
for other ethnic groups (Chen et al., 2010b, Leabman et al., 2003). Recent reports 
using genome-wide polymorphisms suggested that: (i) genetic variation seen outside 
of Africa is generally a subset of the total genetic variation that exists within Africa, 
(ii) genetic diversity decreases with increased geographic distance from Africa, and 
(iii) linkage disequilibrium (LD) patterns increase proportionally to the distance from 
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Africa (Jakobsson et al., 2008, Li et al., 2008, Tishkoff et al., 2009). Moreover, 
Rosenberg et al (2002) found that there is greater genetic diversity among African 
populations compared to Caucasian or Asian populations (Rosenberg et al., 2002). 
However, despite Africa harboring a significant proportion of human genomic 
diversity, this genomic diversity is unfortunately relatively under-studied (Hardy et 
al., 2008, Tishkoff et al., 2009). 
South Africa is home to a large number of indigenous and immigrant population 
groups (Hardy et al., 2008, Benjeddou, 2010). Amongst these are the Bantu-
speaking populations such as the Xhosa, Zulu, and Sotho, which are believed to have 
originated approximately 3000 – 5000 years ago in West Africa between the present-
day Cameroon and Nigeria (Berniell-Lee et al., 2009, Lane et al., 2002). The 
indigenous African populations potentially contain a significant amount of genomic 
diversity (Tishkoff et al., 2009, Hardy et al., 2008).  These populations include the 
Xhosa, historically indigenous to the Eastern Cape Province of South Africa, and the 
second largest ethnic grouping in the country making up an estimated 8 million or 
17.6% of the South African population (Drögemöller et al., 2010, Warnich et al., 
2011). 
This genomic diversity could provide a wealth of information and knowledge, which 
could eventually be applied to aid our understanding of the impact of genetic 
variation on complex diseases such as cancer, diabetes mellitus, hypertension and the 
inter-individual variability in response of patients to drugs used in the treatment of 
these diseases. Although limited, studies that have been conducted in South Africa 
suggest that South African populations have unique genetic profiles which include 
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novel and rare variants, with allele frequencies differing from each other and other 
African populations (Warnich et al., 2011). 
Previous studies have shown that South African populations exhibit unique allele 
frequencies and novel genetic variations in pharmacogenetically relevant genes 
(Ikediobi et al., 2011). However, these studies have primarily focused on variants in 
drug metabolizing enzyme genes. Information on variants in drug transporter genes 
for South African populations is however limited or non-existent. Therefore, the aim 
of this study was to investigate the genotypic and allelic distributions of nineteen 
nonsynonymous and one intronic SNP(s), and to infer the haplotype structure of the 
SLC22A1 gene in the Xhosa population. These SNPs include A306T, A413V, 
M420V, C436F, I421F, V501E, V519F, and I542V for which, to our knowledge, no 
population data exist in the public domain. 
2.3. Materials and Methods 
2.3.1. Subjects 
Samples were obtained from the participants with informed consent. This study was 
approved by the Senate Research Ethics Committee of the University of the Western 
Cape, South Africa. Biological samples were collected in the form of buccal swabs 
from 148 unrelated healthy volunteers from the Xhosa population. Ethnicity of 
volunteers was determined by self-report. 
2.3.2. DNA extraction 
Genomic DNA was isolated from buccal swab samples using a standard salt-lysis 
protocol and stored frozen at -20°C until the time of genotyping (Leat et al., 2004a). 
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2.3.3. SNP selection 
A total of 20 OCT1 gene SNPs (19 nonsynonymous and 1 intronic) were selected for 
this study. SNPs were selected from the literature and the Ensembl database 
(http://www.ensebl.org) (Flicek et al., 2012). Variants A306T, A413V, M420V, 
C436F, I421F, V501E, V519F, and I542V were included in this study based on 
predicted effect on function, using the SIFT (Sorting Intolerant From Tolerant) 
program (Flanagan et al., 2010, Kumar et al., 2009, Ng and Henikoff, 2003). To our 
knowledge no population data exist in the public domain for these variants. 
2.3.4. Primer design 
Multiplex PCR primers, listed in Table 2.1, were designed to have an annealing 
temperature between 55°C and 60°C using Primer3 software 
(www.genome.wi.mit.edu/cgi-bin/primer/primer3). To test for possible non-specific 
amplification, primers were aligned with the NCBI sequence databases using Basic 
Local Alignment Search Tool (www.ncbi.nlm.nih.gov/blast/blast-cgi). Two 
SNaPshot® Multiplex systems were specifically designed for the study, successfully 
optimized and used for genotyping. The single base extension primer sets for 
multiplex 1 and 2 are listed in Tables 2.2 and 2.3. 
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Table 2.1 - Multiplex PCR primers for the generation of SLC22A2 amplicons used in SNaPshot™ genotyping.  
 
Location Forward primer (5´to 3´) Reverse Primer (5ʹto 3ʹ) Amplified region (NC_000006.12) Amplicon length  (bp) 
     
Exon 1 TGCTGAGCCATCATGCCCACCGTG GGACACAGCCAGACACCCACG 160121924 - 160122483 560 
Exon 2 CTCTTGCCGTGGTATGACTGGCAG CAGAGGGGCTTACCTGGACTGG 160130080 - 160130240 161 
Exon 3 CCTCCATGTCTCCTTCTCTCTGAAG CTGGCCTCATCCCCATGATAATTAC 160132207 - 160132411 205 
Exon 4 CCCGCATAACGTCCACACCTCCTG GTAGGCAGGAGGAAGGGCCTCAC 160133927 - 160134148 222 
Exon 5 & 6 GATAGTGATGAGTGGTGTTCGCAG GCGAGCGTGCTGATTCTGCCT 160136196- 160136698 503 
Exon 7 GACTTGAAACCTCCTCTTGGCTCAG TTCCCCACACTTCGATTGCCTGGGA 160139628 - 160139923 296 
Exon 8 GAAGCCCCCATCCACCACCCACACC GGCTACCCCTGTTCCATGCACTCAC 160143495 - 160143674 180 
Exon 9 ATTGCATGGGCAACGGATGGCT CCATGCTGAGCCCACTGCCGAGCTG 160154557- 160154972 416 
Intron 9 GAGTAGGAGGGGTTAATAGAGAGAG GTAGCTGAGACTACATGCATGCACCAC 160151769 - 160152004 236 
Exon 10 TTCCTCTCTTTGGCTGGCTGTGA ACTCCAGCAAACCTTGCTCTCTGT 160155888 - 160156508 621 
Exon 11 TGCCCTTTTCTTCTTTGCTGTTTGC AGCACCAACAGCTTTCCCTAGATCG 160158364 - 160158823 460 
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2.3.5. Multiplex PCR 
All the SLC22A2 exons and the portion of intron 9 spanning rs622342 were 
simultaneously amplified using the primers listed in Table 2.1. The PCR reactions 
were performed in a 20 µl volume, containing 20 – 50 ng of genomic DNA, 1 x 
Qaigen multiplex PCR master mix (Qaigen, Courtaboeuf, France) and 0.2 µM of 
each primer. Cycling consisted of an initial 15 minute activation step for HotStar Taq 
polymerase at 95°C, followed by a total of 35 cycles using the following conditions: 
94°C denaturation for 30 seconds, primer annealing at 60°C for 90 seconds, and 
primer extension at 72°C for 30 seconds, and 15 minutes of final extension at 72°C 
and a 4°C holding step. PCR products were purified to remove excess primers and 
un-incorporated dNTPs using an Exo/SAP protocol. The entire 20 µl of PCR 
products were incubated with 0.5 µl of Exo1 and 1 µl of FastAP for 30 minutes at 
37°C followed by 15 minutes at 80°C for enzyme inactivation. PCR quality and 
yield were checked using NanoDrop. 
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Table 2.2 – SLC22A1 multiplex 1 single base extension primers. 
NCBI 
(dbSNP) 
Amino Acid 
Change 
Nucleotide 
Change 
Single Base Extension Primers 
(5′ to 3′) 
Position 
Accession number 
(NC_000006.12) 
Size bp polydGACT tail 
       
rs34447885 S14F C/T TGACTATTCTGGAGCAGGTTGGGGAGT 160121976 40 13 
rs34104736 S189L C/T GAACTGTGCTGGTCAACGCGGTGT 160132282 45 21 
rs36103319 G220V G/T GGTCAGCAAGGGCAACTGGATGGCTG 160132375 50 24 
rs4646277 P283L C/T GATAACAGCCACCGGGGGACACC 160136228 55 32 
rs34130495 G401S G/A AGCCCTCATCACCATTGACCGCGTG 160139792 60 35 
rs72552763 M420V A/G AACTTACCAGGTGAGATAAAAATCA 160139849 65 40 
rs35956182 M440I G/A CATAATCATGTGTGTTGGCCGAAT 160143584 70 46 
rs34059508 G465R G/A CCACAGGGAGGAACACACCATCACTC 160154805 75 49 
rs78899680 V519P G/T CTACTTCTTCCAGAGACCAAGGGG 160156031 80 56 
rs137928512 I542V A/G CAGAGGTTTGGACCTTAAGGTAAA 160158541 85 61 
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Table 2.3 – SLC22A1 multiplex 2 single base extension primers. 
NCBI 
(dbSNP) 
Amino Acid 
Change 
Nucleotide 
Change 
Single Base Extension Primers 
(5′ to 3′) 
Position 
Accession number 
(NC_000006.12) 
dGACT Size bp 
       
rs622342 Intron A/C ATTTCTTCAAATTTGATGAAAACTTC 160151834 14 40 
rs12208357 R61C C/T TCCTGGGGTGGCTGAGCTGAGCCAG 160122116 20 45 
rs4646278 R287G C/G CAGTGTTTCTTTTTTGTGATAACAGCCACC 160136239 20 50 
rs55918055 C88S T/A TCCAGTCCACTTCATAGCGCCTGC 160122197 31 55 
COSM164365 A306T G/A AGGAGGCAACTTCCCATTCTTTTGAG 160136296 34 60 
rs2282143 P341L C/T CTTCATTTGCAGACCTGTTCCGCACGC 160136611 38 65 
rs144322387 A413V C/T CCCCATGGCCATGTCAAATTTGTTGG 160139829 44 70 
rs151333280 I421F A/T CCAACTTACCAGGTGAGATAAAAA 160143571 51 75 
rs139512541 C436F G/T GCACTGGTTAAACATCATAATCATGT 160143571 54 80 
rs143175763 V501E T/A CACTCCCGCGGCAAGCAGGCCCAAC 160155979 60 85 
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2.3.6. Multiplex minisequencing reactions 
Multiplex minisequencing was performed in a 10 µl reaction volume using 3 µl of a 
1/10 dilution of purified PCR products, 0.1-0.2 µM of primers, and 5 µl of 
SNaPshot® ready reaction mix. Sequence cycling consisted of 25 cycles of 
denaturation at 96°C for 10 seconds, primer annealing at 50°C for 5 seconds, and 
primer extension at 60°C for 30 seconds. Post-extension treatment was done by 
adding 1 U of FastAP to the 10 µl reaction volume and incubation at 37°C for 30 
minutes followed by 15 minutes at 80°C to deactivate the enzyme. 
2.3.7. Electrophoresis of the minisequencing products 
The purified minisequencing products (1 µl) were mixed with 8.7 µl of HiDi™ 
formamide and 0.3 µl of GeneScan-120 Liz size standard (Applied Biosystems) and 
denatured at 95°C for 5 minutes. The fluorescently labelled fragments were 
separated on 36 cm-long capillaries in POP4 polymer on an ABI Prism 3500 Genetic 
Analyzer (Applied Biosystems). Data analyses were performed using GeneMapper® 
IDX Software Version 1.2. 
2.3.8. Statistical Analysis 
Genotype and allele frequencies as well as the deviation from the Hardy-Weinberg 
Equilibrium were calculated using GenAlEx 6.5 software (Peakall and Smouse, 
2012, Wigginton et al., 2005). Allele and genotype frequencies are given with 
binomial proportion 95% confidence intervals (CI) calculated according to the 
method of Wilson. The SHEsis analysis platform was used to infer the haplotype 
frequencies (Yong and Lin, 2005, Li et al., 2009). Statistical significance was 
defined as p<0.05. 
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2.4. Results 
The population studied consisted of 148 healthy Xhosa individuals between the ages 
of 18 and 61 years. There were 80 (54%) female and 68 (46%) male participants. 
The mean age of female participants was 25.3±9.0 years, whereas male participants 
had a mean age of 24.8±7.7 years. 
The genotype and allele frequencies of the 20 OCT1 gene SNPs investigated in the 
148 Xhosa subjects are summarized in Table 4. The allelic frequency of each SNP 
was in HWE (p>0.05), except for rs622342. Sixteen out of the nineteen investigated 
nonsynonymous SNPs were monomorphic in the Xhosa population. None of the 
participants were homozygous for the variant allele for S14F (rs34447885), P341L 
(rs2282143), and V519F (rs78899680). The S14F variant genotype frequencies for 
homozygote wild-type (CC), heterozygote (CT) and homozygote (TT) were 96.6%, 
3.4% and 0.0%, respectively. The MAF observed for S14F was 1.7%.  The P341L 
variant genotype frequencies, on the other hand, for homozygote wild-type (CC), 
heterozygote (CT) and homozygote (TT) were 83.1%, 16.9% and 0.0%, respectively. 
The V519F variant genotype frequencies for homozygote wild-type (CC), 
heterozygote (CT) and homozygote (TT) were 93.9%, 6.1% and 0.0%, respectively. 
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Table 2.4 - Genotype and allele frequencies of OCT1 (SLC22A1) gene SNPs in 148 
healthy Xhosa individuals. 
Amino Acid 
Substitution dbSNP ID 
 Observed Genotype Frequency  Allele Frequency  
Genotype % 95% CI Allele % 95% CI HWE (P) 
         
S14F rs34447885 
CC 96.6 92.0 – 98.8 C 98.3 96.3 – 99.1 
0.834 CT 3.4 1.2 – 8.0 T 1.7 0.9 – 3.7 
TT 0.0 0.0 – 3.1    
         
R61C rs12208357 
CC 100.0 96.9 – 100.0 C 100.0 98.4 – 100.0 
 CT 0.0 0.0 – 1.3 T 0.0 0.0 – 1.6 
TT 0.0 0.0 – 1.3    
         
C88R rs55918055 
TT 100.0 96.9 – 100.0 T 100.0 98.4 – 100.0 
 TA 0.0 0.0 – 1.3 A 0.0 0.0 – 1.6 
AA 0.0 0.0 – 1.3    
         
S189L rs34104736 
CC 100.0 96.9 – 100.0 C 100.0 98.4 – 100.0 
 CT 0.0 0.0 – 1.3 T 0.0 0.0 -1.6 
TT 0.0 0.0 – 1.3    
         
G220V rs36103319 
GG 100.0 96.9 – 100.0 G 100.0 98.4 – 100.0 
 GT 0.0 0.0 – 1.3 T 0.0 0.0 -1.6 
TT 0.0 0.0 – 1.3    
         
P283L rs4646277 
CC 100.0 96.9 – 100.0 C 100.0 98.4 – 100.0 
 CT 0.0 0.0 – 1.3  0.0 0.0 – 1.6 
TT 0.0 0.0 – 1.3    
         
P341L rs2282143 
CC 83.1 74.6 – 80.9 C 91.6 87.0 – 93.7 
0.261 CT 16.9 12.8 – 19.1 T 8.4 6.3 -13.0 
TT 0.0 0.0 – 3.1    
         
G401S rs34130495 
GG 100.0 96.9 – 100.0 G 100.0 98.4 – 100.0 
 GA 0.0 0.0 – 1.3 A 0.0 0.0 -1.6 
AA 0.0 0.0 – 1.3    
         
M440I rs35956182 
GG 100.0 96.9 – 100.0 G 100.0 98.4 – 100.0 
 GA 0.0 0.0 – 1.3 A 0.0 0.0 -1.6 
AA 0.0 0.0 – 1.3    
         
G465R rs34059508 
GG 100.0 96.9 – 100.0 G 100.0 98.4 – 100.0 
 GA 0.0 0.0 – 1.3 A 0.0 0.0 – 1.6 
AA 0.0 0.0 – 1.3    
         
V519F rs78899680 
GG 93.9 88.6 – 96.9 G 97.0 94.2 – 98.5 
0.703 GT 6.1 3.1 – 11.4 T 3.0 1.5 – 3.7 
TT 0.0 0.0 – 3.1    
         
Intronic SNP rs622342 
AA 64.2 54.7 – 70.3 A 78.4 72.2 – 81.8 
0.048 AC 28.4 22.3 – 36.9 C 21.6 18.2 – 23.0 
CC 7.4 6.1 – 16.2    
         
R287G rs4646278 
CC 100.0 96.9 – 100.0 C 100.0 98.4 – 100.0 
 CG 0.0 0.0 – 1.3 G 0.0 0.0 – 1.6 
GG 0.0 0.0 – 1.3    
         
I542V rs137928512 AA 100.0 96.9 – 100.0 A 100.0 98.4 – 100.0  
  AG 0.0 0.0 – 1.3 G 0.0 0.0 – 1.6    GG 0.0 0.0 – 1.3     
         
M420V rs142448543 
AA 100.0 96.9 – 100.0 A 100.0 98.4 – 100.0 
 AG 0.0 0.0 – 1.3 G 0.0 0.0 – 1.6 
GG 0.0 0.0 – 1.3    
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A413V rs144322387 
CC 100.0 96.9 – 100.0 C 100.0 98.4 – 100.0 
 CT 0.0 0.0 – 1.3 T 0.0 0.0 – 1.6 
TT 0.0 0.0 – 1.3    
         
I421F rs151333280 
AA 100.0 96.9 – 100.0 A 100.0 98.4 – 100.0 
 AT 0.0 0.0 – 1.3 T 0.0 0.0 – 1.6 
TT 0.0 0.0 – 1.3    
         
C436F rs139512541 
GG 100.0 96.9 – 100.0 G 100.0 98.4 – 100.0 
 GT 0.0 0.0 – 1.3 T 0.0 0.0 – 1.6 
TT 0.0 0.0 – 1.3    
         
V501E rs143175763 
TT 100.0 96.9 – 100.0 T 100.0 98.4 – 100.0 
 TA 0.0 0.0 – 1.3 A 0.0 0.0 – 1.6 
AA 0.0 0.0 – 1.3    
         
A306T COSM164365 
GG 100.0 96.9 – 100.0 G 100.0 98.4 – 100.0 
 GA 0.0 0.0 – 1.3 A 0.0 0.0 – 1.6 
AA 0.0 0.0 – 1.3    
         
 
The MAF of a selected number of the investigated SLC22A2 gene SNPs in different 
ethnic groups are summarized in Table 2.5 and depicted in Figure 2.1. SLC22A1 
SNP variants R61C (rs12208357), C88R (rs55918055), S189L (rs34104736), G401S 
(rs34130495), and G465R (rs34059508) were not observed in the Xhosa, Sub-
Saharan or Asian populations. However, it was observed in Caucasian populations.  
Two SLC22A1 SNP variants, S14F and V519F, were only observed in the Xhosa and 
the other Sub-Saharan populations, but not in the Asian or Caucasian populations. 
Inferred haplotypes are listed in Table 2.6. 
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Table 2.5 - Comparison of MAF of SLC22A1 gene SNPs of the Xhosa population to other ethnic groups. 
dbSNP ID Amino acid change 
Minor 
Allele 
Minor Allele Frequency (%) 
Xhosaa Luhyab Yorubab African-Americanc Japanesed Chinese-Hanb Caucasian-Finishb Caucasian-Americane 
           
rs34447885 S14F T 1.7 2.6 1.7 3.1 0.0 0.0 0.0 0.0 
rs12208357 R61C T 0.0 0.0 0.0 0.0 0.0 0.0 5.4 7.2 
rs55918055 C88R A 0.0 0.0 0.0 ND ND 0.0 0.0 0.6 
rs34104736 S189L T 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 
rs36103319 G220V T 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 
rs4646277 P283L T 0.0 0.0 0.0 ND ND 0.5 1.3 ND 
rs2282143 P341L T 8.4 8.0 9.0 8.2 16.8 12.4 16.7 0.0 
rs34130495 G401S A 0.0 0.0 0.0 0.7 0.0 0.0 1.6 1.1 
rs35956182 M440I A 0.0 0.0 0.0 0.5 0.0 0.0 2.7 0.0 
rs34059508 G465R A 0.0 0.0 0.0 0.0 0.0 0.0 1.1 4.0 
rs78899680 V519F T 3.0 2.0 6.0 ND ND 0.0 0.0 ND 
rs622342 Intronic C 23.0 22.0 15.0 ND ND 13.2 37.1 ND 
           
This study; b. Data from 1000Genomes; c. Data from (Shu et al., 2003); d. Data from (Itoda et al., 2004) 
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Figure 2.1 - Allele frequencies of selected SLC22A1 SNPs in the Xhosa population compared to other African and world populations. 
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Table 2.6 - Haplotype structure defined by 20 SNPs in the SLC22A1 gene in the 
Xhosa population. 
Haplotype No. Haplotypes a Frequency % 
   
Haplotype *1 CCTCGCCGCGCAAGGAGTGA 69.4 
Haplotype *2 CCTCGCCGCGCAAGGAGTTA 2.8 
Haplotype *3 CCTCGCCGCGCAAGGCGTGA 17.6 
Haplotype *4 CCTCGCCGTGCAAGGAGTGA 5.0 
Haplotype *5 CCTCGCCGTGCAAGGCGTGA 3.2 
Haplotype *6 CCTCGCCGTGCAAGGCGTTA 0.2 
Haplotype *7 TCTCGCCGCGCAAGGAGTGA 1.1 
Haplotype *8 TCTCGCCGCGCAAGGCGTGA 0.6 
 Total 99.9 
a) Haplotype sequences are based on the position of SNPs on chromosome 6. 
 
2.5. Discussion 
Single nucleotide polymorphisms in hOCT1 have been increasingly recognized as a 
possible mechanism explaining inter-individual variation in drug response (Leabman 
et al., 2003). In this study we determined the allelic frequency of 20 SNPs in the 
hOCT1 gene of 148 healthy individuals of the Xhosa population of South Africa, 
and the data was compared with other published studies. No polymorphisms were 
observed for the Xhosa population for sixteen out of the twenty SNPs investigated in 
this study. In a previous study aimed at the development of male specific genotyping 
systems for use in sexual assault cases in South Africa, low levels of polymorphism 
were also observed for the Xhosa population (Leat et al., 2004a, Leat et al., 2007, 
Leat et al., 2004b). 
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hOCT1 carrying the S14F (rs34447885) substitution was previously shown to 
exhibit an increased uptake of the prototypical organic cation MPP+ (Shu et al., 
2003). However, in a subsequent study by Shu et al. (2007) it was shown that the 
S14F variant displayed a reduced uptake of the anti-diabetic drug metformin which, 
was attributed to a reduction in the transporter’s Vmax for metformin (Y Shu et al., 
2007). The MAF of S14F (rs34447885) for the Xhosa population (2.0%) was similar 
to that of African-Americans (3.0%) (Shu et al., 2003) and of two other sub-Saharan 
African populations, the Luhya in Webuye, Kenya (3.0%) and the Yoruba in Ibadan. 
Nigeria (2.0%). However, the MAF was significantly higher than that observed in 
Caucasians (0.0%) and Asians (0.0%). Therefore, it is possible to expect that drugs 
which are substrates of hOCT1 could have different response profiles in the Xhosa 
population compared to Caucasian and Asian populations. 
Previous studies have found that hOCT1 R61C (rs12208357) and G401S 
(rs34130495) variants showed reduced transport of the prototypical organic cation 
MPP+ (Shu et al., 2003). In addition, it was shown that these variants exhibited 
reduced transport of metformin (Y Shu et al., 2007). Furthermore, the R61C variant 
has been reported to be strongly correlated with low hOCT1 protein expression in 
liver tissues of a 150 Caucasian subjects (Nies et al., 2009). Moreover, these 
reduced-function variants were associated with an increase in the renal clearance of 
metformin (Tzvetkov et al., 2009). Both these variants are frequently observed in 
Caucasian populations with MAF of 7.2% and 4%, respectively (Shu et al., 2003). In 
contrast, none of these variants were observed for the Xhosa, Luhya, Yoruba, 
African-Americans or any of the Asian populations. 
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In Xenopus laevis oocytes expression systems, the uptake of the prototypical organic 
cation MPP+ by the C88R (rs55918055) variant transporter was reduced to 1.4% 
compared with the reference, whereas serotonin uptake was reduced to only 13% of 
the wild-type (Kerb et al., 2002). The MAF for C88R in a Caucasian population was 
observed at 6.2% by Kerb et al (Kerb et al., 2002), compared to 0.0% for the Xhosa 
population in this study. 
The hOCT1 variants G220V (rs36103319) and G465R (rs34059508) were first 
identified as non-functional variants. The G220V variant has thus far only been 
observed in the African American population with MAF of 0.5%, whereas, the 
G465R was only observed in the Caucasian population at a MAF of 4.0%. 
Moreover, G465R was associated with reduced localization at the basolateral 
membrane (Y Shu et al., 2007). However, none of these non-functional variants were 
observed in this study for the Xhosa population. These variants were also not 
observed in other African populations or in any of the Asian populations. 
The allele frequency of P341L (rs2282143) in the Xhosa population (8.4%) was 
similar to those of other Sub-Saharan African populations, lower than the Asian 
populations, and significantly higher than that of the Caucasian populations (Table 
5). Functional transport assays conducted in vitro have shown that the P341L variant 
results in a decrease rate of MPP+ transport, and has no effect on the transport of the 
anti-diabetic drug metformin (Sakata et al., 2004, Y Shu et al., 2007). Thus, 
impaired transport activities related to the P341L SNP may differ between Africans, 
Asians, and Caucasians, with consequent effects on the 
pharmacokinetics/pharmacodynamics of certain substrates (Kang et al., 2007). 
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The P283L (rs4646277) variant was first described in a Japanese population and was 
shown to have reduced transport activity despite similar protein expression levels of 
the plasma membrane (Takeuchi et al., 2003, Sakata et al., 2004). The P283L variant 
was subsequently also found in other Asian populations with an allele frequency of 
1.3% in a Korean population and did not differ significantly from those of Chinese 
and Vietnamese populations (Kang et al., 2007).This variant was however not 
observed in the Xhosa population or any of the other African populations nor in any 
of the Caucasian populations (Figure 2.1). 
The hOCT1 Met420 deletion (rs72552763) that occurs in exon 7 is a common 
variant with a MAF of 18.5% in Caucasians and 5% in African Americans, 
respectively (Goswami et al., 2014, Shu et al., 2003). The expression of this variant 
in HEK293 cells resulted in reduced hOCT1 function with a concomitant reduction 
in metformin uptake by altering the kinetics (decreasing Vmax) of metformin (Shu et 
al., 2008). In addition, the Met420del variant is also associated with an increased 
probability of imatinib failure in patients with CML (Giannoudis et al., 2013). 
However, this variant was not observed in the current study population. 
The intronic SNP rs622342 was first reported by Becker et al. (2009) in a group of 
Dutch incident metformin users with a MAF of 37.0% (ML Becker et al., 2009). In 
contrast, the MAF for this variant in the Xhosa population was lower (21.6%). 
Moreover, Becker et al. (2009)  concluded that an association existed between 
genetic variation in the gene encoding for the hOCT1 transporter protein and the 
glucose lowering effect of metformin in diabetes mellitus patients, and that 
metformin therapy was less effective in patients carrying the minor C allele (ML 
Becker et al., 2009). In a subsequent study, by the same group, it was shown that the 
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effect of the hMATE1 rs2289669 polymorphism on the glucose lowering effect of 
metformin was larger in patients with the hOCT1 rs622342 CC genotype than those 
with the AA genotype (Becker et al., 2010). 
In the present study, the nonsynonymous SNP V519F (rs78899680) was also 
genotyped and the observed MAF was 3.0%. This value was higher than that of the 
Luhya (2.0%), a population from Eastern Africa, and lower than that of the Yoruba 
(6.0%) of Western Africa (Table 5). However, this variant was not observed in any 
of the Caucasian or Asian populations, indicating that it may be specific to African 
populations. The impact of this variant on transport function or drug efficacy has not 
yet been determined and requires further investigation. 
It is well known that individual variation in drug response can be attributed to 
specific genetic variants. Moreover, it is believed that the incorporation of 
haplotypes in pharmacogenetic studies will provide a more complete picture of loci 
that are relevant in the practice of “genetic medicine” both at an individual or 
population level (Crawford and Nickerson, 2005). In this study, the haplotype 
structure defined by 20 SNPs in the SLC22A1 gene was inferred for the investigated 
population. The most frequently observed haplotypes were 
CCTCGCCGCGCAAGGAGTGA (69.4%), CCTCGCCGCGCAAGGCGTGA 
(17.6%), and CCTCGCCGTGCAAGGAGTGA (7.0%).  
Although Africa is the continent where the burden of disease is the heaviest, research 
and clinical trials are predominantly performed on Caucasian and Asian populations. 
This contributes to poor treatment response and occurrence of adverse drug reactions 
in the genetically diverse African populations. Thus, hOCT1variant alleles which are 
commonly/only found in African populations will/may have a profound impact on 
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organic cationic drug transport efficacy and toxicity. Given that organic cationic 
drugs are used in the treatment of diseases such as type-2 diabetes mellitus, various 
cancers, and HIV, these variants may impact profoundly on healthcare provided over 
the African continent. Therefore, given the aforementioned reasons studies such as 
this is valuable in the generation of useful pharmacogenetic information specific for 
African populations. 
2.6. Conclusions 
To our knowledge, this is the first study that investigated the allele and genotype 
frequency distributions of SNPs in the SLC22A1 gene of the Xhosa population. This 
study also reports the observed haplotypes in the investigated population. It has also 
been shown that reduced-function nonsynonymous SNPs in the SLC22A1 gene 
found in Caucasian and Asian populations are absent from the Xhosa population. We 
have shown that, although MAF observed for the Xhosa population is largely similar 
to other African populations, differences exist that may translate into differences in 
organic cationic drug transport between these ethnic groups. These variations may 
translate into differences in the transport and efficacy of organic cationic drugs 
commonly used for the treatment of diseases prevalent in Africa. However, it should 
be noted that this was only a descriptive study and that no associations are made 
between any diseases or treatment outcomes. This study contributes towards filling 
the gap that exists with regards to genetic information about important variations in 
organic cation transporter genes, such as SLC22A1, for the indigenous populations of 
South Africa. The uptake transporters hOCT1 and hMATE1 are co-localized in the 
liver and function cooperatively in the elimination of organic cation substrates such 
as metformin from hepatocytes. Thus, Chapter 3 will focus on the investigation of 
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allele frequency distribution of potential deleterious SLC47A1 genetic variants in the 
Xhosa population. 
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CHAPTER 3 
Assessment of Genetic Variations within the SLC47A1 Gene of the Xhosa 
Population 
 
3.1. Abstract 
Multidrug and toxin extrusion 1 (MATE1) is a recently identified organic cation/H+ 
exchanger, localized in the apical membrane of proximal renal tubules, which 
mediates the cellular elimination of organic cations into the renal lumen. These 
organic cations include clinically important drugs such as metformin, oxaliplatin, 
and cimetidine. Moreover, genetic polymorphisms of SLC47A1, the 
pharmacogenetically relevant gene encoding hMATE1, have been implicated in 
reduced transport or accumulation to cytotoxic levels of these drugs in vitro. 
However, little or no information is available on the minor allele frequency 
distribution of known SLC47A1 coding SNPs in the sub-Saharan African 
populations. Thus, the aim of this study was to determine the baseline minor allele 
frequency distribution of 20 known coding SNPs in the SLC47A1 gene of 148 Xhosa 
individuals residing in Cape Town, South Africa. This study did not identify any of 
these known SLC47A1 coding SNPs in the Xhosa individuals that participated in this 
study. This study lays the foundation for future association studies between 
SLC47A1 variations and treatment outcomes in the Xhosa population. However, this 
study has inherent limitations and was not exhaustive with regards to known 
SLC47A1 polymorphisms. Furthermore, whole genome or exome sequencing may 
reveal novel SNPs in the Xhosa and other sub-Saharan African populations, which 
may have been missed with the current genotyping strategy. 
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3.2. Introduction 
Multidrug and toxin extrusion (MATE) proteins are recently discovered secondary 
active transporters responsible for the efflux of organic cations (OCTs) from cells. 
MATEs are widely distributed and have been cloned from various living organisms, 
including prokaryotes, plants, and mammals (Otsuka et al., 2005). This widespread 
distribution of MATEs coupled with their capacity to transport a wide variety of 
endo-/exogenous substrates underlines the importance of these transporters in 
physiological and/or pharmacological processes such as pharmacokinetics, resistance 
to antimicrobials in bacteria, resistance to chemotherapeutic agents in tumour tissues, 
and hormone secretion (Staud et al., 2013). 
hMATE1, consisting of 570 amino acid residues, is encoded by the SLC47A1 gene 
which is located on chromosome 17p11.2 (Otsuka et al., 2005). MATE transporters 
are primarily expressed in the kidney and liver, and they are localized at the apical 
membrane of the renal tubules and bile canaliculi, and transport organic cations 
(OCs) with an oppositely directed H+ gradient as a driving force (Masuda et al., 
2006, Tsuda et al., 2007). However, a recent study found that hMATE1/hMATE 
isoforms are also expressed in the human placenta, albeit with considerable inter- 
and intra-individual variability (Ahmadimoghaddam et al., 2013)  Substantial 
evidence has accumulated that implicates hMATE1, hMATE2, and its kidney-
specific homolog hMATE2-K as critical components in the luminal efflux of OCs 
from renal proximal tubules into urine (Komatsu et al., 2011, Masuda et al., 2006, 
Tsuda et al., 2009a, Watanabe et al., 2010). In vitro studies have shown that MATE1 
and MATE2-K are involved in the transport of prototypical OCs such as 
tetraethylammonium bromide (TEA), the neurotoxin 1-methyl-4-pyridinium (MPP+), 
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the histamine antagonist-receptor inhibitor cimetidine, the antidiabetic drug 
metformin, the antiarrhythmic drug procainamide. In addition, MATE1 can also 
effectively transport the zwitterionic β-lactam antibiotics cephalexin and cephradine 
and the anionic compounds estrone sulphate, acyclovir, and ganciclovir (Tanihara et 
al., 2007, Terada et al., 2006).  Because MATEs and OCTs cooperate in transcellular 
passage, considerable overlap in substrate specificity must exist between these 
transporters (Iwata et al., 2012). 
Mammalian MATE1, similar to other MATE family members have a predicted 
protein fold composed of 12 transmembrane helices (TMHs) (He et al., 2010, Zhang 
et al., 2012). Zhang et al in their study showed that the human orthologue of MATE, 
similar to its rabbit and mouse paralogues, has an extacelluar C-terminus, consistent 
with the presence of 13 TMHs (Zhang and Wright, 2009, Zhang et al., 2012). 
Moreover, Zhang et al. (2012) concluded that the terminal 13th TMH is not required 
for the functional activities of human, rabbit, and mouse MATE1, and that ligand 
binding of truncated proteins consisting of 12 TMHs is essentially normal. This 
supports the general view that the functional core structure of MATE proteins, 
including mammalian MATEs, is comprised of 12 TMHs and that the 13th TMH is 
merely influences transporter turnover activity (Zhang et al., 2012).  Combined in 
vitro/in silico and quantitative structure-activity relationship (QASAR) models 
suggest that MATE preferentially bind large, lipophilic, and positively charged 
molecules (Astorga et al., 2012, Wittwer et al., 2013). 
In animal models of human diseases, Mate1 expression was decreased in renal 
failure and increased in metabolic acidosis, suggesting pathological conditions may 
affect MATE1 expression and resultantly the pharmacokinetics and 
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pharmcodynamics of its substrates (Gaowa et al., 2011, Nishihara et al., 2007). 
Becker et al. (2009) demonstrated that genetic variation in the SLC47A1 gene was 
associated with the glucose-lowering effect of metformin (Matthijs L Becker et al., 
2009). Ha Choi et al. (2009) found that a common promoter variant may affect the 
expression of MATE1 in the kidney, and may ultimately result in variation of drug 
disposition and response (Choi et al., 2009). 
In addition to genetic polymorphisms, adverse drug-drug interactions (DDIs) can 
also affect the pharmacokinetics and/or pharmacodynamics of hMATE substrate 
drugs. In a study by Tsuda et al. (2009) double-transfected Madin-Darby canine 
kidney (MDCK) cells stably expressing both hOCT2 and hMATE transporters were 
used as an in vitro model of proximal tubular epithelial cells to assess the interaction 
of the histamine-receptor antagonist, cimetidine with the biguanide antidiabetic, 
metformin (Tsuda et al., 2009b). Contrary to the findings of previous studies, they 
found that cimetidine showed a higher affinity for hMATEs than hOCT2. 
Subsequently, Ito et al. (2012) showed that competitive inhibition of the luminal 
efflux by hMATE1, and not the basolateral uptake by hOCT2, is the likely 
mechanism underlying the pharmacokinetic DDIs caused by cimetidine in the kidney 
(Ito et al., 2012). Furthermore, in a study by Grün et al. (2013) the antibiotic 
trimethoprim significantly reduced metformin elimination resulting in increased 
exposure to the antidiabetic (Grun et al., 2013). The anti-malarial drug 
pyrimethamine is a potent inhibitor of both hMATE1 and hMATE2-K activity (Ito et 
al., 2010). 
Sub-Saharan Africa, and for that matter South Africa, has a significant disease 
burden of both communicable and non-communicable diseases (Coovadia et al., 
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2009, Mayosi et al., 2012). Although African populations harbour more genetic 
diversity than Caucasians, for example, this genetic diversity is however 
understudied (Hardy et al., 2008). This lack of genetic information with robust allele 
frequencies currently serves as a significant hurdle to designing biomedical research 
and medical implications (May et al., 2013). South Africa is home to several 
indigenous African populations for which there is limited or no genomic 
information. The Xhosa population, historically indigenous to the Eastern Cape 
Province, is the second largest ethnic group in South Africa, and comprises 
approximately 17.6% (~8 million) of the total population (Drögemöller et al., 2010). 
Previous studies have shown that these populations harbour unique genotype and 
allele frequencies for pharmacogenetically relevant drug metabolizing enzymes 
(Ikediobi et al., 2011). However, to our knowledge only a limited number of studies 
have to date been undertaken to establish baseline genotype and allele frequency 
distributions of genetic polymorphisms in membrane transporter genes of the 
indigenous South African populations. Therefore, the aim of this study was to 
determine the baseline genotype and allele frequency distributions of 20 known 
SLC47A1 coding SNPs in 148 Xhosa individuals residing in Cape Town, South 
Africa 
3.3. Materials and Methods 
3.3.1. Subjects 
Subjects were as described in Chapter 2. 
3.3.2. DNA extraction and SNP selection 
A standard salt-lysis method was used for the isolation of genomic DNA was 
isolated from buccal swab samples as described in Chapter 2 and stored frozen at -
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20°C until the time of genotyping (Leat et al., 2004a). A total of 20 SLC47A1 coding 
SNPs were selected for this study. SNPs were selected from the literature and the 
Ensembl database (http://www.ensebl.org) (Flicek et al., 2012). Variants, were 
included in this study based on predicted effect on function, using the SIFT (Sorting 
Intolerant From Tolerant) program (Flanagan et al., 2010, Kumar et al., 2009, Ng 
and Henikoff, 2003). To our knowledge no population data exist in the public 
domain for these variants. 
3.3.3. Primer design 
Multiplex PCR primers for the amplification of all SLC47A1 exons and flanking 
regions were designed using Primer3 software (www.genome.wi.mit.edu/cgi-
bin/primer/primer3) and are listed in Table 3.1. To test for possible non-specific 
amplification, primers were aligned with the NCBI sequence databases using Basic 
Local Alignment Search Tool (www.ncbi.nlm.nih.gov/blast/blast-cgi). Two 
SNaPshot™ Multiplex systems were specifically designed for the study, successfully 
optimized and used for genotyping. The single base extension primer sets for 
multiplex 1 and 2 are listed in Tables 3.2 and 3.3. 
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Table 3.1 - MATE-1 multiplex PCR primers for the amplification of SLC47A1 exons and flanking regions. 
Location Forward primer 5ʹ to 3ʹ Reverse primer 5ʹ to 3ʹ Nucleotide position Amplicon size (bp) 
     
Exon 2 CCCAGGTGACAGTGTGAGAC CAGCAGAAGGCAAACACAGA 19542097 - 19542550 454 
Exon 3 GGTCCAGGCAGCTAACAAAG CTGGCTGCTGAACTCTTCCT 19546291 - 19546599 309 
Exon 4 TATCCAGCCAACCTGCTTCT GGAGGGTGCTTGCAAATCTA 19547879 - 19548374 496 
Exon 5 GGAAACAGCCAAGAATGGAA GACCCCAAGAAGGGAATCTC 19549522 - 19549716 195 
Exon 6 CTGAGACGACAGCCTCTGTG CCCATTCCCAGAAAGGTACA 19551282 - 19551531 250 
Exon 7 CAGTCCTTGCACTGTTGGAA TCCATCCCTGACAGTGCTTT 19554910 - 19555456 547 
Exon 8 - 10 CACGGGAAGGGATGAGTCT GGAGATGGAGAACCAGCAGA 19555502 - 19556294 793 
Exon 11 - 12 TGCTTCTCTGCACGTGTTCT CCTCCTGGGCTCAAGAGATT 19560120 - 19560809 690 
Exon 13 - 14 GGCTGGTCTCAAACTCCTGA GCCCCCTACACTCTCTGACA 19566635 - 19567377 743 
Exon 15 CCTCAGCCATGAAAGCAGAT ATCATCTGGCCCTTCACATC 19571359 -19571748 390 
Exon 16 TGGGATTACAGGTGTGAGCA CTCACTAACAGCCCCTCCAG 19572589 - 19572928 340 
Exon 17 GGGCACTCTGCGATAAGATT CAATGCAGTCAGCACATTGA 19577166 - 19577823 658 
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3.3.4. Multiplex PCR 
All the 17 SLC47A1 exons and their flanking regions were simultaneously amplified 
using the primers listed in Table 3.1. The PCR reactions were performed in a 20 µl 
volume, containing 20 – 50 ng of genomic DNA, 1 x Qaigen multiplex PCR master 
mix (Qaigen, Courtaboeuf, France) and 0.2 µM of each primer. Cycling parameters 
used and PCR product purification were as described in Chapter 2. 
 
3.3.5. SNaPshot™ genotyping reactions 
Multiplex minisequencing was performed in a 10 µl reaction volume using 3 µl of a 
1/10 dilution of purified PCR products, 0.1-0.2 µM of primers, and 5 µl of 
SNaPshot™ ready reaction mix (Applied Biosystems). Sequence cycling was 
performed according to the instructions of the manufacturer. Post-extension 
treatment was done as described in Chapter 2
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Table 3.2 – Multiplex 1 of SLC47A1 single-base extension primers for SNaPshot™ minisequencing reactions. 
NCBI 
(dbSNP) 
Amino Acid 
Change 
Nucleotide 
change 
Nucleotide sequence 
(5′ to 3′) 
Position 
Accession number 
(NC_000006.12) 
Primer length 
(bp) 
polyGACT tail 
       
rs143217368 T75M C>T ACCTGGGCAAGCTGGAGCTGGATGCAGTCA 19542481 30 0 
rs77474263 L125F C>T ATCCTGCAGCGGAGTGCGCTCGTCCTGCTC 19548051 35 5 
rs143542564 S151F C>T TGCTGCTCTTCAGGCAGGACCCAGATGTGT 19548130 40 10 
COSM218508 A193S G>T ATTGTACTGCCCCAGATCGTAACTGGAGTT 19555245 45 15 
rs145720500 M269T T>C TCCTCCGCCTGGCCATCCCCAGCATGCTCA 19555862 50 20 
rs149774861 D328A A>C TCCGGGTAGGAAACGCTCTGGGTGCTGGAG 19560249 55 25 
COSM141490 A409V C>T TGAGGGGGAGTGGAAATCAGAAGGTTGGAG 19567145 60 30 
rs147768037 G424R G>A CAAGTGTGGTTGCAAACATCAGCGCGATCC 19567189 65 35 
rs141945405 A473T G>A CTGAGTTTCATTTTCCAGGCTCAGGTACAC 19572791 70 40 
rs144621154 R545Q G>A AAGAAGACCCCCAGGAGCAGAAGCCCTCGC 19577474 75 45 
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Table 3.3 - Multiplex 2 of SLC47A1 single-base extension primers for SNaPshot™ minisequencing reactions. 
NCBI 
(dbSNP) 
Amino Acid 
Change 
Nucleotide 
change 
Nucleotide sequence 
(5′ to 3′) 
Position 
Accession number 
(NC_000006.12) 
Primer length 
(bp) 
polyGACT tail 
       
rs139122064 R482W C>T CACGCCAATTTGAAAGTAAACAACGTGCCT 19572819 30 0 
rs145557304 Y203C A>G CAGCCAACCTTGTCAATGCCCTCGCCAACT 19555276 35 5 
rs11551331 P148R C>G AGCACATCCTGCTGCTCTTCAGGCAGGACC 19548121 40 10 
rs148155569 A469S G>T AAGCCTGATGGACTGAGTTTCATTTTCCAG 19572780 45 15 
rs77138970 R118Q G>A ACCTGAAGCACGTGGGCGTGATCCTGCAGC 19548031 50 20 
rs149729794 P186T C>A GCGGTGTCCTTTTTCCAGGGAATTGTACTG 19555224 55 25 
rs77630697 G64D A>G TGATCAGCTTCATAAGCTCCGTGTTCTGTG 19542448 60 30 
rs148469848 Y566C A>G TCTTGCTGGTGGGGATTTTAGTGAGATTCT 19577537 65 35 
rs149920616 G397S G>A AATGCTCTCTGCCTGCAGTGCACGAGTGGT 19567108 70 40 
rs141572615 V279D T>A TGCTGTGCATGGAGTGGTGGGCCTATGAGG 19555892 75 45 
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3.3.6. Electrophoresis of the minisequencing products 
. The fluorescently labelled fragments were treated and separated on an ABI Prism 
3500 Genetic Analyzer (Applied Biosystems) as described in Chapter 2. Data 
analyses were performed using GeneMapper® IDX Software Version 1.2. 
3.4. Results and Discussion 
Our study population consisted of a 148 healthy, unrelated Xhosa individuals 
residing in the Cape Town Metropolitan area, South Africa. The age of the 
participants ranged from 18 to 61 years with the mean age of female participants 
being 25.3±9.0 years, while male participants had a mean age of 24.8±7.7 years. 
There were 80 (54%) female and 68 (46%) male participants. 
In this study we have developed two SNaPshot™ multiplex assays for genotyping 20 
known nonsynonymous coding SNPs in the SLC47A1 gene. The results for the 
SNaPshot™ genotyping are summarized in Table 3.4. Genetic variants of the 20 
SNPs assayed were absent in the Xhosa individuals analysed in this study. 
  
77 
 
 
 
 
 
CHAPTER 3 
Table 3.4 - Genotype and allele frequencies of MATE1 (SLC47A1) gene SNPs in 
148 healthy Xhosa individuals. 
Amino Acid 
Substitution dbSNP ID 
Observed Genotype Frequency Allele Frequency 
Genotype % 95% CI Allele % 95% CI HWE (P) 
         
G64D rs77630697 
AA 100.0 96.9.0 – 100.0 A 100.0 98.4 – 100.0 
 AG 0.0 0.0– 1.3 G 0.0 0.0 – 1.6 GG 0.0 0.0 – 1.3    
         
T75M rs143217368 
CC 100.0 96.9 – 100.0 C 100.0 98.4 – 100.0 
 CT 0.0 0.0 – 1.3 T 0.0 0.0 – 1.6 
TT 0.0 0.0 – 1.3    
         
R118Q rs77138970 
GG 100.0 96.9 – 100.0 G 100.0 98.4 – 100.0 
 GA 0.0 0.0 – 1.3 A 0.0 0.0 – 1.6 
AA 0.0 0.0 – 1.3    
         
L125F rs77474263 
CC 100.0 96.9 – 100.0 C 100.0 98.4 – 100.0 
 CT 0.0 0.0 – 1.3 T 0.0 0.0 -1.6 
TT 0.0 0.0 – 1.3    
         
P148R rs11551331 
CC 100.0 96.9 – 100.0 C 100.0 98.4 – 100.0 
 CG 0.0 0.0 – 1.3 G 0.0 0.0 -1.6 
GG 0.0 0.0 – 1.3    
         
S151F rs143542564 
CC 100.0 96.9 – 100.0 C 100.0 98.4 – 100.0 
 CT 0.0 0.0 – 1.3 T 0.0 0.0 – 1.6 
TT 0.0 0.0 – 1.3    
         
P186T rs149729794 
CC 100.0 96.9 – 100.0 C 100.0 98.4 – 100.0 
 CA 0.0 0.0 – 1.3 A 0.0 0.0 – 1.6 AA 0.0 0.0 – 1.3    
         
A193S COSM218508 
GG 100.0 96.9 – 100.0 G 100.0 98.4 – 100.0 
 GT 0.0 0.0 – 1.3 T 0.0 0.0 -1.6 
TT 0.0 0.0 – 1.3    
         
Y203C rs145557304 
AA 100.0 96.9 – 100.0 A 100.0 98.4 – 100.0 
 AG 0.0 0.0 – 1.3 G 0.0 0.0 -1.6 
GG 0.0 0.0 – 1.3    
         
M269T rs145720500 
TT 100.0 96.9 – 100.0 T 100.0 98.4 – 100.0 
 TC 0.0 0.0 – 1.3 C 0.0 0.0 – 1.6 
CC 0.0 0.0 – 1.3    
         
V279D rs141572615 
TT 100.0 96.9 – 100.0 T 100.0 98.4 – 100.0 
 TA 0.0 0.0 – 1.3 A 0.0 0.0 – 1.6 AA 0.0 0.0 – 3.1    
         
D328A rs149774861 
AA 100.0 96.9 – 100.0 A 100.0 98.4 – 100.0 
 AC 0.0 0.0 – 1.3 C 0.0 0.0 – 1.6 CC 0.0 0.0 – 1.3    
         
G397S rs149920616 
GG 100.0 96.9 – 100.0 G 100.0 98.4 – 100.0 
 GA 0.0 0.0 – 1.3 A 0.0 0.0 – 1.6 
AA 0.0 0.0 – 1.3    
         
A409V COSM141490 
CC 100.0 96.9 – 100.0 C 100.0 98.4 – 100.0 
 CT 0.0 0.0 – 1.3 T 0.0 0.0 – 1.6 
TT 0.0 0.0 – 1.3    
         
G424R rs147768037 GG 100.0 96.9 – 100.0 G 100.0 98.4 – 100.0  GA 0.0 0.0 – 1.3 A 0.0 0.0 – 1.6 
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  AA 0.0 0.0 – 1.3     
         
A469S rs148155569 
GG 100.0 96.9 – 100.0 G 100.0 98.4 – 100.0 
 GT 0.0 0.0 – 1.3 T 0.0 0.0 – 1.6 
TT 0.0 0.0 – 1.3    
         
A473T rs141945405 
GG 100.0 96.9 – 100.0 G 100.0 98.4 – 100.0 
 GA 0.0 0.0 – 1.3 A 0.0 0.0 – 1.6 
AA 0.0 0.0 – 1.3    
         
R482W rs139122064 
CC 100.0 96.9 – 100.0 C 100.0 98.4 – 100.0 
 CT 0.0 0.0 – 1.3 T 0.0 0.0 – 1.6 
TT 0.0 0.0 – 1.3    
         
R545Q rs144621154 
GG 100.0 96.9 – 100.0 G 100.0 98.4 – 100.0 
 GA 0.0 0.0 – 1.3 A 0.0 0.0 – 1.6 
AA 0.0 0.0 – 1.3    
         
Y566C rs148469848 
AA 100.0 96.9 – 100.0 A 100.0 98.4 – 100.0 
 AG 0.0 0.0 – 1.3 G 0.0 0.0 – 1.6 
GG 0.0 0.0 – 1.3    
         
 
The human MATE1 is highly expressed at the apical membranes of liver  
hepatocytes and renal proximal tubules, and mediates the biliary and renal excretion 
of many cationic drugs and their metabolites (Otsuka et al., 2005). Functional 
changes in the expression level of SLC47A1 caused by genetic variations in the 
coding and noncoding regions could alter the transport activity of MATE1 and 
ultimately the effects of the substrates translocated by the transporter in vivo. The 
aim of this study was to determine the allelic and genotypic distribution of 20 known 
coding SNPs in the SLC47A1gene, encoding MATE1, in the Xhosa population of 
South Africa. 
This study did not identify any of the known investigated nonsynonymous coding 
variations in the SLC47A1 gene of the Xhosa individuals. However, searching the 
dbSNP database revealed only 60 nonsynonymous coding SNPs, with very low 
minor allele frequencies, in the SLC47A1 gene. This lack of protein sequence and 
mutational diversity was also observed in other studies for hOCT2 and hOCT3 
(Kang et al., 2007, Lazar et al., 2003). This absence of genetic diversity merely 
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demonstrates the critical role the MATE1 transporter performs in the elimination of 
xenobiotics and the maintenance of cellular and organismal homeostasis (Lazar et 
al., 2003, Leabman et al., 2003). 
Kajiwara et al. (2009) identified the hMATE1 variant G64D in their study of 89 
healthy Japanese individuals (Kajiwara et al., 2009). This variant was also observed 
by Chen et al. (2009) in a study with 272 ethnically diverse individuals (Chen et al., 
2009b). Both these groups went on and demonstrated that this variant leads to a 
complete loss of transport activity. When Kajiwara et al. (2009) evaluated membrane 
expression levels using cell surface biotinylation, they found that the expression of 
the G64D variant was significantly decreased compared to that of the wild-type. This 
variant was included in the current study, but was not observed in the Xhosa 
individuals screened in this study. However, because of the limited sample size, and 
the low global allele frequency of this variant the presence of this variant in the 
Xhosa population cannot be excluded. 
This study did not investigate the allele frequency distribution for known genetic 
variants in the proximal promoter region of the SLC47A1 gene. However, in a study 
conducted by Kajiwara et al. (2007) the authors described a variant, g.-32G>A with 
a minor allele frequency of 3.7%  in the SLC47A1 proximal promoter region that 
showed markedly decreased promoter activity (Kajiwara et al., 2007). Their study 
showed that the SpI transcription factor has a critical role in the basal promoter 
activity of the SLC47A1 gene, and that the g.-32G>A variant reduced the binding 
affinity of SpI to the promoter. In a subsequent study, Ha Choi et al. (2009) 
identified novel polymorphisms in the proximal promoter of SLC47A1, and found 
that one of the polymorphisms, g.-66T>C, is associated with a significant reduction 
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of SLC47A1 promoter activity and with lower expression of MATE1 in the kidney 
(Choi et al., 2009). They concluded that this reduced SLC47A1 promoter activity 
seemed to be related to the binding of the transcription factor AP-1 which acts as an 
activator of transcription, and to an increased binding of the repressor AP-2rep to the 
region containing the g.-66T>C substitution. Since these promoter variants can have 
a profound effect on the expression of the gene, which in turn can affect the transport 
activity and the pharmacokinetic and pharmacodynamic consequences of clinical 
drugs transported by MATE1, the determination of allele frequency distributions of 
known promoter SNPs and the extent of rare variants within the Xhosa population 
requires further investigation. 
Metformin, an oral anti-diabetic drug, is one of the most frequently prescribed drugs 
in the treatment of type-2 diabetes. Tanihara et al. (2007) demonstrated that MATE1 
transports metformin and could be a determinant of its efficacy (Tanihara et al., 
2007).  The elimination of metformin from the body mainly depends on renal 
clearance, including excretion mediated by OCT and  MATE transporters (Graham 
et al., 2011). Genetic variations in the genes encoding the hOCT1, hOCT2, hOCT3, 
MATE1 and MATE2-K transporters have been associated with an altered 
pharmacokinetic and pharmacodynamic response to metformin (Christensen et al., 
2011). Becker et al. (2009) reported that a SNP located in the intronic region of 
SLC47A1, rs2289669G>A, was associated with the glucose-lowering effect of 
metformin in a group of Dutch diabetic patients (Matthijs L Becker et al., 2009). 
However, Tzvetkov et al. (2009) found no association between rs2289669G>A and 
the renal or extrarenal clearance of orally administered metformin (Tzvetkov et al., 
2009). In addition, a recent study by Toyama et al. (2012) found that heterozygous 
nonsynonymous variants of both MATE1 and MATE2-K do not affect metformin 
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disposition in diabetic patients (Toyama et al., 2012). As current knowledge in this 
field is still limited and contradictory, further studies are required to confirm the 
clinical relevance of SLC47A1 SNPs in the pharmacokinetics and 
pharmacodynamics of metformin and other clinical substrates of MATE1 (Matthijs L 
Becker et al., 2009, Tkáč et al., 2013, Tzvetkov et al., 2009). 
3.5. Conclusions 
To our knowledge this study is the first that prioritized the genotyping of known 
coding SNPs of SLC47A1, a pharmacogenetically relevant gene, in the Xhosa 
population. The SNPs genotyped in this study are known variants that have been 
observed in other populations and may not be present in the Xhosa population. 
Given the under-studied genomic diversity harboured within sub-Saharan indigenous 
African populations, the potential exist that novel and rare low frequency variations 
could be identified in the Xhosa population. This study also lays the foundation for 
future association studies between SLC47A1 variations and treatment outcomes in 
the Xhosa population. The H+/organic cation efflux transporter hMATE1 also co-
operatively functions with the organic cation uptake transporter hOCT2 in the kidney 
where it is involved in the elimination of organic cations from the body. Therefore, 
Chapter 4 will prioritize the investigation of nonsynonymous variants of the 
SLC22A2 gene in the Xhosa participants. 
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CHAPTER 4 
Genotype and Allele Frequency Distribution of 20 SLC22A2 Single Nucleotide 
Polymorphisms in the Xhosa Population 
4.1. Abstract 
The solute carrier family of the major facilitator membrane transporters play an 
important role in maintaining cellular and organismal homeostasis. Organic cation 
transporters, which belong to the SLC22A2 family, are polyspecific transporters that 
mediate the electrogenic transport of small organic cations with different molecular 
structures, independent of sodium gradient. The kidney-specific hOCT2, which is 
encoded by SLC22A2, is an organic cation transporter which is involved in the 
translocation of a diverse group of therapeutic drugs including metformin, 
cimetidine, procainamide, cisplatin, and lamivudine. Moreover, single nucleotide 
polymorphisms of SLC22A2 are clinically significant because they can alter the 
transport of substrate drugs, and as such can influence the efficacy and toxicity 
thereof. Although it is widely accepted that African populations harbour a greater 
amount of genomic diversity compared to other populations, limited information is 
available regarding genetic polymorphisms in SLC genes, and for that matter the 
SLC22A2 gene, of sub-Saharan African populations or on the ethnic differences 
between African and other populations and among African populations themselves 
regarding genetic polymorphisms related to impaired functional activity of hOCT2. 
Therefore, the initial aim of this study was to develop a multiplex SNaPshot™ 
genotyping assay system for 20 previously reported SLC22A2 nonsynonymous SNPs 
and to assess the baseline allele frequencies of these variants in 148 Xhosa 
individuals residing in Cape Town, South Africa. We identified three 
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nonsynonymous SNPs namely, A270S, R400C, and K432Q in the population studied 
at minor allele frequencies of 6.1%; 3.4%; and 0.7%, respectively. The genetic 
variants and the allele frequencies observed in this study again highlight the fact that 
the distribution of these variants and their allele frequencies differ amongst African 
and other populations. Moreover, the distribution of genetic variants and their allele 
frequencies differ even among the African populations themselves. This study lays 
the foundation for ethnicity-specific genotype-to-phenotype correlates of treatment 
outcome for SLC22A2 genetic polymorphisms and hOCT2 substrate drugs. In 
addition to SNPs, the haplotypes identified in this study can in future also aid in 
identifying associations between causative genetic variants and drug response. 
4.2. Introduction 
At physiological pH, approximately 40% of drugs are organic cations or weak bases 
which cellular uptake may be mediated by organic cation transporters (OCTs) 
(Neuhoff et al., 2003). Polyspecific OCTs belong to the major facilitator family of 
solute carrier transporters, and are involved in the bidirectional transport of a variety 
of structurally diverse lipophilic organic cations of endogenous or xenobiotic origin 
across the plasma membrane (Koepsell et al., 2007). 
OCT-mediated transport is electrogenic and independent of sodium ion or proton 
gradient. Three isoforms of human OCTs exist, namely hOCT1, hOCT2, and 
hOCT3, which share a partially overlapping substrate spectra and have a similar 
membrane topology consisting of 12 transmembrane helices (TMHs), an intracellular 
N-terminus, a large glycosylated extracellular loop between TMHs 1 and 2, a large 
intracellular loop with phosphorylation sites between TMHs 6 and 7, and an 
intracellular C-terminus (Koepsell et al., 2007). However, OCTs show different 
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affinities to particular substrates and differ in their tissue distribution, membrane 
localization as well as in their regulation (Ciarimboli and Schlatter, 2005, Hayer‐
Zillgen et al., 2002). 
The hOCT2 gene SLC22A2, consisting of 11 exons, was first cloned in 1997 and is 
located on chromosome 6q26, adjacent to SLC22A1 which encodes for hOCT1 
(Gorboulev et al., 1997, Koehler et al., 1997, Koepsell et al., 2007). The hOCT1 
paralogue hOCT2 consists of 555 amino acid residues and has been detected in the 
kidney, placenta, spleen, intestine, and neuron (Busch et al., 1998, Gorboulev et al., 
1997, Koepsell et al., 2007). The hOCT1 is predominantly localized in the liver 
whereas hOCT2 is mainly expressed in the basolateral membrane of kidney proximal 
tubules and is the major facilitator for the uptake of cationic substrates from the 
circulation into renal epithelial cells (Gorboulev et al., 1997, Motohashi et al., 2002). 
Examples of clinically important drugs transported by hOCT2 include the 
antidiabetic drugs metformin and phenformin, the antineoplastic drugs cisplatin and 
oxaliplatin, the anti-HIV drugs lamivudine and zalcitabine, and the histamine 
receptor antagonist cimetidine (Barendt and Wright, 2002, Busch et al., 1998, 
Ciarimboli et al., 2005b, Dresser et al., 2002, Kimura et al., 2005b, Jung et al., 
2008). In addition, hOCT2 is also responsible for the transport of endogenous 
compounds such as monoamine neurotransmitter 5-hydroxytryptamine (5-HT), 
agmatine, choline, dopamine, epinephrine, histamine, and norepinephrine, as well as 
compounds such as creatinine (Amphoux et al., 2006, Busch et al., 1998). Moreover, 
the transporter is critical in the detoxification and elimination of xenobiotics from the 
systemic circulation and is also involved in the transport of toxic substances such as 
tetraethylammonium bromide (TEA), HPP+, and 1-methyl-4-phenylpyridinium 
(MPP+) (Burckhardt and Wolff, 2000, Gorboulev et al., 1997, Okuda et al., 1999, 
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Otsuka et al., 2005, Zhang et al., 1997, Zhang et al., 1998). Tissue expression and 
membrane localization of hOCT2 are closely linked to the tissue distribution, 
pharmacological effects, and/or adverse effects of its substrate drugs (Aoki et al., 
2008). 
Polymorphisms that change expression level, regulation, turnover, membrane 
trafficking, and/or substrate affinity of OCTs can potentially influence the 
therapeutic efficiency of substrate drugs and may lead to  severe or even fatal 
adverse drug reactions (Bachtiar and Lee, 2013). Recent studies have identified 
several single nucleotide polymorphisms in the SLC22A2 gene in ethnically diverse 
populations (Fukushima-Uesaka et al., 2004, Leabman et al., 2002, Kang et al., 
2007). However, in comparison to its liver-specific paralog, hOCT1, hOCT2 is less 
diverse in terms of both amino acid mutations and functional activity (Fujita et al., 
2006). However, single nucleotide polymorphisms identified in SLC22A2 have been 
associated with changes in the pharmacokinetic/pharmacodynamics responses in 
substrate drugs such as metformin (Wang et al., 2008). 
Metformin, the biguanide anti-diabetic drug, has been identified as a superior 
substrate of hOCT2 (Wang et al., 2008, Leabman et al., 2002). Song et al. (2008) 
found that the uptake of metformin was greater in oocytes expressing the hOCT2 
wildtype, than in ones expressing hOCT1 wild-type (Song et al., 2008b). Moreover, 
transport of metformin was significantly reduced in oocytes expressing the 
nonsynonymous hOCT2 variants T199I (rs201919874), T201M (rs145450955), and 
A270S (rs316019) compared to the hOCT2 wild-type (Song et al., 2008a, Song et 
al., 2008b). In a recent study Chen et al. (2009) demonstrated that the A270S 
(rs316019) variant was associated with a greater clearance of renal metformin in 
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healthy volunteers of European and African ancestries (Chen et al., 2009a). 
Moreover, Li et al. (2010) found that the A270S (rs316019) variant can affect the 
plasma lactate levels and the incidence of hyperlactacidemia (lactic acidosis), a 
severe and sometimes lethal side-effect of metformin treatment, in Chinese Han 
patients with type-2 diabetes that are on metformin therapy (Li et al., 2010).  
Furthermore, solute carrier transporters (SLCs), in particular OCTs, have been 
implicated in the cellular uptake and elimination of platinum-containing anti-cancer 
compounds. Burger et al. (2010) found that hOCT2 is a critical determinant in the 
uptake and toxicity of various platinum compounds, especially oxaliplatin (Burger et 
al., 2010). This finding was supported by Sprowl et al. (2013) who found that 
hOCT2 is an important factor in oxaliplatin-induced neurotoxicity because it is 
responsible for the accumulation of oxaliplatin in the root ganglia cells of the 
nervous (Sprowl et al., 2013). 
In contrast to our understanding of the effects of ethnicity on drug metabolism, little 
information is known about ethnicity-related differences in the disposition and 
effects of drugs that are substrates of membrane transporters (Cropp et al., 2008). 
Moreover, ethnic specific variations are currently not taken into account in most 
commercially available pharmacogenetic tests or on FDA drug labels (Ikediobi et al., 
2011). Although African populations harbour more genetic diversity than other 
populations, most pharmacogenetic studies to date have been conducted most 
frequently in Western European and North American Caucasians population groups 
only (Frazer et al., 2009, Hardy et al., 2008, Ikediobi et al., 2011). 
The SLC22A2 gene is relevant for the pharmacokinetic disposition of a number of 
clinically important drugs, including those used in the treatment of type-2 diabetes, 
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cancer, and HIV (Burger et al., 2010, Burger et al., 2011, Jung et al., 2008, Jung et 
al., 2013, Kimura et al., 2005a, Kimura et al., 2009). Sub-Saharan Africa currently 
has the highest global prevalence of HIV/AIDS and rates for lifestyle diseases are 
rising due to rapid urbanisation (Mayosi et al., 2012, Shisana et al., 2009). It is 
estimated that approximately 60% of deaths in southern African countries are 
attributable to communicable diseases, whilst 30% are caused by non-communicable 
disorders (Coovadia et al., 2009, Mayosi et al., 2012). Although the role of OCTs in 
the pathogenesis and transport of drugs used in the treatment of these diseases are 
generally recognized, little or no information is available regarding genetic 
polymorphisms of the SLC22A2 gene in African populations residing in southern 
Africa. In addition, no information is available on the inter-ethnic differences among 
African populations with regards to genetic polymorphisms related to impaired 
functional activity of hOCT2. Thus, the aim of this study was to develop a multiplex 
SNaPshot™ genotyping assay system for 20 previously reported SLC22A2 
nonsynonymous SNPs and to assess the baseline minor allele frequencies (MAFs) of 
these variants in 148 Xhosa individuals residing in Cape Town, South Africa. 
Secondly, to compare the MAF estimates obtained for other African, American, 
European, and Asian populations. Finally, to determine the haplotype structure of the 
SLC22A2 gene in the Xhosa population based on the selected loci. 
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4.3. Materials and Methods 
4.3.1. Subjects 
As described in Chapter 2. 
4.3.2. Multiplex PCR and Single-Base Extension Primer Design 
Multiplex PCR and single base extension (SBE) primers, listed in Tables 4.1 to 4.3, 
were designed using Primer3 software (www.genome.wi.mit.edu/cgi-
bin/primer/primer3). To test for possible non-specific amplification, primers were 
aligned with the NCBI sequence databases using Basic Local Alignment Search Tool 
(www.ncbi.nlm.nih.gov/blast/blast-cgi). Two SNaPshot® SBE Multiplex systems 
were specifically designed for this study, successfully optimized and used for 
genotyping. A total of 20 SLC22A2 gene SNPs were selected for this study. SNPs 
were selected from the literature and the Ensembl database (http://www.ensebl.org) 
(Flicek et al., 2012). Variants M1V; R176H; C282G; L351W; R207H; T357M; 
M393T; R404C; G439E; R463K; R487Q R487W; V502E/G; and V502M were 
included in this study based on predicted effect on function, using the SIFT (Sorting 
Intolerant From Tolerant) program (Flanagan et al., 2010, Kumar et al., 2009, Ng 
and Henikoff, 2003). To our knowledge no population data exist in the public 
domain for these variants. 
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4.3.3. DNA isolation and SNaPshot™ genotyping 
DNA isolation and SNaPshot™ genotyping were performed as described in Chapter 
2. 
4.3.4. Electrophoresis of the minisequencing products 
The purified fluorescently labelled minisequencing products were mixed with  
HiDi™ formamide and GeneScan-120 Liz size standard (Applied Biosystems), 
denatured, and separated on an ABI Prism 3500 Genetic Analyzer (Applied 
Biosystems) as described in Chapter 2. Data analyses were performed using 
GeneMapper® IDX Software Version 1.2. 
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Table 4.1 - Multiplex PCR primers for the generation of SLC22A2 amplicons used in SNaPshot™ genotyping. 
 
Location Forward primer (5´to 3´) Reverse Primer (5ʹto 3ʹ) Amplified region (NC_000006.12) Amplicon length (bp) 
     
Exon 1 TTTGGGAAGTGCAGAAGGAC CCATTTGCTTCTCCATCTGAG 160258972 - 160258303 670 
Exon 2 GGAACACTTCTCCCCTGCT CACCACAGGTGATTCAACCTAC 160256741 - 160256592 150 
Exon 3 GTGAATGGGGCTTATCATGC TCTATTTTGGCAGCGAGGTT 160250933 - 160250491 443 
Exon 4 CAGGCCTTTCATCCCATCTA GGGTCTGGAGAGTGAAAGCA 160249613 - 160249098 516 
Exon 5 GGATGGGGTAAGGAGGATTC TTTCTCCATCCCCTGATTTG 160247353 - 160247143 211 
Exon 6 TGACCCAGGGACACTAGCAT TACCGGGATGAGGTCATGTT 160245603 - 160245344 260 
Exon 7 CACAGCCAGCCACTGAAGTA GCTGGCCATATGAATTTGCT 160243961 - 160243408 554 
Exon 8 ATTCTGGGATGGGGAATTTG TCCTTTGTCTGCACTTGTGG 160242504 - 160242212 293 
Exon 9 AGGGGTGGATGGGAGATAAC ACATCCAGGAAGAACGCAAG 160241655 - 160241313 343 
Exon 10 TTCAATGGAGTTTGGAACTGG TGAATTTATCTCAGTGTATGGTGTGA 160224991 - 160224588 404 
Exon 11 AATTTCTTTCTCCCCTCTCCA TTTTAAAATCCACAAATGTTAAGACA 160217538 - 160216700 839 
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Table 4.2 - SLC22A2 gene multiplex 1 single base extension primers for SNaPshot™ genotyping assay of selected SNPs. 
NCBI 
(dbSNP) 
Amino Acid 
Change Nucleotide sequence (5′ → 3′) 
Position 
Accession number 
(NC_000006.12) 
Primer 
length 
(bp) 
polyGACT tail 
      
rs57371881 R176H ATGAGGACTGTAGTTAGGAGGCAGAGCTTA rs57371881 30 0 
rs201919874 T199I CAGCTGGAGTTCTCATGGCCATTTCCCCAA 160250625 35 5 
rs8177508 M165V TCAGTGAATGTAGGATTCTTTATTGGCTCT 160256639 40 10 
rs144729356 C282G AGATCAGCCACCTGGGAGACTCAGGTATGC 160247297 45 15 
rs45599131 L351W GTGAAAAATATTCCTTACCAGTTGTACATC 160245451 50 20 
rs8177517 K432Q TCTTTTCCCTCTTAGATCTACAATGGCTA 160242388 55 25 
rs145450955 T201M CCTTGGATTAAGCGAAAAATTAACATCCAC 160250619 60 30 
rs316019 S270A CCTCACTGGAGGTGGTTGCAGTTCACAGTT 160249250 65 35 
rs8177516 R400C ATGCAGCCCAAGGGTAACGGCGTCCGATGC 160243653 70 40 
rs141582772 M1V GCAGCCTCGGGCCCTCCTGCCTGCAGGATC 160258757 75 45 
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Table 4.3 - SLC22A2 gene multiplex 2 single base extension primers for SNaPshot™ genotyping assay of selected SNPs.  
NCBI 
(dbSNP) 
Amino Acid 
Change Nucleotide sequence (5′ → 3′) 
Position 
Accession number 
(NC_000006.12) 
Primer 
length 
(bp) 
polyGACT tail 
      
rs141205337 M393T CGTCCGATGCGGTCGATGGTGAGGATGATC 160243673 30 0 
rs141405449 G439E ATCTCATAGGCCATTGTGATCCCCATTCTT 160242366 35 5 
rs3907239 R463K CCCTCGTCATTCTAAGGAAAATGCACTCAC 160242294 40 10 
rs184227446 T357M ATGATGAGGCCCTGGTAGAGCACAGAGCTC 160243781 45 15 
rs140829992 R487W GGTGGCATCATCACGCCATTCCTGGTCTAC 160241516 50 20 
rs17853948 V502E/G AGCACCAGACCTCCAGCAACCAAGCCAAGC 160224801 55 35 
rs137885730 R404C CAACCATATTTGATGCAGCCCAAGGGTAAC 160243641 60 30 
rs140033522 V502M ATGTGATATTCATCTGTTTGGCTTTCAGGC 160224802 65 25 
rs151282335 R487Q AGCGGGAGCTCAAGCCAGATGTTAGTGAGC 160241515 70 40 
rs199783132 R207H GCTGCTTTGCTGACCAGTCCTTGGATTAAGC 160250602 75 45 
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4.4. Results 
4.4.1. SNaPshot™ Genotyping 
To determine the allele frequencies of 20 known coding variants of OCT2 we 
screened 148 Xhosa individuals. The genotype and allele frequencies of the 20 SNPs 
are summarized in Table 4.5. A typical electropherogram of the SLC22A2 SNaPshot 
genotyping system is displayed in Figure 4.1. All the variants observed were in 
Hardy-Weinberg equilibrium (p>0.05). Seventeen out of the 20 investigated 
nonsynonymous SNPs were monomorphic in the Xhosa population. Heterozygosity 
was only observed for three of the investigated nonsynonymous SNP in this study as 
shown in Table X. The A270S (rs316019) genotype frequencies for wild-type (GG), 
heterozygote (GT), and homozygote (TT) were 87.8%; 12.2%; and 0.0% 
respectively. The MAF for A270S (rs316019) observed in this study was 6.1%. The 
genotype frequencies for the R400C (rs8177516) variant wild-type (CC), 
heterozygote (CT), and homozygote (TT) were 93.2%; 6.8%; and 0.0%, respectively. 
The MAF for R400C (rs8177516) was 3.4%. The K432Q (rs8177517) genotype 
frequencies wild-type (AA), heterozygote (AC), and homozygote (CC) were 98.6%; 
1.4%; and 0.0%, respectively. The MAF for the K432Q (rs8177517) was 0.7%. 
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Figure 4.1 – Typical electropherogram of SLC22A2 multiplex 1 minisequencing 
fragments. Black represents C, green A, blue G, and red T. 
 
Table 4.4 – Haplotype structure of SLC22A2 gene in the Xhosa population as 
defined by the 20 selected loci. 
Haplotype Id Haplotype Frequency 
   
Haplotype *1 AAGGCGGTTGACGAGCCGAC 90.0% 
   
Haplotype *2 AAGGCGTTTGACGAGCCGAC 6.0% 
   
Haplotype *3 AAGGCGGTTGATGAGCCGAC 3.2% 
   
Haplotype *4 AAGGCGGTTGACGCGCCGAC 0.7% 
   
Haplotype *5 AAGGCGTTTGATGAGCCGAC 0.1% 
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4.4.2. Haplotype Analysis 
Haplotypes were constructed using the SHesis online platform. Five haplotypes 
listed in Table 4.4 were identified from the 20 investigated nonsynonymous SNPs. 
The most observed haplotype was Haplotype *1 which had a frequency of 90.0%. 
Haplotype *2 and *3 were observed at frequencies of 6.0% and 3.2%, respectively. 
The two least observed haplotype, Haplotype *4 and *5, were observed at 
frequencies of 0.7% and 0.1%, respectively. 
Table 4.5 - Genotype and allele frequencies of 20 known SLC22A2 coding SNPs in 
148 healthy Xhosa individuals. 
Amino Acid 
Substitution dbSNP ID 
Observed Genotype Frequency Allele Frequency 
Genotype % 95% CI Allele % 95% CI HWE (P) 
         
M1V rs141582772 
CC 100.0 96.9 – 100.0 C 98.3 98.4 – 100.0 
 CT 0.0 0.0 – 1.3 T 1.7 0.0 – 1.6 TT 0.0 0.0 – 1.3    
         
M165V rs8177508 
TT 100.0 96.9 – 100.0 T 100.0 98.4 – 100.0 
 TC 0.0 0.0 – 1.3 C 0.0 0.0 – 1.6 
CC 0.0 0.0 – 1.3    
         
R176H rs57371881 
TT 100.0 96.9 – 100.0 T 100.0 98.4 – 100.0 
 TA 0.0 0.0 – 1.3 A 0.0 0.0 – 1.6 
AA 0.0 0.0 – 1.3    
         
T199I rs201919874 
CC 100.0 96.9 – 100.0 C 100.0 98.4 – 100.0 
 CT 0.0 0.0 – 1.3 T 0.0 0.0 -1.6 
TT 0.0 0.0 – 1.3    
         
T201M rs145450955 
GG 100.0 96.9 – 100.0 G 100.0 98.4 – 100.0 
 GT 0.0 0.0 – 1.3 T 0.0 0.0 -1.6 
TT 0.0 0.0 – 1.3    
         
R207H rs199783132 
CC 100.0 96.9 – 100.0 C 100.0 98.4 – 100.0 
 CT 0.0 0.0 – 1.3  0.0 0.0 – 1.6 
TT 0.0 0.0 – 1.3    
         
S270A rs316019 
TT 87.8 81.5 – 92.2 C 91.6 90.9 – 96.4 0.655 TG 12.2 7.2 – 17.8 T 8.4 3.6 -9.1 
GG 0.0 0.0 – 1.9     
         
C282G rs144729356 
GG 100.0 96.9 – 100.0 G 100.0 98.4 – 100.0 
 GA 0.0 0.0 – 1.3 A 0.0 0.0 -1.6 
AA 0.0 0.0 – 1.3    
         
L351W rs45599131 
GG 100.0 96.9 – 100.0 G 100.0 98.4 – 100.0 
 GA 0.0 0.0 – 1.3 A 0.0 0.0 -1.6 
AA 0.0 0.0 – 1.3    
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T357M rs184227446 GG 100.0 96.9 – 100.0 G 100.0 98.4 – 100.0  
  GA 0.0 0.0 – 1.3 A 0.0 0.0 – 1.6    AA 0.0 0.0 – 1.3     
         
M393T rs141205337 
GG 100.0 88.6 – 96.9 G 100.0 98.4 – 100.0 
 GT 0.0 0.0 – 1.3 T 3.0 0.0 – 1.6 TT 0.0 0.0 – 1.3    
         
R400C rs8177516 
CC 91.3 87.8 96.4 A 96.6 94.2 – 98.4 
0.886 CT 8.5 3.1 – 11.4 C 3.4 18.2 – 23.0 
TT 0.0 0.0 – 1.9    
         
R404C rs137885730 
CC 100.0 87.8– 96.4 C 100.0 98.4 – 100.0 
 CG 0.0 0.0 – 1.3 G 0.0 0.0 – 1.6 
GG 0.0 0.0 – 1.3    
         
K432Q rs8177517 
AA 98.6.0 94.8 – 99.9 A 100.0 97.9 – 100.0 
0.934 AC 1.4 0.0 – 4.2 G 0.0 0.0 – 2.1 
CC 0.0 0.0 – 1.9    
         
G439E rs141405449 
AA 100.0 96.9 – 100.0 A 100.0 98.4 – 100.0 
 AG 0.0 0.0 – 1.3 G 0.0 0.0 – 1.6 
GG 0.0 0.0 – 1.3    
         
R463K rs3907239 
CC 100.0 96.9 – 100.0 C 100.0 98.4 – 100.0 
 CT 0.0 0.0 – 1.3 T 0.0 0.0 – 1.6 
TT 0.0 0.0 – 1.3    
         
R487Q rs151282335 
AA 100.0 96.9 – 100.0 A 100.0 98.4 – 100.0 
 AT 0.0 0.0 – 1.3 T 0.0 0.0 – 1.6 
TT 0.0 0.0 – 1.3    
         
R487W rs140829992 
GG 100.0 96.9 – 100.0 G 100.0 98.4 – 100.0 
 GT 0.0 0.0 – 1.3 T 0.0 0.0 – 1.6 
TT 0.0 0.0 – 1.3    
         
V502E/G rs17853948 
TT 100.0 96.9 – 100.0 T 100.0 98.4 – 100.0 
 TA 0.0 0.0 – 1.3 A 0.0 0.0 – 1.6 
AA 0.0 0.0 – 1.3    
         
V502M rs140033522 
GG 100.0 96.9 – 100.0 G 100.0 98.4 – 100.0 
 GA 0.0 0.0 – 1.3 A 0.0 0.0 – 1.6 
AA 0.0 0.0 – 1.3    
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Table 4.6 - Comparison of MAF of selected SLC22A2 SNPs in the Xhosa population to other ethnic groups. 
dbSNP ID Amino acid change 
Minor 
Allele 
Minor Allele Frequency (%) 
Xhosaa Luhyab Yorubab African-Americanb Japaneseb Chinese-Hanb Caucasian-Finishb Caucasian-Americanb 
           
rs8177508 M165V T 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 
rs201919874 T199I T 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 
rs145450955 T201M A 0.0 0.0 0.0 0.0 2.2 0.5 0.0 0.0 
rs199783132 R207H T 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 
rs316019 S270A T 8.4 16.0 15.9 14.8 0.0 14.7 5.9 8.8 
rs8177516 R400C T 3.4 0.0 2.3 1.6 0.0 0.0 0.0 0.0 
rs8177517 K432Q T 1.4 5.2 6.2 1.6 0.0 0.0 0.0 0.0 
           
a.This study; b. Data from 1000 Genomes 
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4.5. Discussion 
The kidney-specific hOCT2 is responsible for therapeutic drug uptake from the 
circulation into renal proximal tubules. Therefore it is an important determinant of 
drug disposition and response, and adverse events that result from drug-drug 
interactions. Genetic polymorphisms of the SLC22A2, which codes for hOCT2, have 
been implicated in altered transport which in turn influences drug disposition and 
response. However, little information is available on the genetic variation of 
SLC22A2 in African populations residing in southern Africa. Therefore, the aim of 
this study was to develop a SNaPshot genotyping system in order to assess the 
baseline allele frequency distributions of previously identified nonsynonymous 
SLC22A2 SNPs in the Xhosa population of South Africa. 
The reduced-function variant M165I (rs8177508) was first observed by Leabman et 
al. (2002) in African-American participants who formed part of a group of 247 
ethnically diverse individuals (Leabman et al., 2002). The minor allele frequency 
recorded for the M165I variant in the Leabman study was 1%. However, this variant 
was not observed in the current study and is also absent from those African 
populations included in the 1000 Genomes database. 
The two nonsynonymous SLC22A2 variants T199I (rs201919874) and T201M 
(rs145450955) were previously identified as rare SNPs in Asian populations with 
MAF <1% ((Fukushima-Uesaka et al., 2004, Kang et al., 2007). These variants 
showed decreased transport of prototypical organic cations in functional studies in 
vitro which were not attributable to either protein expression or plasma membrane 
localization. The T199I (rs201919874) and T201M (rs145450955) were not 
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observed in this study and can be considered an Asian-specific variants since it has 
not been observed in any of the other population groups. 
The A270S (rs316019) variant has been identified as a common SNP that occurs at a 
high allelic frequency (7-15%) in all ethnic groups studied (Fujita et al., 2006, Kang 
et al., 2007, Leabman et al., 2002). The MAF for the A270S (rs316019) variant in 
the Xhosa population was recorded at 6.1% which is significantly lower than the 
global MAF for this variant of 12%. Moreover, the MAF for the Xhosa population 
was substantially lower than that recorded for the Luhya of Kenya (16%), and 
Yoruba of Nigeria (15.9%), showing that inter-ethnic variability does exist between 
populations in Southern Africa and those from West and East Africa for the A270S 
(rs316019) variant. The functional activity of the A270S (rs316019) variant has been 
well characterized, and it has been shown to result in decreased transport of 
prototypical substrates in vitro, compared with the wild-type. Recent studies by Song 
et al. (2008) and Wang et al. (2008) showed significantly lower renal clearance of 
metformin in carriers homozygous for A270 (rs316019)S as compared to 
homozygous wild-type (Song et al., 2008a, Wang et al., 2008). This observation was 
supported by Tzvetkov et al. (2009) who made a similar in a population of 
Caucasian men (Tzvetkov et al., 2009). In addition, Li et al. (2010) showed that the 
A270S (rs316019) variant can affect the plasma lactate level and the incidence of 
hyperlactacidemia in type-2 diabetes patients on metformin therapy (Li et al., 2010). 
The R400C (rs8177516) variant of hOCT2 is of particular interest because it changes 
an arginine that is evolutionary conserved amongst the OCT paralogs (OCT1-3) 
(Leabman et al., 2002). The MAF for R400C (rs8177516) in this study was 6.8%, 
compared to 2.3% and 1.6% MAF reported for the Yoruba and African Americans in 
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the 1000 Genomes project, respectively. This variant has thus far only been observed 
in African populations (Fukushima-Uesaka et al., 2004, Kang et al., 2007, Leabman 
et al., 2002). Functional analysis of R400C (rs8177516) revealed that this variant 
had significant reduced transport activity of prototypical cationic substrates in vitro 
compared to the hOCT2 reference (Leabman et al., 2002). However, the role of this 
variant on the pharmacokinetics and efficacy of its substrate drugs in vivo had not 
been establish yet. Given the high MAF of this variant in the Xhosa individuals 
studied, and its effect on hOCT2 transport activity in vitro, the impact of this variant 
on drug disposition and efficacy in the Xhosa population requires closer 
investigation. 
Another hOCT2 variant, K432Q (rs8177517) , in an in vitro assay showed a stronger 
affinity for the prototypical organic cation MPP+ and a sensitivity to TBA (Leabman 
et al., 2002). This variant has thus far only been observed in Admixed Americans, 
Colombians, African Americans, and Africans. The MAF for K432Q (rs8177517) 
observed in this study was 1.4%, compared to that observed in the 1000 Genomes 
project of 6.6%, 5.6%, and 1.6% for the Luhya, Yoruba and African Americans, 
respectively. Although this variant has shown reduced transport activity in vitro, no 
information is available on the clinical impact of this SNP in vivo. Thus, given the 
fact that this variant occurs at a higher allele frequency in African populations, the in 
vivo effect of this variant on hOCT2 substrate drug transport requires further 
scrutiny. 
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4.6. Conclusions 
In this study the 20 investigated nonsynonymous SLC22A2 SNPs showed a low level 
of heterozygosity, with 85% of the loci displaying monomophism in the Xhosa 
subjects. This study once again highlighted the fact that the distribution of SNPs and 
the MAFs thereof differ between African and other populations, and even amongst 
African populations themselves. These differences in allele frequencies, although not 
fully understood, might provide us with the insight into inter-ethnic and inter-
individual variability in drug response for substrate drugs of hOCT2. Moreover, the 
single SNPs identified and haplotypes inferred for the Xhosa population may be 
important in future pharmacogenetic in identifying association between causative 
variants and altered drug response. While Chapters 1-3 have dealt with genetic 
variation in the uptake and efflux transporters which are co-localized in the liver and 
kidney, respectively, Chapter 5 explores genetic variations of SLC22A3, the gene of 
the ubiquitously expressed organic cation transporter hOCT3  
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CHAPTER 5 
Evaluation of 18 Single Nucleotide Polymorphisms in the SLC22A3 Gene of the 
Xhosa Population 
5.1. Abstract 
Organic cation transporters of the amphiphilic solute facilitator family of membrane 
proteins are involved in the translocation of a diverse range of endogenous and 
exogenous organic cations. These organic cations include clinically important 
substrates such as the anti-diabetic drug metformin, the anti-neoplastic drug 
oxaliplatin, and the anti-retroviral drug lamivudine. Inter-individual variation in drug 
disposition and efficacy is a major clinical problem and the role of these transporters 
is increasingly being recognized as a possible mechanism explaining this variation. 
Moreover, it is estimated that genetic factors can account for between 15-30% of 
inter-individual variation of drug disposition and response. The aim of this study was 
to determine the baseline minor allele frequency distribution of 18 known coding 
SNPs in the SLC22A3 gene of 148 Xhosa individuals residing in Cape Town, South 
Africa. This study found no genetic polymorphisms in the coding region of the 
SLC22A3 gene of the Xhosa individuals investigated. To our knowledge this study 
represents the first of its kind to investigate the baseline allele and genotype 
frequency distributions of known genetic polymorphisms within the SLC22A3 gene 
of the Xhosa population. This study has shown that SLC22A3 coding SNPs observed 
in other populations are absent in the sample of Xhosa individuals studied. The lack 
of protein sequence variation was consistent with other studies and may reflect the 
significant physiological role of hOCT3 in maintaining cellular and organismal 
homeostasis. 
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5.2. Introduction 
Organic cation transportes (OCTs) belong to the amphiphilic solute facilitator (ASF) 
family integral transmembrane proteins and are involved in various metabolic 
processes and detoxification (Schömig et al., 1998). These transporters are 
characterized by a specific organ and species-dependent expression and mediate the 
transport of organic cations (OCs) in an electrogenic and Na+-independent manner 
(Burckhardt and Wolff, 2000). 
The human organic cation transporter 3 (hOCT3), also known as extraneuronal 
monoamine transporter (EMT), has a broad distribution and is found in various 
tissues, including the liver, heart, placenta, skeletal muscle, kidney, and brain 
(Gründemann et al., 1998, Wu et al., 2000). Moreover, hOCT3 is a polyspecific 
transporter that is involved in the cellular uptake and elimination of small OCs with 
different molecular structures. These OC substrates include endogenous bioamines, 
clinically important drugs and xenobiotics. Examples of substrates transported by 
hOCT3 include the antidiabetic metformin, the biogenic amines histamine, 
dopamine, and epinephrine, and the xenobiotics tetraethylammonium bromide (TEA) 
and the neurotoxin 1-methyl-4-pyridinium (MPP+) (Martel 2003). 
The gene encoding for hOCT3, SLC22A3, encodes a protein consisting of 556 amino 
acid residues and is located on chromosome 6 where it is clustered together with 
SLC22A1 and SLC22A2 the genes coding for hOCT3’s paralogues hOCT1 and 
hOCT2, respectively (Koehler et al., 1997, Verhaagh et al., 1999). The SLC22A3 
gene is 77kb in length and consists of 11 exons with consensus GT/AG splice sites 
and conserved intron locations (Gründemann and Schömig, 2000). Moreover, the 
SLC22A3 gene contains two transcriptional start points and the promoter, located 
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within a CpG island, lacks a canonical TATA box but contains a prototypical 
initiator element and a number of potential binding sites for ubiquitous transcription 
factors SpI and NF-1 (Gründemann and Schömig, 2000). Recently, Chen et al. 
(2013) demonstrated that genetic polymorphisms in the proximal promoter region of 
SLC22A3 alter the transcription rate of the gene and may be associated with altered 
expression levels of hOCT3 in the liver (Chen et al., 2013). In addition, they also 
showed that hypermethylation of the CpG island in the proximal promoter region is 
the probable mechanism accounting for decreased expression of hOCT3 in prostate 
cancer. 
The ubiquitously expressed hOCT3 is also increasingly been recognized as an 
important transporter of anti-cancer drugs. For example, a study by Yokoo et al. 
(2008) investigated whether hOCT3 was significantly involved in oxaliplatin-
induced cytotoxicity and accumulation of platinum in colorectal cancer (Yokoo et 
al., 2008). They concluded that hOCT3-mediated uptake of oxaliplatin into cancer 
cells was indeed important for its toxicity, and that hOCT3 may be a marker for 
cancer chemotherapy. In another study, Shnitsar et al. (2009) found that renal cell 
carcinoma (RCC) cell lines, usually chemoresistant, expressing hOCT3 increases 
chemosensitivity to the antineoplastics, melphalan, irinotecan, and vincristine 
(Shnitsar et al., 2009). In a recent study, Li et al. (2012) found that hOCT3 also 
partially contributed to the sensitivity of human cervical adenocarcinoma cells to 
cisplatin cytotoxicity (Li et al., 2012). 
The hOCT3 gene, SLC22A3, was also identified as an important risk locus for 
prostate cancer, and was markedly under-expressed in aggressive prostate cancers 
(Eeles et al., 2008). This study also revealed that hypermethylation of the SLC22A3 
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promoter region in prostate cancer was one of the important mechanisms for the 
reduced expression of this transporter. Furthermore, a  study by Mohelnikova-
Duchonova et al. (2013) found a significant upregulation of SLC22A3 in pancreatic 
ductal adenocarcinoma (PDAC) tumours compared to non-neoplastic tissues 
(Mohelnikova-Duchonova et al., 2013). In addition to cancer, the SLC22A3-LPAL2-
LPA gene cluster was also previously identified in a genome-wide association 
(GWAS) haplotype study as a risk locus for coronary artery disease (CAD) 
(Trégouët et al., 2009). 
The biguanide antidiabetic drug metformin is usually the first-line therapeutic used 
in the treatment of type-2 diabetes (Kirpichnikov et al., 2002, Nathan et al., 2009). 
The action of metformin appears to be related to its activation (phosphorylation) of 
the energy sensor AMP-activated kinase (AMPK), which results in suppression 
glucagon-stimulated glucose production and enhancement of glucose uptake in 
muscle and hepatic cells (Abbud et al., 2000, Zhou et al., 2001). Previous studies 
have shown that OCTs, the hOCT3 paralogues hOCT1 and hOCT2, together with 
MATEs play a critical role in the disposition response and that genetic variants of 
these transporters are associated with variation in pharmacokinetic and anti-diabetic 
action of the drug (ML Becker et al., 2009, Becker et al., 2010, Kimura et al., 2009, 
Yan Shu et al., 2007, Shu et al., 2008). Subsequently, a study by Chen et al. (2010) 
has suggested that in addition to hOCT1, hOCT2 and MATE1, hOCT3 should be 
considered an important mechanism for metformin uptake in muscle cell types and 
that variation in this transporter may modulate the response to metformin (Chen et 
al., 2010a).  
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The role of hOCT3 is not only recognized as a pharmacogene in the transport of 
metformin but is also considered a promising drug target in antidepressant therapy 
(Zhu et al., 2012). Because of its expression pattern and physiological profile, 
hOCT3 is also considered as a candidate gene for various neuropsychiatric disorders 
of inherent monoaminergic dysfunction (Wultsch et al., 2009). hOCT3’s importance 
in the regulation of neurotransmission has been well documented in a number of 
animal studies (Amphoux et al., 2006, Baganz et al., 2008, Cui et al., 2009, Wultsch 
et al., 2009) and more recently, in humans (Cui et al., 2009). Aoyama et al. (2006) 
found that certain SNPs in the SLC22A3 gene were associated with the development 
of polysubstance abuse in Japanese individuals with dependence on the amphetamine 
derivative methamphetamine (Aoyama et al., 2006). In addition, Lazar et al. (2008) 
in a case-control study of 84 Caucasian children and adolescents found that known 
SLC22A3 genetic polymorphisms were not associated with obsessive compulsive 
disorder (OCD) in their study sample, but did identify two novel polymorphisms that 
were associated with  OCD (Lazar et al., 2008). 
Mental disorders are a major contributor to the burden of disease globally, with 
about 14% of the global burden being attributed to neuropsychiatric disorders 
(Prince et al., 2007, Tomlinson et al., 2009). Moreover, in sub-Saharan Africa 
neuropsychiatric disorders account for nearly 10% of the total burden of disease 
(Lopez et al., 2006, Tomlinson et al., 2009). The genetic basis for several diseases, 
including neuropsychiatric disorders is well established. To bridge the gap in 
pharmacogenetic mapping in African populations, especially those residing in 
southern Africa, this study prioritized the genotyping of 18 known variable sites in 
the coding region of the SLC22A3 gene in the Xhosa population living in the Cape 
Town, South Africa. 
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5.3. Materials and Methods 
5.3.1. Subjects 
As described in Chapter 2. 
5.3.2. DNA extraction and SNP selection 
Isolation of genomic DNA from buccal swab samples was carried out as outlined in 
Chapter 2 using a standard salt-lysis protocol and stored frozen at -20°C until the 
time of genotyping (Leat et al., 2004a). A total of 18 SLC22A3 coding SNPs were 
selected for this study. SNPs were selected from the literature and the Ensembl 
database (http://www.ensebl.org) (Flicek et al., 2012). Variants N162I; A169T; 
R212H; M248V; G269E; R293C; R310C; S337F; R348W; I381T; V388M; R403H; 
R407H; I431K; and R490Q were included in this study based on predicted effect on 
function, using the SIFT (Sorting Intolerant From Tolerant) program (Flanagan et 
al., 2010, Kumar et al., 2009, Ng and Henikoff, 2003). To our knowledge no 
population data exist in the public domain for these variants. 
5.3.3. Primer design 
Multiplex PCR primers for the amplification of all 11 SLC22A3 exons and flanking 
regions were designed using Primer3 software (www.genome.wi.mit.edu/cgi-
bin/primer/primer3) and are listed in Table 5.1. To test for possible non-specific 
amplification, primers were aligned with the NCBI sequence databases using Basic 
Local Alignment Search Tool (www.ncbi.nlm.nih.gov/blast/blast-cgi). Two 
SNaPshot™ Multiplex systems were specifically designed for the study, successfully 
optimized and used for genotyping. The single base extension primer sets for 
multiplex 1 and 2 are listed in Tables 5.2 and 5.3.
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Table 5.1 - Multiplex PCR primers for the generation of SLC22A3 amplicons used in SNaPshot™ genotyping.  
 
Location Forward primer (5´to 3´) Reverse Primer (5ʹto 3ʹ) Amplified region (NC_000006.12) Amplicon length (bp) 
     
Exon 2 TGCATTCTGGCATGTCTCCATGTGT ACCGGGAACAGCCTCAGACCT 160397935 - 160398311 377 
Exon 3 GTTTAAGGTGAGCTCTTTTCCTGT TTGGCTCCCAAAGTAAGGTGG 160407004 -160407404 401 
Exon 4 CTGCAAGTGTGGAAGCCTCCGT GCTGGGCAGCGTGATGGCTA 160408607 -160408898 292 
Exon 5 TGCAGGAATAATCTGTATTTCAGGG ACTGAAAATGATTTCCCAGATGTT 160410569 - 160411034 466 
Exon 6 & 7 TGAAAGCCCCTAGTCACTTCAG TGGAGTGACATCACGAAAGACT 160436664 - 160437340 677 
Exon 8 CTTCAGACTGGAGGCCACTAAGCA ACGCTGGTCTACAGAGTTACTTAG 160442659 - 160442921 263 
Exon 9 GGATAACACCCTCCACCCAC ACTGAATTGGCTCTCAAAACTG 160443405 - 160443934 530 
Exon 10 TGTTTCCCTGTGATGCAGGA TGCTTCTCTCTTCACAACCACAT 160447401 -160448051 651 
Exon 11 TGATCCTGGAGACAGATATTGTTGT GTCAGAGACCACAGGGAACA 160450844 - 160451347 504 
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5.3.4. Multiplex PCR 
All the 11 SLC22A3 exons and their flanking regions were simultaneously amplified 
using the primers listed in Table 5.1. The PCR reactions were performed in a 20 µl 
volume, containing 20 – 50 ng of genomic DNA, 1 x Qaigen multiplex PCR master 
mix (Qaigen, Courtaboeuf, France) and 0.2 µM of each primer. Cycling parameters 
used and PCR product purification were as described in Chapter 2. 
5.3.5. Multiplex minisequencing reactions 
Multiplex minisequencing was performed in a 10 µl reaction volume using 3 µl of a 
1/10 dilution of purified PCR products, 0.1-0.2 µM of primers, and 5 µl of 
SNaPshot™ ready reaction mix (Applied Biosystems). Sequence cycling and post-
extension treatment was performed according to the instructions of the 
manufactureras described in Chapter 2 
5.3.6. Electrophoresis of the minisequencing products 
The fluorescently labelled fragments were separated on 36 cm-long capillaries in 
POP4 polymer on an ABI Prism 3500 Genetic Analyzer (Applied Biosystems) as 
described in Chapter 2.. Data analyses were performed using GeneMapper® IDX 
Software Version 1.2. 
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Table 5.2 - SLC22A3 gene multiplex 1 single base extension primers for SNaPshot™ genotyping assay of selected SNPs. 
NCBI 
(dbSNP) 
Amino 
Acid 
Change 
Nucleotide 
change Nucleotide sequence (5′ → 3′) 
Position 
Accession number 
(NC_000006.12) 
Primer 
length 
(bp) 
polyGACT tail 
       
rs183669984 R310C C>T AAAGGAGATAAAGCATTACAGATCCTGAGA 160410799 30 0 
rs137958808 M370I G>T AAGCGCAGTGGTGTATCAAGGACTTGTCAT 160437033 35 5 
rs199688797 R212H G>A CACCAAACTTCCCTGTGTTTGTGATCTTCC 160407142 40 10 
rs150004342 A169T G>A ACCTGTCTGCTGCATAGCCTAAGGTGAATG 160398054 45 15 
rs142228053 R293C C>T TTCTTTGCCAGGGTGGTCCCTGAGTCTCCC 160410748 50 20 
rs149424049 I431K T>A AATGTAGCCACTGTGGTCCTCAACCATGCT 160442764 55 25 
rs147863404 G269E G>A AAGCTGGGCAGCGTGATGGCTAACTGGATT 160408870 60 30 
rs8187725 T400I C>T AAGGGGAGGCGTCGTCCAAGGCGCTCAATG 160437122 65 35 
rs149101094 M248V A>G CAAAGGAGGATTGTGGGAATCGTGATTCAA 160408806 70 40 
rs141104413 S337F C>T CTGTTACAGATGAGGAAGTTAGTAATCCAT 160436814 75 45 
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Table 5.3 - SLC22A3 gene multiplex 2 single base extension primers for SNaPshot™ genotyping of selected SNPs. 
NCBI 
(dbSNP) 
Amino Acid 
Change 
Nucleotide 
change Nucleotide sequence (5′ → 3′) 
Position 
Accession number 
(NC_000006.12) 
Primer 
length (bp) polyGACT tail 
       
rs139266499 N162I A>T GGATGCTGGACCTCACCCAAGCCATCCTGA 161081878 35 5 
rs145328121 R348W A>T TTTTTAGATCTGGTGAGAACTCCCCAAATG 160436846 45 15 
rs187750009 I381T T>C GCCTGGGAATTATAGGGGGCAACCTCTATA 160437065 50 20 
rs189883656 V388M G>A AGATCAAGAGAGCTCCTGGCAGTTCCACCA 160437085 55 25 
rs200478210 R403H G>A GAGCTCTCTTGATCTTACTAACCATTGAGC 160437131 60 30 
rs145082363 R407H G>A GCCACTATATTGCTTGCCGCAAAGGGGAGG 160437143 65 35 
rs12212246 A439V C>T CAGGAATAGCATGGTTGAGGACCACAGTGG 160442788 70 40 
rs144856002 R490Q G>A AGAGGTAGTTCTAGCCACACGGCTGCTAGC 160443701 75 45 
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5.4. Results and Discussion 
The population studied consisted of 148 healthy Xhosa individuals between the ages 
of 18 and 61 years. There were 80 (54%) female and 68 (46%) male participants. 
The mean age of female participants was 25.3±9.0 years, whereas male participants 
had a mean age of 24.8±7.7 years. 
In this study we have developed two SNaPshot™ multiplex assays for genotyping 18 
known nonsynonymous coding SNPs in the SLC22A3 gene. The genotype and allele 
frequencies of the 18 SLC22A3 gene SNPs investigated in the 148 Xhosa subjects 
are summarized in Table 5.4. All 18 coding SNPs genotyped in this study were 
monomorphic in the Xhosa population. 
Table 5.4 - Genotype and allele frequencies of the OCT3 (SLC22A3) gene SNPs in 
148 healthy Xhosa individuals. 
Amino Acid 
Substitution dbSNP ID 
Observed Genotype Frequency Allele Frequency 
Genotype % 95% CI Allele % 95% CI HWE (P) 
         
N162I rs139266499 
AA 100.0 96.9 – 100.0 A 100.0 98.4 – 100.0 
 AT 0.0 0.0 – 1.3 T 0.0 0.0 – 1.6 TT 0.0 0.0 – 1.3    
         
A169T rs150004342 
GG 100.0 96.9 – 100.0 G 100.0 98.4 – 100.0 
 GA 0.0 0.0 – 1.3 A 0.0 0.0 – 1.6 
AA 0.0 0.0 – 1.3    
         
R212H rs199688797 
GG 100.0 96.9 – 100.0 G 100.0 98.4 – 100.0 
 GA 0.0 0.0 – 1.3 A 0.0 0.0 – 1.6 
AA 0.0 0.0 – 1.3    
         
M248V rs149101094 
AA 100.0 96.9 – 100.0 A 100.0 98.4 – 100.0 
 AG 0.0 0.0 – 1.3 G 0.0 0.0 -1.6 
GG 0.0 0.0 – 1.3    
         
G269E rs147863404 
GG 100.0 96.9 – 100.0 G 100.0 98.4 – 100.0 
 GA 0.0 0.0 – 1.3 A 0.0 0.0 -1.6 
AA 0.0 0.0 – 1.3    
         
R293C rs142228053 
CC 100.0 96.9 – 100.0 C 100.0 98.4 – 100.0 
 CT 0.0 0.0 – 1.3 T 0.0 0.0 – 1.6 
TT 0.0 0.0 – 1.3    
         
R310C rs183669984 
CC 100.0 96.9 – 100.0 C 100.0 98.4 – 100.0 
 CT 0.0 0.0 – 1.3 T 0.0 0.0 – 1.6 TT 0.0 0.0 – 1.3    
         
S337F rs141104413 CC 100.0 96.9 – 100.0 C 100.0 98.4 – 100.0  CT 0.0 0.0 – 1.3 T 0.0 0.0 -1.6 
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  TT 0.0 0.0 – 1.3     
         
R348W rs145328121 
AA 100.0 96.9 – 100.0 A 100.0 98.4 – 100.0 
 AT 0.0 0.0 – 1.3 T 0.0 0.0 -1.6 
TT 0.0 0.0 – 1.3    
         
M370I rs137958808 
GG 100.0 96.9 – 100.0 G 100.0 98.4 – 100.0 
 GT 0.0 0.0 – 1.3 T 0.0 0.0 – 1.6 
TT 0.0 0.0 – 1.3    
         
I381T rs187750009 TT 100.0 96.9 – 100.0 T 100.0 98.4 – 100.0    TC 0.0 0.0 – 1.3 C 0.0 0.0 – 1.6    CC 0.0 0.0 – 1.3     
         
V388M rs189883656 
GG 100.0 96.9 – 100.0 G 100.0 98.4 – 100.0 
 GA 0.0 0.0 – 1.3 A 0.0 0.0 – 1.6 AA 0.0 0.0 – 1.3    
         
T400I rs8187725 
CC 100.0 96.9 – 100.0 C 100.0 98.4 – 100.0 
 CT 0.0 0.0 – 1.3 T 0.0 0.0 – 1.6 
TT 0.0 0.0 – 1.3    
         
R403H rs200478210 
GG 100.0 96.9 – 100.0 G 100.0 98.4 – 100.0 
 GA 0.0 0.0 – 1.3 A 0.0 0.0 – 1.6 
AA 0.0 0.0 – 1.3    
         
R407H rs145082363 
GG 100.0 96.9 – 100.0 G 100.0 98.4 – 100.0 
 GA 0.0 0.0 – 1.3 A 0.0 0.0 – 1.6 
AA 0.0 0.0 – 1.3    
         
A439V rs12212246 
CC 100.0 96.9 – 100.0 C 100.0 98.4 – 100.0  CT 0.0 0.0 – 1.3 T 0.0 0.0 – 1.6 
TT 0.0 0.0 – 1.3     
         
I431K rs149424049 
TT 100.0 96.9 – 100.0 T 100.0 98.4 – 100.0  TA 0.0 0.0 – 1.3 A 0.0 0.0 – 1.6 
AA 0.0 0.0 – 1.3     
         
R490Q rs144856002 
GG 100.0 96.9 – 100.0 G 100.0 98.4 – 100.0 
 GA 0.0 0.0 – 1.3 A 0.0 0.0 – 1.6 
AA 0.0 0.0 – 1.3    
         
 
Over the last number of years hOCT3 has increasingly being recognized as an anti-
diabetic and anti-cancer drug transporter (Chen et al., 2010a, Nies et al., 2009, 
Yokoo et al., 2008). Recently published reports also provide evidence of the 
increased interest in the role of hOCT3 in neurotransmission and maintenance of 
homeostasis in the central nervous system (CNS) as a result of its recognized ability 
to translocate monoamines (Amphoux et al., 2006). In addition, hOCT3 is also 
drawing interest as a potential target in the treatment of selected neuropsychiatric 
disorders. 
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In the current study we genotyped 18 known SNPs in the SLC22A3 gene of 152 
Xhosa individuals residing in the Cape Town metropolitan area, South Africa. We 
observed no genetic variation for the 18 noncoding SNPs genotyped in the 
investigated population. However, this lack of genetic variation in the coding region 
of SLC22A3 in the Xhosa population is not a unique situation and has also been 
observed in other populations (Kang et al., 2007, Lazar et al., 2003). Moreover, 
according to Lazar et al. (2008), this high degree of genetic preservation and lack of 
protein sequence variation may reflect the crucial physiological role hOCT3 plays in 
maintaining homeostasis (Lazar et al., 2008). 
Unlike its paralogues hOCT3 has a broad distribution in the human body and 
because of its localization in the CNS and its affinity for monoamines is believed to 
play a significant role in neuropsychiatric disorders. Methamphetamine (MAP) is a 
powerful highly addictive psycho-stimulant that affects the CNS. The illicit us of 
MAP has become a growing problem in a number of countries over the last two 
decades, and has recently emerged as a significant problem in South Africa 
(Plüddemann et al., 2010). Smoking crystalline MAP has been associated with high 
levels of harm. The most salient harms associated with MAP use are mental health 
problems, including psychosis, depression, anxiety, and violent behaviour. Ayoma et 
al. (2006), in a study with Japanese MAP users, found that SLC22A3 polymorphisms 
may be related to the development of polysubstance use in patients with MAP 
dependence (Aoyama et al., 2006). The polymorphisms used in the Aoyama study 
were not included in the present study and as such no inferences can be drawn. 
However, given the health problems associated with, and the current prevalence of 
MAP use in South Africa, the role of genetic polymorphisms of SLC22A3 in the 
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development of polysubstance use in individuals with MAP dependence in 
indigenous African populations need further investigation. 
The role of hOCT3 in monoamine transport in vivo is well established. Because of its 
role in monoamine transport and its localization in the CNS, hOCT3 has also been 
implicated in non-neuronal termination of noradrenergic signalling in the CNS and 
as a candidate gene for a variety of neuropsychiatric disorders (Lazar et al., 2008, 
Wultsch et al., 2009). Moreover, Lazar et al. (2008) identified two SNPs, -
106/107delAG and Met370Ile in a group of Caucasian patients diagnosed with 
obsessive compulsive disorder (OCD), which lead to a decrease in promoter activity 
and transport of norepinephrine, respectively, in assays performed in vitro (Lazar et 
al., 2008). Haenisch et al. (2012) showed that two psychoactive drugs nefazodone 
and clozapine had the potential to inhibit hOCT3 activity. However, their study was 
unable to demonstrate whether this direct inhibition of hOCT3 plays a role in the 
clinical effects of these drugs (Haenisch et al., 2012). 
The ubiquitously expressed hOCT3 has not only been implicated in the transport of 
anti-cancer drugs, but more recently also as a biomarker for cancer pathogenesis. For 
example, in colorectal cancers hOCT together with its paralogues, hOCT1 and 
hOCT2, have been shown to be determinants of oxaliplatin cytotoxicity (Yokoo et 
al., 2008, Zhang et al., 2006). Moreover, SLC22A3 expression in renal cell 
carcinoma cell lines enhances the sensitivity of these cell lines towards the 
chemotherapeutic agents melphalan, irinotecan, and vincristine (Shnitsar et al., 
2009). Cui et al. (2011) recently identified the SLC22A3 SNP rs7758229 as a risk 
locus for distal colon cancer in an Asian population (Cui et al., 2011). In addition, a 
study by Grisanzio et al. (2012) showed that SLC22A3 is inversely correlated with 
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prostate cancer progression, with markedly decreased expression in aggressive 
prostate cancers (Grisanzio et al., 2012). 
Metformin is a biguanide anti-diabetic drug and is widely used as a first-line 
therapeutic in the treatment of type-2 diabetes. Earlier studies have shown that 
metformin is transported by OCT1 and OCT2, and that genetic polymorphisms of 
these transporters affect the pharmacokinetic and therapeutic effect of the drug (ML 
Becker et al., 2009, Becker et al., 2010, Kimura et al., 2009, Yan Shu et al., 2007, 
Shu et al., 2008). Recent studies have now also implicated hMATEs and hOCT3 in 
metformin absorption, disposition, and pharmacological action (Becker et al., 2010, 
Chen et al., 2010a). Chen et al (2010) found that the OCT3 variant T400I 
significantly reduced metformin uptake by the transporter (Chen et al., 2010a). 
Structural modelling suggested that this variant may be located in the pore lining of 
the TMHs, where it plays a critical role in substrate translocation. The T400I variant 
is a rare variant that has a low allele frequency and was not observed in the 
individuals that participated in this study. Given the prevalence of type-2 diabetes in 
South Africa and the widespread use of metformin as a therapeutic, the distribution 
of this variant in the indigenous African populations require further investigation. 
The effect of this variant in vivo on metformin pharmacokinetics and efficacy has not 
been demonstrated yet, but should be assessed if the T400I variant is identified in the 
Xhosa or any of the indigenous African populations. 
Ideally a larger sample size and complete sequencing of the SLC22A3 gene would 
provide a more complete picture of the spectrum of genetic variation within this gene 
for the Xhosa population. In addition, a number of SNPs in the proximal promoter 
region had been associated with altered expression of the SLC22A3 gene previously, 
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however the current approach of genotyping coding SNPs only, excluded these 
variants from being assayed. Furthermore, although medical research has primarily 
focused on protein-coding variants, this picture has changed with advances in the 
systematic annotation of functional non-coding elements (Ward and Kellis, 2012). 
However, the genotyping strategy adopted in this study have excluded the typing of 
non-coding SNPs, which could be useful when performing linkage disequilibrium 
analysis or extracting information about disease association. 
5.5. Conclusions 
To our knowledge this study represents the first of its kind to investigate the baseline 
allele and genotype frequency distributions of known genetic polymorphisms within 
the SLC22A3 gene of the Xhosa population. This study has shown that SLC22A3 
coding SNPs observed in other populations are absent in the sample of Xhosa 
individuals studied. The lack of protein sequence variation was consistent with other 
studies and may reflect the significant physiological role of hOCT3 in maintaining 
cellular and organismal homeostasis. The lack of heterozygosity at known 
polymorphic sites observed within SLC22A1-3 and SLC47A1 in the Xhosa subjects 
prompted the question whether the Xhosa subjects harboured any novel variants 
within these genes. Since kidney-specific hOCT2 is a critical determinant of drug 
disposition and toxicity, and a known site of drug-drug interactions, Chapter 6 
prioritized the sequencing of the SLC22A2 gene to search for novel genetic variants 
within the Xhosa population. 
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CHAPTER 6 
Identification of Novel Genetic Variations within the SLC22A2 Gene of the 
Xhosa Population 
6.1. Abstract 
Human organic cation 2 (hOCT2) is an important determinant of organic cation 
uptake from the circulation into the renal proximal tubules. These organic cations 
include clinical drugs such as metformin, lamivudine, cimetidine, cisplatin and the 
neurotoxin 1-methyl-4-phenyl-pyridinium. Considerable interindividual variation 
exists in drug responses and toxicity. It is estimated that genetic factors account for 
at least 15-30% of variations in drug disposition and responses. Moreover, genetic 
polymorphisms in drug transporters are increasingly being recognized as a possible 
mechanism explaining this variation in drug disposition and response. However, to 
date only a few studies have explored the genetic diversity harboured in the 
pharmacogenetically relevant organic cation transporter (OCT) genes of indigenous 
southern African populations. Therefore, the aim of this study was to determine 
whether the SLC22A2 gene of the Xhosa participants harbours any novel SNPs using 
direct sequencing of the 11 exonic and flanking intronic regions of the gene in 96 of 
the participants. Twenty-three genetic polymorphisms, including 7 novel SNPs, were 
identified in the SLC22A2 gene of the Xhosa individuals that participated in this 
study. This study represents the first report of novel SLC22A2 SNPs in the Xhosa 
population. The rare singleton SNPs identified and haplotypes inferred for the Xhosa 
population in this study is an important step in filling the gap with regards to genetic 
information on the pharmacogenetically relevant SLC22A2 gene in indigenous 
southern African populations. The information generated in this study can potentially 
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lay the foundation for future pharmacogenetic study design and for the identification 
of association between the rare SNPs and drug response and toxicity. 
 
6.2. Introduction 
Human organic cation 2 (hOCT2) is primarily expressed in the kidney and located 
on the basolateral membrane of renal proximal tubules (Gorboulev et al., 1997, 
Motohashi et al., 2002). Because of this tissue distribution and membrane 
localization hOCT2 is thought to play a critical role in the uptake, pharmacological 
effects and/or adverse effects of many cationic clinical therapeutics and xenobiotics. 
Examples of clinical drugs transported by hOCT2 include metformin (antidiabetic), 
lamivudine (antiretroviral), cisplatin (antineoplastic) and cimetidine (antihistamine) 
(Jung et al., 2008, Ciarimboli et al., 2005b, Kimura et al., 2005b, Koepsell et al., 
2007). In addition, hOCT2 is also involved in the translocation of endogenous 
bioactive amines such as dopamine and norepinephrine, and in the elimination of 
toxic substances such as the neurotoxin 1-methyl-4-phenyl-pyridinium (MPP+) 
(Burckhardt and Wolff, 2000, Dresser et al., 2002, Gorboulev et al., 1997, Okuda et 
al., 1999). Clinical studies and in vivo animal experiments with knockout mice have 
demonstrated that variation in the expression level of SLC22A2 can be responsible 
for individual variation in pharmacokinetics. Moreover, SLC22A2 genetic 
polymorphisms have been implicated in the altered function of hOCT2 which may 
lead to a change in the disposition and response of substrate drugs. 
To date several single nucleotide polymorphisms (SNPs) have been identified in the 
SLC22A2 gene of ethnically diverse populations (Fukushima-Uesaka et al., 2004, 
Kang et al., 2007, Leabman et al., 2002, Tzvetkov et al., 2009). Functional 
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characterization have revealed that several of these SNPs affect the transport 
function of hOCT2 in vitro (Leabman et al., 2002). Although in vivo evidence for the 
involvement of these SNPs in clinical phenotype is limited, recent studies have 
shown that homozygous carriers of the hOCT2 variant A270S (rs316019) have a 
lower renal clearance of metformin compared to those carrying the homozygous 
wild-type (Song et al., 2008a, Wang et al., 2008). Furthermore, this reduced-
function SLC22A2 SNP, rs316019, was also associated with reduced nephrotoxicity 
from cisplatin in cancer patients (Filipski et al., 2009). However, these 
pharmacogenetic association studies have primarily been conducted in non-African 
populations, usually Western European and North American Caucasians, and have 
focused on genetic variants which are common to these populations (Urban, 2010). 
The results of these studies are often extrapolated for use and interpretation in other 
populations. This is in spite of the fact that variant allele frequencies in 
pharmacogenetic genes can differ significantly between populations and even within 
populations (Drögemöller et al., 2010, Yen-Revollo et al., 2009). In addition, 
population-specific variants exist in non-Caucasians which will probably be more 
relevant to treatment/study outcomes then those found in Caucasians. 
Although it is widely accepted that African populations harbour more genomic 
diversity than non-African populations, this genetic diversity is however 
understudied (Frazer et al., 2009, Hardy et al., 2008, Tishkoff et al., 2009). 
However, in recent years African populations have started to attract research interest, 
with especially northern and central African countries being increasingly 
incorporated into studies assessing population structure (Ramsay, 2012, Tishkoff et 
al., 2009). The HapMap and 1000 Genomes projects currently include information 
on the Luhya and Maasai of Kenya, Yoruba and Esan of Nigeria, Gambian of The 
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Gambia, and the Mende of Sierra Leone. However, the current opinion is that the 
population genetics of these groups cannot represent the total genomic diversity of 
the remaining populations in West and East Africa, nor the populations residing in 
southern Africa (Ikediobi et al., 2011, May et al., 2013). Moreover, the role of this 
genetic diversity in disease pathogenesis and treatment is currently not fully 
understood. Thus, in order to fully understand and correlate this genomic diversity 
with pharmacogenetic phenotypes, the extent of variation in pharmacogenetically 
relevant genes such as SLC22A2 in more African populations needs to be studied. 
Therefore, the aim of this study was to determine whether the SLC22A2 gene of the 
Xhosa participants harbours any novel SNPs, using direct sequencing of the 11 
exons and flanking intronic regions of the gene in 96 healthy individuals. Secondly, 
to determine the haplotype structure of the SLC22A2 gene based on the genetic 
information acquired by sequencing, and finally, to compare the minor allele 
frequencies obtained for the Xhosa to the HapMap estimates for other African, 
American, European and Asian populations.  
6.3. Materials and Methods 
6.3.1. Subjects 
The DNA from 96 of the 148 unrelated healthy Xhosa subjects (As described in 
Chapter 2)  was used to screen for novel SNPs by direct sequencing. 
6.3.2. DNA extraction and direct sequencing 
Genomic DNA samples were collected in the form of buccal swabs and were 
extracted using a standard salt-lysis method as described in Chapter 1 (Leat et al., 
2004a). The proximal promoter region and 11 exonic fragments of the SLC22A2 
gene were generated using self-designed primer sequences. These primers were 
122 
 
 
 
 
 
CHAPTER 6 
designed using Primer3 software (www.genome.wi.mit.edu/cgi-bin/primer/primer3) 
and obtained from Integrated DNA Technologies (San Diego, California, USA). The 
PCR reactions were performed in a 50 µl volume, containing 20 – 50 ng of genomic 
DNA, 1 x Qaigen multiplex TopTaq master mix (Qaigen, Courtaboeuf, France) and 
0.2 µM of each forward and reverse primer. The PCR conditions included an initial 
denaturation at 95°C for 15 minutes, followed by 35 cycles of denaturation at 95°C 
for 1 minute, annealing for 1 minute, and extension at 72°C for 1minute, and then a 
final extension at 72°C for 10 minutes. The sequences and details of all the primers 
used in this study are listed in Table. The fragments were sequenced at Macrogen 
(Seoul, South Korea). 
6.3.3. Statistical Analysis 
Genotype and allele frequencies as well as the deviation from the Hardy-Weinberg 
Equilibrium were calculated using as described in Chapter 2. Statistical significance 
was defined as p<0.05. 
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Table 6.1 - PCR primer sequences for SLC22A2 sequencing amplicon generation. 
Location Forward Primer (5′ to 3′) Reverse Primer (5′ to 3′) Amplified region (NC_000006.12) Amplicon length (bp) 
     
Promoter GGGAAGATTACTGGGCTGTG GAGAGCAGAGCCAAGAGGAA 160259130 - 160258669 462 
Exon 1 GCTGGTCACTTGCAGAGGTA TCTCCACCATTTGCTTCTCC 160258886 - 160258297 590 
Exon 2 AGGGCAAGCCTTTTGGTTAT GAAAGGATGGGATTCAAGCA 160257099 - 160256522 578 
Exon 3 GGGTATTCAGCACAGGATGG GAAGCTGGGTCCCTTTTCTT 160251022 - 160250450 573 
Exon 4 AGCTGGACAGCCAACTCATT TTCCTCTGAGTGGGGAGAGA 160249445 - 160248858 588 
Exon 5 ATCCAGTCCTTGACCCCTCT CTCTGTTGCATTCCGCTACA 160247625 - 160247038 588 
Exon 6 ATTGCACCACTGCACTCAAG GGGGTTTTGGCTTTGGTATT 160245764 - 160245169 596 
Exon 7 CACAGCCAGCCACTGAAGTA GCTGGCCATATGAATTTGCT 160243961 - 160243408 554 
Exon 8 CCTTCCTCTCCATTTTGCTG TTGGGTAATCCCTGTCTTGC 160242666 - 160242059 608 
Exon 9 GTTTATTCAGGGGTGGATGG TCAGGAAGGGTGGAAATCAG 160241663 - 160241110 554 
Exon 10 CAGCAGTCAGAGATGGCAAA TTGTTAGGAAAATTAGCCCAATG 160224947 - 160224328 620 
Exon 11 TGGCATTCACGAAGACAAGA GCTGCCATCAAAGCTAGGTC 160217981 - 160217387 595 
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6.4. Results 
6.4.1. Variant Screening 
To identify variants of hOCT2 we screened all 11 exons and the proximal promoter 
region of the SLC22A2 gene in 96 Xhosa participants, using direct sequencing. 
Twenty-eight variable sites including four novel ones were found in this study 
(Table 6.2). Eight of these variations were in the coding region and 20 were in the 
non-coding or intronic region of the gene. Four of the SNPs present in the coding 
region were non-synonymous and four were synonymous substitutions. 
The four non-synonymous SNPs observed in this study, A270S (rs316019), R400C 
(rs8177516), K432Q (rs8177517), and N552I (rs139045661) had ethnic-specific 
minor allele frequencies (MAFs) greater than or equal to 1%. The R400C 
(rs8177516) and N552I (rs139045661) variants have thus far only been observed in 
African populations or ethnic groups with a link to the African continent such as the 
African-Americans. Two of the synonymous SNPs, T130T (rs624249) and V502V 
(rs316003) were reported previously by Leabman et al. (2002) and Fukushima et al. 
(2004), while the S133S (rs112210325) variant was only submitted to the dbSNP 
database in the last year and had not been reported in any study yet. In addition, a 
novel synonymous SNP V94V (MBPG_OCT2002) in exon 1 (Figure 6.1) had been 
identified in this study and will be submitted to the dbSNP database in due course.  
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Table 6.2 - Summary of SNPs identified with direct sequencing in the SLC22A2 gene of Xhosa subjects. 
dbSNP ID Location 
Nucleotide 
Position Accession 
number 
(NC_000006.12) 
Position from 
the 
translational 
initiation site or 
the nearest 
exon 
Nucleotide change 
and flanking 
sequence  
(5′ to 3′) 
Amino Acid 
Position 
Amino Acid 
change 
MAF HWE 
         
rs55920607 Promoter 160259003 -246 C>T   0.084 0.370 
rs59695691 Promoter 160258952 -195 A>G   0.263 0.000 
MBPG_OCT2001 Promoter 160258913 -156 C>T   0.005 0.959 
rs150063153 Promoter 160258852 -95 A>C   0.016 0.876 
MBPG_OCT2002 Exon 1 160258476 282 G>A 94 Val>Val 0.011 0.914 
rs624249 Exon 1 160258368 390 G>T 130 Thr>Thr 0.128 0.566 
rs112210325 Exon 1 160258359 399 G>T 133 Ser>Ser 0.012 0.913 
rs8177511 Intron 2-3 160250720 -18 T>C   0.026 0.793 
rs112710522 Intron 3-4 160250473 +75 A>G   0.086 0.581 
rs372467753 Intron 4-5 160247329 -31 A>G   0.011 0.958 
rs316019 Exon 4 160249250 808 T>G 270 Ser>Ala 0.149 0.090 
rs112425400 Intron 4-5 160247418 -120 G>A   0.011 0.917 
rs2279463 Intron 4-5 160247357 -59 T>C   0.183 0,536 
MBPG_OCT2003 Intron 6-7 160245318 +65 G>T   0.010 0.918 
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Table 6.2 Continued - Summary of SNPs identified with direct sequencing in the SLC22A2 gene of Xhosa subjects. 
 
 
         
rs617217 Intron 6-7 160245324 +71 G>C   0.278 0.661 
rs115889347 Intron 6-7 160245346 +93 G>A   0.005 0.959 
MBPG_OCT2004 Intron 6-7 160245368 +115 G>C   0.052 0.590 
rs8177516 Exon 7 160243653 1198 C>T 400 Arg>Cys 0.052 0.590 
rs8177517 Exon 8 160242388 1293 A>C 432 Lys>Gln 0.011 0.917 
rs17588242 Intron 8-9 160242198 +96 A>G   0.011 0.917 
rs11967308 Intron 9-10 160241327 +147 G>A   0.146 0.973 
rs114897022 Intron 9-10 160241316 +158 A>G   0.016 0.876 
MBPG_OCT2005 Intron 9-10 160241261 +213 A>T   0.005 0.959 
MBPG_OCT2006 Intron 9-10 160241210 +272 G>A   0.005 0.959 
rs316003 Exon 10 160224800 1506 G>A 502 Val>Val 0.333 0.635 
MBPG_OCT2007 Intron 10-11 160217752 -254 C>A   0.005 0.959 
rs3103352 Intron 10-11 160217693 -195 C>T   0.235 0.00015 
rs139045661 Exon 11 160217445 1656 T>A 552 Ile/Asn 0.016 0.876 
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Figure 6.1 - Electropherograms of novel SNPs observed in the proximal promoter 
region and exon 1 of the SLC22A2 gene. (A) MBPG_OCT2001 (wild-type -156 G/G 
and variant -156 G/A) a novel SNP detected in the proximal promoter region. (B) 
MBPG_OCT2002 (wild-type 282 GG; variant 282 G/A) a novel synonymous SNP 
detected in exon 1. 
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Figure 6.2 - Electrophoretograms of novel SNPs observed in the intronic region 
between exon 6 and 7 of SLC22A2. (A) MBPG_OCT2003 (wild-type 
MBPG_OCT2003G/G and variant MBPG_OCT2003G/T) a novel SNP detected in 
the intronic region between exons 6 and 7. (B) MBPG_OCT2004 (wild-type 
MBPG_OCT2004 G/G; variant MBPG_OCT2004G/C) a novel SNP detected in the 
intronic region between exons 6 and 7. 
 
 
Figure 6.3 - Electropherograms of novel SNPs observed in the intronic region 
between exons 6 and 7 and exon 9 and 10 of SLC22A2. (A) MBPG_OCT2005 (wild-
type MBPG_OCT2005A/A and variant MBPG_OCT2005A/T) a novel SNP detected 
in the intronic region between exons 6 and 7. (B) MBPG_OCT2006 (wild-type 
MBPG_OCT2006 A/A; variant MBPG_OCT2006G/C) a novel SNP detected in the 
intronic region between exons 9 and 10. 
 
129 
 
 
 
 
 
CHAPTER 6 
 
Figure 6.4 - Electropherogram of a novel SNP observed in the intronic region 
between exons 10 and 11of SLC22A2. MBPG_OCT2007 (wild-type 
MBPG_OCT2007C/C and variant MBPG_OCT2007C/A) a novel SNP detected in 
the intronic region between exons 10 and 11. 
Fourteen of the 15 non-coding or intronic SNPs (Table 6.2) have been observed only 
in African populations or populations with an African connection. The MAF for nine 
SNPs is compared to other populations in Table 6.3 and is depicted in Figure 6.5 
These variations were observed at MAFs between 0.5% and 26.3%. Moreover, seven 
novel SNPs (Figures 6.1 to 6.4), one in the 5′-untranslated region at position -156 
from the start codon, with a MAF of 0.5%, and four in the intronic regions with 
MAFs between 0.1% and 0.5% were identified in this study. We also observed a 
singleton for rs112425400 a variant that has thus far only been observed in the 
Bushman of southern Africa. In addition, we also observed rs2279463, a MAF of 
18.3%, a SNP that was identified as a risk locus in chronic kidney disease. 
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Figure 6.5 - Allele frequencies of selected SLC22A2 SNPs in the Xhosa population compared to other African and world populations. 
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Table 6.3 - Comparison of MAF of selected SLC22A2 SNPs identified by direct sequencing in the Xhosa population to other ethnic groups. 
dbSNP ID Minor Allele 
Minor Allele Frequency (%) 
Xhosaa Luhyab Yorubab African-Americanb Japaneseb Chinese-Hanb Caucasian-Finishb Caucasian-Americanb 
          
rs55920607  8.4 4.5 6.2 3.3 0.0 0.0 0.0 0.0 
rs59695691  26.3 2.6 1.7 0.0 0.0 0.0 0.0 0.0 
rs150063153  1.6 0.5 0.0 0.8 0.0 0.0 0.0 0.0 
rs8177511  2.6 3.1 8.0 4.9 0.0 0.0 0.0 0.0 
rs112710522  8.6 3.1 3.4 4.9 0.0 0.0 0.0 0.0 
rs372467753  1.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 
rs112425400  1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
rs11967308  14.6 5.7 5.7 2.5 0.0 0.0 0.0 0.0 
rs114897022  1.6 1.0 5.1 1.6 0.0 0.0 0.0 0.0 
          
a.This study; b. Data from 1000 Genomes 
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6.4.2. Haplotype Analysis 
Haplotypes were calculated using an inferential procedure (Yong and Lin, 2005). 
This method identified 47 distinct haplotypes. The ten major haplotypes are listed in 
Table 6.4.the seven major haplotypes were observed at frequencies of 28.46%, 
11.24, 7.00%, and 6.00% respectively. 
Table 6.4 - Major haplotypes inferred from 28 SLC22A2 SNPs identified with direct 
sequencing. 
Haplotype ID Haplotype Frequency (%) 
   
Haplotype *1 GCCTGGGTTTGCTGGGGCTACAAAGCCT 28.46% 
Haplotype *2 GCCTGGGTTTGCTGCGGCTACAAAGCCT 11.24% 
Haplotype *3 GCCTGGGTTTGCTGGGGCTACAAAGCTT 7.00% 
Haplotype *4 GTCTGGGTTTGCTGGGGCTACAAAACCT 6.00% 
Haplotype *5 GCCTGGGTTTGCCGGGGCTACAAAGCCT 2.26% 
Haplotype *6 GCCTGGGTTTGCTGGGGCTACATAGCCT 2.17% 
Haplotype *7 GCCTGTGCTTGCTGGGGCTACAAAGCCT 2.00% 
   
 
6.5. Discussion 
The kidney-specific hOCT2 plays an important role in the uptake of a wide range of 
OCs from the circulation and has been identified as a site of DDIs. The aim of this 
study was to determine the extent of the genetic variation in the SLC22A2 gene, 
which codes for hOCT2, within the Xhosa population of South Africa. We have 
identified 28 SNPs in the SLC22A2 gene, including seven novel variants, of 96 
healthy Xhosa individuals. 
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Twenty-one of the SNPs identified in this study were already reported and listed in 
the dbSNP database. In a study by Leabman et al. (2002) 28 SNPs were also 
identified in ethnically diverse populations which included the African-American 
population (Leabman et al., 2002). Among these five coding SNPs, T130T 
(rs624249), A270S (rs316019), R400C (rs8177516), K432Q (rs8177517), and 
V502V (rs316003), were also observed in this study. Leabman et al. (2002) went on 
to demonstrate that A270S (rs316019), R400C (rs8177516), and K432Q (rs8177517) 
are reduced-function variants that alter hOCT2 affinity for prototypical organic 
cations in vitro. In addition, they observed that the less frequent variants, R400C 
(rs8177516) and K432Q (rs8177517), resulted in significantly more and deleterious 
functional changes compared to the more frequently occurring A270S (rs316019). In 
another study Fukushima et al. (2004) identified 33 SNPs, including fourteen novel 
ones, in a group of 118 arrhythmic Japanese patients (Fukushima-Uesaka et al., 
2004). Only six of the variants observed were common among the Leabman and 
Fukushima studies. In this study we have observed nine SNPs (Figure 6.5), including 
seven novel variants, which are specific to African populations or populations with a 
link to the African continent and that were not observed by either the 
abovementioned studies. 
Furthermore, we have identified a novel promoter SNP at position -156, which can 
potentially alter transcription of the SLC22A2 gene. In addition, we also observed 
two promoter SNPs (rs59695691 and rs150063153) that are found only in African 
population groups. Basal promoter activity is an important determinant of 
SLCA22A2 expression in vivo, and may influence the transport function of hOCT2, 
which in turn may affect the uptake, disposition, and elimination of its substrates. A 
deletion analysis of the hOCT2 proximal promoter region by Asaka et al. (2007) 
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suggested that the region spanning -91 to -58 base pairs (bp) was essential for basal 
transcriptional activity of the SLC22A2 gene (Asaka et al., 2007). However, on 
closer inspection of their results this essential region could probably be expanded to 
between -214 and -58 bp. This region lacks a canonical TATA-box, but does contain 
a CCAAT box and an E-box. The electrophoretic mobility assays revealed that the 
SLC22A2 E-box binds upstream stimulating factor 1 (USF-1) which functions as a 
basal transcriptional regulator of the gene. The effect of these African-specific 
variations on basal promoter regulation has not yet been determined and requires 
further investigation. 
In addition to the novel promoter variant, we have also identified five intronic 
genetic variants novel. Although the functional impact of these intronic SNPs are 
currently unknown, the importance of non-coding variants in complex traits and 
human disease are increasingly being recognized (Ward and Kellis, 2012). 
Moreover, rare and low-frequency (MAF between 0.5 and 1.0%) variants, such as 
the novel polymorphisms identified in this study, have been hypothesized to explain 
a substantial fraction of the heritability of common, complex diseases (McClellan 
and King, 2010, Tennessen et al., 2012). 
Although this study revealed seven novel SNPs, the coding region of the SLC22A2 
gene of individuals investigated lacked the genetic diversity we expected to see in 
this population. Leabman et al. (2002) have ascribed the low mutational rate and 
amino acid substitutions observed with hOCT2 to selection pressure that has acted 
against amino acid changes within the transporter (Leabman et al., 2002). According 
to them such selection may be due to the important function hOCT2 plays in the 
renal elimination of endogenous compounds and xenobiotics. Moreover, they have 
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concluded that amino acid residues in the TMHs tend to be evolutionary more 
conserved than those found in the loops of membrane transporters (Leabman et al., 
2003). This lack of amino acid and genetic diversity observed with hOCT2 and 
SLC22A2 is not unique, and was also observed with hOCT3 and SLC22A3 (Lazar et 
al., 2003, Lazar et al., 2008). 
6.6. Conclusions 
The kidney-specific hOCT2 plays an important role in the renal uptake of many 
commonly used clinical drugs. Moreover, hOCT2 is an important site of drug-drug 
interactions and is therefore clinically relevant. Several SNPs have been identified in 
the SLC22A2 gene that alters the function of hOCT2 and consequently the 
pharmacokinetics/pharmacodynamics of its substrate drugs. This study represents the 
first report which investigated the presence of novel SLC22A2 SNPs in the Xhosa 
population. The rare singleton SNPs identified and haplotypes inferred for the Xhosa 
population in this study is an important step in filling the gap with regards to genetic 
information on the pharmacogenetically relevant SLC22A2 gene in indigenous 
southern African populations. The information generated in this study can potentially 
lay the foundation for future pharmacogenetic study design and for the identification 
of association between the rare SNPs and drug response and toxicity. 
.  
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Summary and Future Perspectives 
Membrane transporters of the SLC family, and specifically the OCTs and MATEs, 
play a critical role in maintaining organismal and cellular homeostasis. They perform 
this important function by being involved in the absorption of nutrients essential for 
cellular metabolism and the elimination of metabolic waste products and toxic 
xenobiotics. Moreover, the current body of knowledge suggest that these transporters 
also play an important part in vivo drug disposition, therapeutic efficacy, and adverse 
drug reactions. A great deal of inter-individual variability exists in drug disposition, 
therapeutic efficacy, and adverse drug reactions. Although numerous factors can 
contribute to this variation, it is estimated that genetic factors account for between 
15-30% of inter-individual variations in drug disposition, efficacy and adverse 
responses, and for certain drugs this estimate can even be as high as 95%. Genetic 
polymorphisms in SLC22A1-3 and SLC47A1 have been associated with reduced 
transport and efficacy of clinically important drugs such as, for example, the 
biguanide anti-diabetic metformin. However, these studies with reduced-function 
variants have primarily focused on genetic polymorphisms that are prevalent within 
Caucasian and Asian populations. This is in spite of numerous studies which have 
shown that the genomic diversity found within African populations is greater than 
the genetic variation found within other populations. However, this genomic 
diversity, especially in the southern African context, is currently relatively 
understudied. Given the enormous health burden that sub-Saharan Africa, and for 
that matter South Africa, faces, this lack of local genetic information with robust 
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allele frequency distribution currently serves as a significant hurdle to designing 
biomedical research, and may have important medical implications.  
Our investigation into the allele and genotype frequency distributions of previously 
reported nonsynonymous SNPs revealed that SLC22A1 reduced-function variants 
found in Caucasians (R61C, C88R, S189L, G401S, M440I and G465R) and Asians 
(P283L and R287G) were not only absent in the Xhosa subjects genotyped in this 
study, but are also absent from other African populations that are included in the 
HapMap and 1000 Genomes projects. Given that these variants have been implicated 
in reduced transport of the anti-diabetic metformin, screening for them in the Xhosa 
and African populations still remains clinically relevant. 
The high frequency, reduced-function nonsynonymous variants which are common 
amongst populations such as P341L in SLC22A1 and A270S in SLC22A2 have 
different frequency distributions for African populations when compared to other 
populations. For example the average reported MAF for P341L is higher for Asians 
(13.5%) and Africans (7.1%) compared to that observed for Caucasians (1.0%). On 
the other hand, the average reported MAF for A270S is higher for Africans (15.7%) 
than that recorded for Asians (13.3%), European-Caucasians (10.6%) and American-
Caucasians (8.8%). 
Furthermore, ethnic-specific nonsynonymous genetic variants that have been 
observed at allele frequencies >1% within the Xhosa and other African populations, 
such as S14F and V519F (SLC22A1) and R400C, K432Q, and I552N (SLC22A2) 
have to date not been reported for Asian or Caucasian populations or are very rare in 
these populations with MAF of <1%. Moreover, the in vitro and in vivo 
consequences of the V519F and I552N variants on hOCT1 and hOCT2 function, 
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respectively, have not yet been established. The effect in vivo of these Africa-
specific nonsynonymous variants on drug disposition, efficacy, and adverse reactions 
in African patients has not yet been determined, and requires further investigation. 
The M420del deletion variant of hOCT1 had been implicated in the reduced 
transport and efficacy of the anti-diabetic drug metformin. In addition, this variant is 
also associated with increased failure rate of imatinib, an antineoplastic TKI, 
treatment in CML patients. Although the M420del variant was not observed in the 
current study, screening for it in indigenous African populations still remain a 
priority. 
Genotyping of the SLC22A3 and SLC47A1 genes, which encode hOCT3 and 
hMATE1 respectively, revealed that none of the nonsynonymous SNPs assayed were 
present in the Xhosa subjects screened. However, these polymorphisms are rare 
variants that occur at very low frequency in a population and therefore the results are 
consistent with studies conducted in other populations. This lack of protein sequence 
and mutational variability was ascribed to selective pressures that act at the SLC22A3 
and SLC47A1 loci and pointed at the important physiological roles the hOCT3 and 
hMATE1transporters perform in vivo. Furthermore, the SNPs typed in this study 
were previously identified in other populations and therefore we cannot rule out the 
presence of novel SNPs in the SLC22A3 and SLC47A1 genes of Xhosa individuals. 
In the current study we have identified seven novel SNPs in the SLC22A2 gene of 
the Xhosa population. These novel SNPs include a variant in the 5′-untrnaslated 
region of SLC22A2 -156 bp from the initiation codon. In addition, we have also 
observed two other promoter SNPs that have to date only been observed in African 
populations. We have searched the literature and to our knowledge no studies have 
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thus far investigated the impact of these substitutions on SLC22A2 expression. The 
effect of the aforementioned promoter SNPs on the expression of SLC22A2 and the 
turnover of hOCT2 needs to be investigated given the importance of hOCT2 in drug 
disposition and efficacy, as well as a site of DDIs. In addition, the correlation 
between genotype of the newly identified SLC22A2 intronic SNPs and clinical 
phenotype also needs to be investigated. 
The sample size of this study compared well to that of the HapMap and 1000 
Genomes Projects, which have more than demonstrated their value as reference 
panels for specific populations, but a larger sample size and complete individual 
gene/genome sequences would give a more accurate account of the full spectrum of 
genetic diversity within the Xhosa population. However, sequencing whole 
genomes/exomes remains an expensive exercise. 
To our knowledge this study is the first of its kind to investigate the allele 
frequencies of known SNPs in four pharmacogenetically relevant genes, SLC22A1, 
SLC22A2, SLC22A3 and SLC47A1, in the Xhosa population. Furthermore, through 
sequencing of the promoter, exonic, and intronic flanking regions of SLC22A2, this 
study has revealed seven novel variants. This study again highlights the fact that not 
all African populations share the same allele frequencies of key pharmacogenes and, 
that care should be exercised in using a single African population as a proxy for all 
African populations in pharmacogenetic studies. In addition, a total of eight robust 
and cost-effective SNaPshot™ multiplex genotyping systems were developed and 
optimized for 78 SLC22A1-3 and SLC47A1 SNPs. These systems have since been 
routinely used to genotype additional indigenous and admixed populations. The 
variants included deleterious SNPs which have been implicated in altered 
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CHAPTER 7 
pharmacokinetics and pharmacodynamics of the widely-prescribed antidiabetic drug 
metformin and as a predictor of treatment outcome for the antineoplastic imatinib. 
Firstly, these genotyping systems can now potentially be used to screen routinely for 
these reduced-function variants in responders and non-responders to metformin 
therapy. Secondly, it can also be used to determine whether CML patients carry the 
M420del allele which is a predictor of imatinib treatment outcome. Thirdly, the 
genotyping systems for SLC22A2 and SLC47A1 can potentially be used to determine 
whether certain individuals have a genetic predisposition for drug-drug interactions. 
Lastly, the genotyping systems developed for the screening of SLC22A3 SNPs can 
be used to screen patients with psychiatric disorders in order to determine whether 
they carry any of the variant alleles included in these systems.  
Future studies require a more comprehensive sequencing of the SLC22A1-3 and 
SLC47A1-2 genes and to expand this to more individuals or, where such sequencing 
information becomes available from other large-scale sequencing projects, use it to 
determine correlation between genotypes and clinical phenotypes. Furthermore, the 
effect of the newly identified and the other African-specific promoter SNPs on the 
expression on SLC22A2 and on hOCT2 transport function needs to be assessed in 
future work. In addition, the effects of the African-specific nonsynonymous V519F 
and I552N variants on transport kinetics, protein turnover, and plasma membrane 
localization of hOCT1 and hOCT2, respectively, also requires further investigation. 
Assessing of the genetic variation of SLC transporter genes with emerging clinical 
importance in the absorption and disposition of drugs such as SLCO1B1, SLCO1B3, 
SLCO1A2, SLCO2B1, SLC15A1, SLC15A2, SLC22A6, SLC22A8 in the Xhosa and 
other indigenous African populations should also be prioritized in future studies. 
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